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Abstract 
 
The largest UK outbreak of respiratory disease in metalworking fluid (MWF) exposed 
workers (Powertrain) led to a heightened awareness of the health hazards 
associated with MWF. A literature review identified 29 outbreaks of ill health 
associated with MWF exposure with a peak incidence between 1996 and 2000. 
Microbial contamination was suspected but no unifying causative agent could be 
found. Six different case definitions for extrinsic allergic alveolitis (EAA) were 
indentified, only one of which was validated. The process of developing an evidence 
based case definition for MWF-EAA required the identification of a group of patients 
with unequivocal MWF associated EAA. The Powertrain database (created at the 
time of the outbreak and subsequent follow up appointments) was utilised and an 
Expert Panel of five occupational lung disease consultants concluded that there was 
sufficient clinical evidence to diagnose 14 workers as definite cases of EAA. By 
calculating the positive predictive value of the data points relevant to a diagnosis of 
EAA combined with knowledge and experience of previous EAA diagnostic criteria, it 
was possible to develop a new evidence-based EAA diagnostic score (the MWF EAA 
Score). The MWF EAA Score was applied to the Powertrain data demonstrating 
agreement with the Expert Panel opinion in over 80% of the cases with a greater 
number of workers correctly classified than with other published diagnostic criteria1. 
The score was also applied to previously published case series of workers diagnosed 
with MWF EAA, in order to externally validate the new EAA rating system. The MWF 
EAA Score appeared to perform well and there was sufficient data provided in almost 
half of these published cases indicating that the MWF EAA Score would have shown 
agreement. This scoring system is a simple and reproducible tool and provides an 
evidence-based case definition suitable for use in future UK outbreaks. 
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Introduction 
The History of Occupational disease 
Occupational disease is any illness associated with a particular occupation or 
industry. Such diseases result from a variety of chemical, biological, psychological 
and physical factors that are present in the work environment or are encountered in 
the course of employment 2.  
The first recorded observation of occupational disease may be that documented in 
the 4th century BC by Hippocrates. The Greek physician described a case of severe 
lead colic suffered by a worker who extracted metals. During the middle ages the 
German mineralogist Georgius Agricola made a detailed study of gold and silver 
mining operations. He described the primitive methods of ventilation and personal 
protection in use and the “difficulty in breathing and destruction of the lungs” caused 
by the harmful effects of dust inhalation. A more comprehensive account of 
occupational disorders was written by the ‘father of occupational medicine’, 
Bernardino Ramazzini. His book entitled ‘Diseases of Workers’ contains descriptions 
of the diseases associated with 54 different occupations including mercury poisoning 
of Venetian mirror makers. Ramazzini believed that a physician must determine the 
patient’s occupation in order to discover the cause of the patient’s disorder 2. 
The Industrial Revolution of the 18th century had a profound impact on occupational 
diseases. Industrial growth led to crowded, unsanitary working and living conditions; 
as well as new machinery and exposure to toxic materials; with a corresponding rise 
in occupational mortality and morbidity. Charles Turner Thackrah, a Leeds physician, 
described lung diseases caused by dust that commonly afflicted miners and metal 
grinders and documented this in his book ‘The Effects of the Principal Arts, Trades 
and Professions . . . on Health and Longevity . .’ (1831) 2.  
In the twentieth century, although some of the original occupational diseases were 
largely conditions of the past, new diseases continued to be described. In the first 
half of the 20th century, asbestos-related disease was identified. The incidence of 
mesothelioma is still increasing with 153 deaths in 1968 to 2347 in 2010. Over 80% 
of asbestos related deaths in 2010 were among men, due to asbestos exposures 
mainly in the workplace 3 . 
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As well as increased mortality and morbidity, occupational respiratory disease is also 
associated with increased sickness absence rates, in 2011/2012 667 000 working 
days were lost due to work related breathing or lung problems4. Affected workers 
may also be forced to relocate or leave employment with subsequent loss of income, 
and benefit requirements, with a third of workers with occupational asthma (OA) 
being unemployed up to 6 years after diagnosis 5-13. These factors combine to 
produce a huge burden on society which has been estimated at an annual cost 
between 4,600 euros to 9,670 euros per ‘‘average’’ afflicted person (at 2004 prices) 
14. In 2003 there was an estimated 631 new cases of OA and the Health and Safety 
Executive (HSE) has estimated that the overall costs to society from these new 
cases of OA ranges from £3.4 to £4.8 million per year over the lifetime of the disease 
15.  
With the introduction of new materials and changes in manufacturing practices, new 
occupational diseases are continuing to be discovered. For example, lung disease 
has been associated with exposure to indium, nylon flock, nanoparticles and the 
world trade center disaster 16. It is important that novel causes of occupational 
disease are identified in order to, where possible, lead to changes in the work place 
to protect others and by so doing reduce their risk of disease. Diacetyl (used as an 
artificial butter flavouring) exposure in popcorn manufacturing has been associated 
with lung disease, including bronchiolitis obliterans, in factory workers 17 and to a 
lesser extent consumers 18. This association has been supported by research 19 and 
has lead to recommendations by government authorities to attempt to reduce the risk 
of associated lung disease. HSE state fumes should be controlled in accordance with 
the Control of Substances Hazard to Health (COSHH) regulations 20. These 
regulations commence with substitution where possible with a safer chemical. This 
has been attempted but evidence suggests that using chemically similar agents may 
lead to the same respiratory problems 21.  
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Occupational Asthma 
Classical asthma is a common respiratory disease in Britain affecting approximately 
5 – 10 % of adults 22. Patients with atopic asthma often present with recurrent 
episodes of wheezing, shortness of breath, coughing and chest tightness. These 
symptoms may be precipitated by contact with allergens or irritants and in part relate 
to changes in airway calibre, and hyper-responsive airways 23. These changes form 
the basis of established diagnostic tests for asthma which include demonstrating 
variable airflow obstruction by examining serial peak flow records, documenting 
airway reversibility to inhaled bronchodilators, and measuring the level of airway 
responsiveness to non-specific inhaled irritants such as histamine and methacholine. 
Chronic inflammation is also present in asthmatic airways, with an associated 
increase in eosinophils, mast cells, and Th2 lymphocytes 24. Untreated, this may lead 
to airway remodelling with goblet cell hyperplasia, reticular basement membrane 
thickening, vascular proliferation, and smooth muscle hypertrophy 23. The resulting 
eosinophilic bronchial inflammation may be demonstrated by higher than normal 
numbers of eosinophils in the sputum of patients with active asthma 25, and this is 
used as an alternative objective method of monitoring asthma control in some 
centres 26. 
Recent evidence supports the estimate that occupational factors account for 
approximately one in six cases of adult asthma. The annual population incidence of 
occupational or work-related related asthma ranges from an estimated 12 to 300 
cases per million workers 27-35. It is estimated that OA accounts for somewhere in the 
region of 9-16% of all new adult cases of asthma 36-38, making it the most frequently 
reported work-related airway disease in Britain 4. A significant under-identification of 
OA is thought to persist 35 39. In the UK this can be demonstrated by the number of 
OA reported cases each year (321 cases) 40, compared to the suggested annual 
population incidence of occupational or work-related related asthma ranges from (an 
estimated 12 to 300 cases per million workers) 41. 
OA may be caused by a demonstrated or presumed immunological response to a 
workplace exposure (sensitiser induced occupational asthma), or can be due to high 
level irritant exposure, (for which the most clear example is reactive airways 
dysfunction syndrome, RADS). Work-exacerbated asthma refers to unrelated asthma 
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(preceding or with concurrent onset with work) which is worsened either on a 
sporadic or frequent basis by conditions at work 42.  
Sensitiser induced OA can often be related directly to a specific antigen exposure. 
Overall, the most frequently reported agents include isocyanates 27 30 33-35 43-47, flour 
and grain dust 27 30 33-35 43-45 47, latex 27 28 33 35 45 47, aldehydes 27 30 33-35 47, hairdressing 
products 27 34, adhesives 35, metals or metal working fluids 28 30 33 34 45, resins and 
wood dust 27 30 33-35 46, colophony and fluxes 28 30 33 34 44 46 47 and animals 28 30 34 35 43 47.  
OA should be suspected in individuals of working age who develop symptoms of 
asthma; particularly those who report worsening symptoms at work or improving 
symptoms during holiday periods and those with exposure to a known or presumed 
sensitiser 48 49. Workers developing this condition often do so within the first 1-2 years 
of exposure 42 50, although longer latent periods do occur, particularly in workers 
exposed to bakery allergens 51. Typical symptoms of occupational asthma include 
episodic wheezing, breathlessness, chest tightness and coughing, all of which may 
occur at or after work. Such work-related symptoms may be associated with allergic 
eye or nasal symptoms. Specifically, rhino-conjunctivitis may precede or coincide 
with the onset of OA, the risk of OA development being highest in the year following 
the onset of rhino-conjunctivitis. If OA remains unrecognised, ongoing allergen 
exposure is associated with accelerated lung function decline and chronic persistent 
asthma may develop. This form of chronic respiratory ill health may persist after 
allergen exposure has ceased, requiring long-term medication and health service 
utilisation 41 50.  
Certain factors have been shown to affect an individual’s risk of developing OA. 
Atopy is the tendency to produce specific immunoglobulin IgE on ordinary exposure 
to common allergens, demonstrated by immunological testing or a history of allergic 
disease (asthma, eczema or hay fever). The European Respiratory Society (ERS) 
Task Report concluded there is no relationship between atopy and the outcome of 
occupational asthma 14 52. The British Occupational Health Research Foundation 
(BOHRF) state that the risk of developing OA to certain high molecular weight agents 
that induce the production of specific IgE antibodies has been shown to be increased 
in atopic individuals 53-75. The ERS Task Force conclude that a longer duration of 
bronchial hyper responsiveness was seen in those workers with asthma induced by 
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high molecular weight allergens compared with low molecular weight allergens 14. 
Maestrelli et al. in their review of 36 papers agree with the task force that high 
molecular weight antigens and older age at presentation are negative predictors of 
outcome 76. An increased incidence of OA has also been linked to the higher levels of 
sensitisation seen in exposure to more concentrated levels of antigen 51 54 57 62 64 68 69 
74 77-100. 
Some groups have identified smoking as a factor that increases the risk of 
occupational asthma in workers exposed to certain asthmagens, for example: 
isocyanates 94 101 102, seafood (fish and crustacea) 64 103 104 and platinum salts 13 82. 
Although the ERS Task Force Report found that despite smoking cessation being 
beneficial to the prognosis of asthma in general, smoking at the time of diagnosis 
does not seem to have a major impact on the prognosis of OA 14. This is in 
agreement with Maestrelli et al. who found smoking at diagnosis did not seem to 
influence the outcome of occupational asthma 76.  Both concluded that older age at 
presentation was associated with a poorer prognosis 14 76. 
Occupational rhinitis and occupational asthma commonly occur together, especially 
with high molecular weight sensitisers 105 106. The onset of rhinitis may coincide with 
or precede the onset of OA, in which case the risk of developing OA is highest in the 
first year after the onset of occupational rhinitis 57 61 95 106-111.  
 
Investigations of suspected occupational asthma 
Investigations in to OA aim to provide evidence to support or reject the hypothesis 
that a person’s asthma is related to their working conditions. They can be 
categorised in to pulmonary function testing to demonstrate the work associated 
variation in lung function and allergen testing to identified the causative agent. 
Fishwick et al. approved the British Thoracic Society (BTS) Standards of care for 
occupational asthma 112 and confirmed there is a considerable evidence base for the 
use of serial peak expiratory flow (PEF) measurements (recorded at least four times 
a day for at least three continuous weeks) to investigate workers when OA is 
suspected. High-quality recordings can be obtained for over 70% of patients, on 
 7 
condition that the appropriate training and explanation is provided 112. While these 
tests may be susceptible to errors, they offer the best and easiest first-line approach 
to assessing physiological response to asthmagens at work. All recordings should be 
entered onto a computer for analysis using suitable software.  A calculated work-
effect index allows charts to be graded positive, equivocal or negative for a diagnosis 
of OA 112. A positive chart has a quoted sensitivity of approximately 75% and a 
specificity of 95% for a diagnosis of OA 113-116, although these estimates are quality 
dependent and pooled estimates suggest 64% sensitivity and a specificity of 77% 
117. It is important to note that PEF charts do not confirm a specific cause nor do they 
distinguish OA from work-aggravated asthma 118.  
Pre-shift to post-shift changes in lung function may support a diagnosis but they are 
frequently absent in people subsequently confirmed to have OA as they have a high 
specificity but only low sensitivity. It is recommended that pre-shift and post-shift 
forced expiratory volume in one second (FEV1) changes are only used in conjunction 
with other diagnostic approaches 112 119-121.  
Skin prick and serological testing are highly sensitive for detecting specific IgE and 
hence type I sensitisation and OA caused by most high molecular weight agents. 
However these tests are not specific for diagnosing asthma or OA. This means that 
there are some asymptomatic sensitised workers who will never develop 
occupational asthma 14 69 112 117 122 123.  
While assessment of non-specific bronchial responsiveness to inhaled irritants such 
as histamine and methacholine is a useful diagnostic investigation, single and serial 
measures have only moderate specificity and sensitivity for the diagnosis of OA 117 
124-127. However a positive specific broncho-provocation test, that is a change in 
airway calibre associated with increasing levels of exposure to a specific antigen, 
comes closest to a gold standard test for the diagnosis of OA, provided exposures 
received are equivalent to those in the workplace 14. However due to lack of 
standardisation, the complexity of the test and the inability to always replicate 
exposures in the workplace, a negative tests does not necessarily exclude OA 14 103 
119 120 128-133. The laborious nature of a specific broncho-provocation test and the 
availability of more convenient alternatives mean it is generally reserved for the more 
difficult diagnostic conundrums 112.  
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Frequent monitoring of FEV1 or PEF on multiple days of work, during and between 
periods of exposure to the suspected agents is referred to as a workplace challenge 
and is sometimes used to aid diagnosis. Workplace challenges are an alternative but 
are not standardised and lack external validation 134. One way of approaching this 
type of challenge is to take data from non-exposed days to calculate a mean and 
95% CI of the ‘expected’ FEV1 at each time point. These are compared with 
FEV1 values measured on exposed days 
112. 
Newer techniques are available to investigate potential cases of OA. The 
measurement of sputum eosinophils and exhaled nitric oxide maybe helpful in the 
diagnosis 129 135-142  but the absence of them does not exclude OA 125 127 136 137 139 141-
143.   
The use of ENO as a surrogate marker for monitoring airway response to specific 
inhalation challenges (SIC) was demonstrated by Sastre et al. 144. 65 workers with 
suspected OA were evaluated, 45 of whom had positive specific inhalation 
challenges (SIC). It was found that a baseline FeNO value of 25 ppb predicted a 
positive SIC with 60% sensitivity and 80% specificity. The increase in % FeNO cut off 
point providing maximal sensitivity and specificity for predicting a positive SIC was 
41% (sensitivity 50%, specificity 95%). It was concluded that asthmatic reactions 
induced by occupational agents during SICs are associated with a consistent 
increase in FeNO, however, the predictive diagnostic capacity of FeNO 
measurements is low 144.  
 
Disease Prevention 
Disease prevention can be divided into primary, secondary and tertiary prevention. 
Primary prevention in occupational disease aims to prevent the onset of the 
condition. Such measures include limiting exposure to known asthmagens by 
hygiene methods, such as ventilation or substitution of the asthmagen with a less 
harmful agent. It is important to education a workforce exposed to asthmagens, 
regarding symptoms potentially attributable to exposure, how agents in the workplace 
can affect health and how best to avoid problems. Key to this positive strategy is the 
development of a workplace culture that encourages workers to report health 
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complaints and an understanding of the action plan were they to report work-related 
respiratory symptoms 14 112.  
Respiratory protective equipment has a role to play where control at source is not 
feasible, however, although it reduces the incidence it does not completely prevent 
occupational asthma 101 145 146.  
Health surveillance, as defined by HSE, is a system of on-going health checks to 
detect ill health effects at an early stage 147. This is an important part of secondary 
prevention which aims to identify disease at a pre-symptomatic stage or early stage. 
Fishwick et al. in a multi-centre hospital study, demonstrated a mean delay of four 
years between the onset of symptoms and a confirmation of diagnosis in a group of 
patients that were largely not afforded annual health surveillance 148. This contrasts 
with the findings of Mackie et al. who found a mean delay of nine months in those 
whose symptoms were detected at health surveillance and who attended for 
subsequent investigations 149. Although it is difficult to dissociate the effects of health 
surveillance from the effects of other risk management procedures it is felt that 
outcome is improved in workers who are included in a health surveillance programme 
150.  
Respiratory questionnaires, lung function testing and where appropriate identification 
of specific IgE by skin prick test or serology are commonly used in health 
surveillance. There is no generally accepted questionnaire for use in surveillance for 
OA and some studies of the value of questionnaires to detect asthma suggest that 
they are insensitive and may lead to an underestimate of the prevalence of asthmatic 
symptoms 151-153. It has also been suggested that spirometry may lead to no or few 
additional cases of asthma that are not identified by questionnaire and can identify 
many false positives if technique is poor 149 154 155. Skin prick tests and serological 
tests can detect specific IgE in workers who have become sensitised to specific 
allergens (mainly but not exclusively high molecular weight allergens). As IgE 
sensitisation is related to exposure, sensitisation rates can be used as an indirect 
measure exposure control and an increased risk of occupational rhinitis and/or OA in 
workers 156 157. A combination of these investigation and importantly good technique 
and correct interpretation of their findings should be able to detect a largely 
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preventable condition, however health surveillance in OA continues to prove 
challenging 158. 
Tertiary prevention aims to alleviate the effects of established disease. The 
avoidance of further exposure to the causative agent increases the likelihood of 
improvement or resolution of symptoms and reduces the chance of additional 
deterioration 99 159-168. However, unfortunately the symptoms and functional 
impairment of occupational asthma may persist for many years after avoidance of 
further exposure to the causative agent 169. The chance of a positive outcome is 
improved in those workers who have relatively normal lung function at the time of 
diagnosis 124 160 165 170-173, who have a shorter duration of symptoms prior to diagnosis 
11 160 163-165 172-178 and who have shorter duration of symptoms prior to avoidance of 
exposure 11 165 172 176-179. 
The European Respiratory Taskforce identified nine studies that compared the 
effects of persistent exposure to causal agents, with those workers who attained 
complete avoidance 14 44 99 161 165 170 180-183. In workers diagnosed with OA, 33.7% of 
those who avoided further exposure recovered from their asthma whereas symptoms 
persisted in 93% of patients who remained exposed. The two studies that provided 
information on worsening of asthma reported that the condition deteriorated in 10 
(59%) out of 17 subjects who remained exposed, but in none of those who avoided 
exposure 181 182.  
Unfortunately, although tertiary prevention through redeployment to a non-exposed 
area may lead to improvement or resolution of symptoms or prevent deterioration in 
some workers, it is not always effective 104 159 161 164 165 184 185. In practice the advice to 
completely avoid exposure maybe rejected for social or financial reasons 186. In this 
setting, reduction of exposure may be a useful alternative although once sensitised a 
worker’s symptoms may be precipitated by exposure to extremely low concentrations 
of the allergen. Respiratory protective equipment is effective only if it is worn, 
removed, stored and maintained correctly. It has been demonstrated that air fed 
helmet respirators may improve or prevent symptoms in some but not all workers 
who continue to be exposed to the causative agent 164 187-191. 
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The cost of occupational asthma 
There is consistent evidence derived from workforce and clinical case series that 
about one third of workers with OA are unemployed up to six years after diagnosis 5-
13 192 and that loss of employment following a diagnosis of OA is associated with loss 
of income 5 6 9 10 12 162 192-194. In comparison with other adult asthmatics those with OA 
may find employment more difficult 8 9 and their financial loss may be greater 194. 
Based on prices in 2004, an annual total cost per ‘‘average’’ person diagnosed with 
OA was estimated at £305–£2,735 15. The best case scenario for a worker is that 
they are relocated to jobs without exposure to the causative agent. It has been 
shown that these workers are more likely to remain in employment and are unlikely to 
leave those jobs because of their asthma 195. 
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Extrinsic allergic alveolitis 
Extrinsic allergic alveolitis (EAA), or hypersensitivity pneumonitis (HP) as it is more 
commonly referred to outside the UK, was first described in the early 20th century in 
farmers exposed to mouldy hay or straw, hence the term farmer’s lung 196 197. EAA is 
a group of immune mediated lung diseases resulting from an inappropriate response 
to the inhalation of an antigen to which the subject has been previously sensitized 
immunologically. This typically results in shortness of breath, a restrictive lung defect 
and interstitial infiltrates seen on lung imaging caused by the accumulation of T 
lymphocytes in the lungs 198-200.  
Over time a larger number of antigens have been described from a variety of 
environmental settings, e.g. farmer’s Lung (Thermophilicactinomyces, Aspergillus 
spp, Candida albicans, Sporobolomyces spp, Micropolyspora faeni) bird fancier’s 
lung (avian proteins), bagassosis (Thermoactinomyces sacchari), mushrooom 
worker’s lung (Thermoactinomyces sp, Agarieus hortensis spores) and hot-tub lung 
(Mycobacterium avium intracellulare) 200 201. Most EAA causing antigens are organic 
particles; however some chemical compounds (e.g. isocyanates and zinc) can act as 
haptens which link the host albumin to create an antigenic particle 202 203.   
The pathogenesis of EAA involves repeated antigen exposure, immunological 
sensitization of the host to the antigen and immune response causing respiratory and 
systemic symptoms. Only a small percentage of those exposed to an antigen will be 
susceptible and therefore develop EAA. Interstitial and alveolar inflammation with 
granuloma formation is the characteristic result of the immune response 201. This is 
thought to involve a combination of type III hypersensitivity reactions; supported by 
the lag in onset of symptoms after initial exposure and high levels of antigen specific 
IgG in serum and bronchalveolar lavage (BAL) and type IV delayed hypersensitivity 
reactions to the inhaled antigen; supported by the presence of granulomas 201 and 
evidenced by anecdotal clinical accounts. Such histories include the confirmation of 
EAA in a patient with known hypogammaglobulinaemia and therefore an inability to 
mount a type III hypersensitivity reaction 204 and the development of EAA in a patient 
with AIDS, when she was successfully treated with anti retrovirals 205.  
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Studies regarding the incidence or prevalence of farmer’s lung over the past two or 
three decades, have illustrated the difficulties in studying the epidemiology of EAA. 
Methodological issues including study design and the definition of farmer’s lung have 
made definite conclusions elusive 198 206-208. The majority of studies are cross-
sectional surveys in order to determine the prevalence of farmer’s lung or associated 
markers such as the presence of precipitating antibodies against offending antigens. 
Few if any cohort studies have been published on the incidence of the disease 207 209-
211. Those patients admitted to hospital with such extreme symptoms that they 
underwent investigations so rigorous to enable the diagnosis of farmer’s lung, e.g. 
chest X-ray (CXR), high resolution CT scan (HRCT), Bronchoalveolar lavage (BAL) 
and/or lung biopsy, are likely to represent severe manifestations of the disease 
process. Thus the prevalence of disease estimated using epidemiological reports 
based on cases admitted to hospital are likely to under estimate the true burden of 
disease 207. 
Prevalence rates vary widely between countries and are influenced by factors such 
as climate, seasonal and geographical conditions, local customs, smoking habits and 
differing work practices and processes 198. In a population based study, the estimated 
annual incidence of interstitial lung disease was 30 per 100 000. In that study, EAA 
accounted for less than 2% of the incident cases, however the study was conducted 
in New Mexico, in a dry environment that is not propitious to the development of 
many forms of EAA 212. 
Clinical presentation of EAA varies and has traditionally been divided in to acute, 
sub-acute or chronic 203. The mode of presentation depends on the frequency, 
intensity and duration of exposure to the aetiological agent and on the host’s 
immunological reaction. Classification of EAA in to acute and chronic forms can be 
misleading as it may be assumed that there is an inevitable progression from acute 
to chronic disease if antigen exposure continues. The interaction of antigen exposure 
and host response in the initiation and progression of the disease is considerably  
more complex and the clinical course of the disease is unpredictable 198.  
Typically both respiratory and systemic symptoms are apparent. Respiratory 
symptoms such as cough and shortness of breath are usual but not universal. In the 
acute form systemic symptoms often predominate, presenting with recurrent 
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episodes of flu like illness consisting of chills, fever, sweating, headaches, nausea, 
general malaise and lethargy. Symptoms usually begin 2-9 hours after exposure and 
peak after 6-24 hours, potentially lasting for days. The subacute form may occur 
gradually over weeks and tends to have more predominant respiratory symptoms. 
The chronic form has an insidious onset with increasing cough and shortness of 
breath over months. Fatigue and weight loss may be prominent features 207. Recent 
research using the SF-36 questionnaire concluded that compared with patients with 
idiopathic interstitial pulmonary fibrosis with similar pulmonary function, patients with 
chronic EAA perceived a significantly lower quality of life 213.  
Clinical examination may be normal, particularly between episodes of acute 
exacerbations, or may demonstrate signs such as bibasal crackles, fever, clubbing 
and in cases of severe chronic disease, right sided heart failure and cyanosis 198 203 
214. Lacasse et al., during their work evaluating predictors of hypersensitivity 
pneumonitis, studied 116 patients with HP and found that 87% had inspiratory 
crackles, 32% were cyanosed and 21% had clubbing 215.  
Others have suggested a classification that takes in to account the progression of the 
disease (acute intermittent, acute progressive, chronic progressive, chronic non-
progressive) that can only be assessed retrospectively 206 216. Lacasse et al. 
addressed the issue of clinical diagnostic criteria of EAA by completing a prospective 
multi-centre cohort study in order to develop a clinical prediction rule for the 
diagnosis of active EAA. This tool was designed to aid physicians by calculating an 
accurate probability of EAA and so assist in decision making regards further 
investigations to rule the diagnosis in or out 207 215. Girard et al. re-analysed the data 
that had been collected for the development of the Lacasse prediction rule 215, to 
determine whether the current classification of EAA truly reflected categories 
(‘clusters’) of patients with maximally differing clinical patterns. A two cluster solution 
best fitted the data. Cluster one (41 patients) had more recurrent systemic symptoms 
(chills, body aches) and normal CXR. Cluster two (127 patients) had significantly 
more clubbing, hypoxaemia, restrictive patterns on pulmonary function testing and 
fibrosis on HRCT. Nodular opacities on HRCT were seen equally in both clusters 217 
207. There was considerable disagreement between the current classification of EAA 
and the result of Girard’s analysis. 
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Investigative results are often variable and there is no gold standard test with which 
to diagnose EAA. The diagnosing physician may initially suspect EAA on the basis of 
the presenting history and examination findings. A key element in the history is often 
exposure to a known causative agent. For example mouldy hay causing farmer’s 
lung and avian droppings or feathers leading to bird fancier’s lung. If the allergen is 
not recognised by the physician or is a novel agent, as is the case with metalworking 
fluids (MWF), the diagnosis may be missed. Patients are often initially diagnosed with 
an infective condition 198 203. 
 
Investigation of suspected extrinsic allergic alveolitis 
Blood tests may be helpful. In the acute setting peripheral blood neutrophillia and 
lymphopenia are common.  Inflammatory markers may also be raised. If the specific 
antigen is known it may be possible to demonstrate serum antibodies in a peripheral 
blood sample. This shows significant exposure but does not prove causation 198. For 
example, 10% of people exposed to Saccharopolyspora rectivirgula, the main agent 
in farmer’s lung, develop antibodies; but only 0.3% will develop the EAA 218. 
Nevertheless, specific antibody analysis can be useful as supportive evidence. In 
Girard’s clinical prediction model, positive serum antibodies were found to be a 
significant predictor of EAA (odds ratio: 5.3; 95% CI: 2.7-10.4) 207. 
Chest X-ray (CXR) is often one of the initial steps in the investigation of suspected 
EAA. In the acute phase it would be expected to show small, poorly defined 
nodulation, occasionally symmetrically sparing the apices or bases. A diffuse, soft, 
patchy infiltrate may also be seen with or without nodulation however in 20% of 
cases it is normal 219 203. In the chronic fibrotic phase a linear element, particularly at 
the periphery, becomes more distinct and there is a loss of lung volume. None of 
these findings are specific to EAA 203. 
More sensitive than CXR and commonly key to the diagnosis of EAA is the high 
resolution computed tomography scan (HRCT). A study of 21 patients with subacute 
and chronic bird breeder HP found 7 patients to have normal CXRs but all 21 had 
abnormal HRCT 220. However, Lacasse et al. found that 16 of 199 (4%) patients with 
proven EAA had a normal HRCT 215.  
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Due to the radiological similarities with pulmonary oedema and the rapid resolution of 
symptoms, patients with acute EAA rarely undergo HRCT imaging. In subacute 
disease, the characteristic HRCT pattern is the presence of patchy or diffuse ground-
glass opacities (reflecting the presence of diffuse interstitial pneumonitis and to a 
lesser extent a degree of organising pneumonitis), poorly defined centrilobular 
nodules (secondary to cellular bronchiolitis), mosaic attenuation on inspiratory 
images and expiratory air trapping (due to small airway obstruction by cellular 
bronchiolitis or constrictive bronchiolitis) 221.  
No one radiological finding is pathogonomic for EAA, for example ground glass 
changes can be seen in a variety of other disease, e.g. pneumocystis carini 
pneumonia, bronchoalveolar carcinoma and alveolar haemorrhage; but a 
combination of these findings supports the diagnosis of EAA. The combination of 
increased attenuation (ground glass), decreased attenuation (air trapping) and 
normal lung attenuation on an inspiratory film, is referred to as ‘head cheese’ (the 
different densities seen in a slice of a specific continental sausage) 199.   
Chronic HP is characterized on HRCT by the presence of reticulation and traction 
bronchiectasis and bronchiolectasis due to fibrosis, superimposed on findings of 
subacute HP. The fibrosis typically spares the lung bases but can be patchy, random, 
or have a predominantly subpleural and peribronchovascular distribution. The 
radiological and pathological findings frequently overlap with those of nonspecific 
interstitial pneumonia and usual interstitial pneumonia. EAA must always be 
considered as a diagnosis in patients found to have changes consistent with these 
diagnosis 203 221. 
The role of pulmonary function testing (PFT) is two-fold. It may assist in diagnosis, 
and also, if abnormal, can guide therapy and monitor response. Pulmonary function 
testing has no role in discriminating EAA from other interstitial lung disease 215. The 
typical pattern would be one of a restrictive defect (with a reduced forced expiratory 
volume in one second (FEV1) and a reduced forced vital capacity (FVC) and because 
of the inflamed or fibrotic alveolar wall membrane, it would be expected that the gas 
transfer would be reduced 222 203. This is however far from consistent and spirometric 
findings may be normal, obstructive or mixed. In farmer’s lung the most frequent 
defect is obstructive due to emphysema 223. Girard et al. found that 39 of the 177 
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patients (22%) in whom the transfer factor of the lung for carbon monoxide (TLCO) 
had been measured had results in the normal range (defined as TLCO > 80% 
predicted) at the time of the diagnosis 207.  
When comparing HRCT and PFT as means to monitor disease progression in 92 
patients with chronic EAA, Walsh et al. found that HRCT patterns, especially the 
extent of traction bronchiectasis and honey combing, are superior to PFT and are 
strongly predictive of poor survival 224. 
Inhalation challenges involve inhalation of the suspected causative antigen, usually 
at the workplace or as specific provocation tests in controlled conditions, with 
monitoring of symptoms and lung function 225. These are occasionally used but there 
are no standardised techniques available or criteria defining a positive response. 
Some experts state that further studies are needed before recommending inhalation 
challenges in the diagnosis of EAA 207. Others, however, feel that in some cases 
inhalation challenges provide useful information in the diagnosis of patients 203.  
Bronchoalveolar lavage (BAL) and the measurement of white cell sub-type, is an 
invasive test that is used in some centres to aid diagnostic evaluation of interstitial 
lung disease. It is traditionally thought that EAA can be differentiated from other 
causes of interstitial lung disease based on the proportion of different cell types. A 
normal lymphocyte count rules out all but residual disease 207 226. Although the 
presence of an alveolar lymphocytosis would support a diagnosis of EAA, it is by no 
means pathognomic as it can also occur in other respiratory conditions e.g. 
sarcoidosis 227, silicosis 228, bronchioloitis obliterans with organising pneumonia 229 
230, drug induced pneumonitis 231, non-specific pneumonitis 231. 
Lymphocytosis is also seen in asymptomatic exposed people. Cormier et al. studied 
24 asymptomatic dairy farmers. Thirteen had serum precipitins to Micropolyspora 
faeni (MF) antigens (Group 1), and 11 were seronegative control subjects (Group 2). 
Thirteen of 24 subjects (9 in Group 1 and 4 in Group 2) had a high percentage of 
lymphocytes (greater than or equal to 20%) in their BAL 232. Cormier et al. also 
concluded that although an increase in BAL lymphocytes is seen in acute Farmer’s 
Lung Disease it does not correlate with physiological changes 233. To verify the 
outcome of this lymphocytosis in asymptomatic farmers, they were restudied 2 or 3 
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years later. All subjects were still working on the farm and none had had symptoms 
suggestive of farmer's lung disease. Lymphocytes from BAL were still increased in 9 
of 12 subjects, whereas 3 had returned to normal; of the 15 subjects with previous 
normal values, 3 now had an abnormal lavage lymphocytosis. There was no 
correlation between lung function variations and the percentage of lymphocytes in 
the previous or the present BAL. It was concluded that a bronchoalveolar 
lymphocytosis is a persistent phenomenon in a large number of asymptomatic dairy 
farmers, and that this finding does not seem to be related to significant disease 226.  
Twenty seven of the asymptomatic farmers with or without precipitins or 
lymphocytosis on BAL were restudied 20 years after the initial study. 16 were 
subjects were missing, 11 refused follow up, 3 had died and 2 could not be located. 
Only one of the 27 described shortness of breath and that was thought to be 
secondary to asthma. It was concluded that serum precipitins and asymptomatic 
lymphocytic alveolitis in an asymptomatic exposed dairy farmer have no clinically 
meaningful long-term consequences 234. 
Sarcoidosis is typically associated with a predominance in CD4+ T cells and a 
CD4+/CD8+ ratio of >1 compared to an increase in CD8+ cells and a ratio <1 in EAA 
235. Traditionally this has been used to differentiate the two conditions however it is 
now known that CD4+/CD8+ ratio in EAA can be increased to levels as high as those 
seen in sarcoidosis 236-238. Recent studies suggest that in chronic EAA and 
asymptomatic exposed people, a low CD4+/CD8+ ratio is typical; however in the 
acute presentation a predominance of CD4+ cells can be expected 201 239. Type, dose 
and duration of inhaled antigen may also play a role in the CD4+/CD8+ ratio 200 201 
240. 
The histopathology of EAA has been well described. During the active phase of the 
disease biopsy would typically show an interstitial alveolar infiltrate consisting of 
plasma cells, lymphocytes and occasional eosinophils, usually accompanying small 
necrotising granulomata. Interstitial fibrosis is common and bronchiolitis is found in 
about half of cases. Vasculitis is not a feature 203 214. In chronic stages, widespread 
fibrotic reaction is a predominate feature. Emphysema is also a recognised 
complication of long term EAA 223, however the mechanism for this is not clear 220.  
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Transbronchial biopsy (TBB) performed at bronchoscopy is thought to be of limited 
usefulness in the diagnosis of EAA, as documented in farmer’s lung by Lacasse et al. 
Analysis of 105 TBBs (55 cases of farmer’s lung matched with 50 control samples 
with other parenchymal disease) was performed by two independent pathologists. 
The assessors were asked to assign each TBB in to one of 
four diagnostic categories: (1) probable farmer’s lung, (2) possible farmer’s lung, (3) 
nonspecific and (4) alternative diagnosis. 48.6% of the TBBs were considered to be 
nonspecific. It was concluded that TBB should be reserved for patients with 
intermediate pretest probability of farmer’s lung 241. A retrospective study in China, 
including 96 patients with HP also concluded that TBB was of limited value, giving a 
positive result in only 8.2% of cases 242.  
Open lung biopsy is more likely to provide a useful tissue sample enabling 
recognition of a characteristic combination of interstitial pneumonia, bronchiolitis, and 
granulomatous inflammation 243. This needs to be weighed against the invasive 
nature and associated risk of the test as well as the potential change in clinical 
management depending on the findings of the biopsy. Several retrospective studies 
have addressed these issues, with mixed results. The diagnostic yield, i.e. the 
proportion of specific diagnosis obtained from the procedure, ranged from 34% to 
100%; therapy was altered in 46% to 76% of cases. The selection of patients for lung 
biopsy, the timing of the procedure along the course of the disease and the expertise 
of the pathologist are all factors that contribute to the variation in results 207. It has 
been recommended to only perform surgical biopsy on those patients with unusual 
clinical presentation or when the clinical course or response to therapy is not as 
expected 244. 
Lung biopsy can have a key role in recognising patients with chronic hypersensitivity 
pneumonia and hinges on recognition of a characteristic combination of interstitial 
pneumonia, bronchiolitis and granulomatous inflammation. Late-stage disease is 
associated with fibrosis that may mimic other forms of fibrotic lung disease, including 
importantly UIP. The available evidence suggests that fibrosis predicts a worse 
prognosis, although this has not been prospectively validated 221 245. 
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Diagnositc Criteria 
The lack of one specific test to diagnose EAA has led to the formation of many 
diagnostic criteria in an attempt to standardise the diagnosis 203 210 244 246. These 
criteria generally consist of a combination of signs, symptoms and investigative 
results, none of which have been validated (table 1and 2). 
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Table 1: Summary of diagnostic criteria for EAA for clinical purposes 207 
Author Minor Criteria Major Criteria 
Terho 210 1.Exposure to offending antigens (revealed by history 
aerobiological or microbiologic investigations of the 
environment, or measurements of antigen specific 
IgG antibodies 
2.Symptoms compatible with HP present and 
appearing or worsening some hours after antigen 
exposure 
3.Lung infiltrations compatible with HP visible on 
chest x-ray 
1.Basal crackles 
2.Impairment if the diffusion capacity  
3.Oxygen tension (or saturation) of the arterial blood either 
decreased at rest, or normal normal at rest but decreased 
during exercise 
4.Restrictive ventilation defect in the spirometry 
5.Histological changes compatible with HP 
6.Positive provocation test either by work exposure or by 
controlled inhalation challenge 
Richerson 
et al 203 
 
1.The history and physical findings and pulmonary 
function testing indicate an interstitial lung disease 
2.The X-ray film is  consistent 
3.There is exposure to a recognised cause 
4.There is antibody to that antigen 
 
Cormier 
et al 248 
1.Appropriate exposure 
2.Inspiratory crackles 
3.Lymphocytic alveolitis (if BAL is done) 
4.Dysponea 
5.Infiltrates on chest radiograph or HRCT 
1.Recurrent febrile episodes 
2.Decreased DLCO 
3.Precipitating antibodies to HP antigens 
4.Granulomas  on lung biopsy (usually not required) 
5.Improvment with contact avoidance or appropriate treatment 
Schuyler 
246 
1.Symptoms compatible with HP 
2.Evidence of exposure to appropriate antigen by 
history or detection in serum and/or BAL fluid 
antibody 
3.Findings compatible with HP on chest radiograph or 
HRCT 
4.BAL fluid lymphocytosis 
5.Pulmonary histological changes compatible with HP 
6.Positive ‘natural challenge’  
1.Bibasilar rales 
2.Decreased DLCO 
3.Arterial hypoxaemia either at rest or during exercise 
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Table 2: Probability (%) of having hypersensitivity pneumonitis* 207 217 
 Crackles 
+                - 
Exposure 
to a known 
offending antigen 
Recurrent 
Episodes of 
symptoms 
Symptoms 
4-8 h after 
exposure 
Weight 
loss 
Serum 
precipitins 
+          - 
Serum 
precipitins 
+          - 
+ + + + 98 92 93 72 
+ + + - 97 85 87 56 
+ + - + 90 62 66 27 
+ + - - 81 45 49 15 
+ - + + 95 78 81 44 
+ - + - 90 64 68 28 
+ - - + 73 33 37 10 
+ - - - 57 20 22 5 
- + + + 62 23 26 6 
- + + - 45 13 15 3 
- + - + 18 4 5 1 
- + - - 10 2 2 0 
- - + + 33 8 10 2 
- - + - 20 4 5 1 
- - - + 6 1 1 0 
- - - - 3 1 1 0 
 
 
 
-Absent  + present  *All the predictors are dichotomous variables.  
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Treatment 
The ideal treatment for EAA is removal of the patient from the offending antigen or in 
circumstances where this is not possible, to substantially reduce the exposure. The 
achievability of this is variable for example, farmers are often reluctant to change 
profession. There are means of significantly reducing the amount of antigen 
exposure in the farming industry, e.g. ensuring adequate drying of fodder, using 
silage instead of hay and avoiding the barns when animals are eating 207. Similarly 
pigeon fanciers unwilling to stop their pastime are encouraged to reduce the time 
spent with their pigeons, avoid excess handling of the birds and activities that involve 
high levels of exposure and increase loft ventilation 201. Antigen exposure can be 
further reduced by the application of appropriate respiratory protection. 
 A study reviewing 142 patients with EAA found that 75 (53%) did not have a 
demonstrable causative antigen. After adjusting for mean age, presence of fibrosis, 
mean % forced vital capacity (FVC), diffusing capacity of the lung for carbon 
monoxide (DLCO) and history of smoking, survival was longer for patients with an 
identified causative agent (median, 8.75 years vs 4.88 years; P = .047) 247. 
Pharmacological treatment for EAA is limited in its value. 36 patients in the acute 
phase of farmer’s lung were randomised in to two groups, one group was treated with 
corticosteroids and the other was given a placebo. Following one month of treatment 
there was a significant difference (p = 0.03) in DLCO between the treatment groups. 
However, after a follow-up of 5 yr no statistically significant differences were found 
between the treatment groups in FVC, FEV1, or DLCO 
248. 
These findings compare to those previously reported by Mönkäre in 1983, when in a 
prospective study of farmer's lung disease, 93 patients were subjected to a follow-up 
period of an average of 18.6 months. Lung function, examination and CXR findings 
were recorded at intervals of one, three, six and 12 months and every six months 
after that. The patients were treated with either a zero, four or twelve week course of 
corticosteroids. Lung function or the prognosis of working capacity did not seem to be 
related in any way to the amount of corticosteroids received. However, 
corticosteroids were found to improve the appearance of CXR changes. It was 
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concluded that corticosteroids should be given to severely ill patients to improve 
symptoms, but no apparent benefit is derived from long-term treatment 249.  
Treatment with less traditional immunosuppressants such as rituximab, a B 
lymphocyte depleting monoclonal antibody, have also been used in patients with 
severe progressive interstitial lung disease resistant to corticosteroids, including 
EAA, with some success. However more research needs to be completed in order to 
validate these findings and assess safety outcomes 250. 
Unfortunately on some occasions, even with apparent discontinued exposure, the 
disease process will progress. The reason for this is not clear. In bird fancier’s lung 
(BFL), despite intensive environmental control measures, bird antigen can be found 
in patients’ homes for up to 18 months after the removal of the bird. This may 
account for the persistence of symptoms in some cases. In severe cases of BFL, the 
preferred option maybe to temporarily relocate the patient away from the room in 
which the bird was housed 251. 
When patients are in the chronic phase of the disease, the disease pattern is one of 
irreversible fibrotic changes and little can be done to improve the clinical picture other 
supportive treatments such as pulmonary rehabilitation 252 and supplementary 
oxygen and in some cases lung transplantation 198. However, when compared 
directly to patients with idiopathic interstitial pulmonary fibrosis causing the same 
amount of fibrosis, the prognosis of patients with chronic EAA was favourable 253.  
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Metal working fluids 
History 
Metal working operations such as drilling, grinding and boring, create significant heat 
as well as other waste products such as metal debris and swarf (metal turnings). 
Metal working fluids (MWFs) are used as coolants and lubricants to facilitate 
manufacture of metal components. The fluids carry away metal chips and protect the 
surfaces of the metal being processed 254.  
As early as 31 BC, Vitruvius who’s ten books, the only work of its kind to survive from 
the Roman world, describes a water pump with bronze pistons and cylinders that 
were machined on a lathe with ‘oleo substracti’, indicating the use of olive oil to 
precision turn the castings 255. In China, Sung Ying Hsing (1637) wrote about the 
advantage of oil in cart axles. Hooke (1685) advised on the need for sufficient 
lubrication for carriage bearings, and Amontons (1699) explained laws of friction in 
machines through experimentation. In the same year (1699), De la Hire described 
the practice of using lard oil in machinery. Desaugliers (1734) suggested that the role 
of lubricant was to fill up the imperfections on the surfaces and act as tiny rollers, and 
Leupold (1735) recommended that rough surfaces should be lubricated with tallow 
(animal based fat) or vegetable oil 256.  
One of those most important factors in the development of lubricants was the 
discovery of huge amounts of petroleum in the USA in 1859. Petroleum at that time 
was largely refined for the production of kerosene for illumination and fuel. Oil was 
considered a by product and as such was discarded. The refiners, forced to find a 
solution to what was becoming an environmental problem, induced industry to use oil 
for lubricant applications. As a result petroleum oil began to replace some of the 
popular animal and vegetable oil-based lubricants 256.  
In 1938 in Germany, Schallbroch, Schaumann and Wallichs provided empirical 
evidence through experimentation, to support the relationship between tool life and 
cutting tool temperature. In the US, during the same time period, Ernst, Merchant and 
Shaw studied the mechanics of the cutting process. Merchant found that the right 
type of cutting fluid could greatly reduce the frictional resistance in both metal 
deformation and in chip formation, as well as reduce the heat produced in 
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overcoming friction. This heralded many more experiments by several researchers. 
Compiling the findings, Ernst, Merchant and Shaw theorised that if they could 
combine those chemicals that had been proved to be effective friction reducers, with 
water, in the form of a stable chemical emulsion, a new cutting fluid having both 
friction reducing and cooling attributes could be created. In 1945, as a result of this 
research, their company compounded a new type of ‘synthetic’ cutting fluid. Two 
years later the same company introduced the first ‘semi synthetic’ MWF. It was a 
preformed emulsion very similar to a soluble oil but with better rust control and chip 
washing action 256.  
 
Modern day 
Transformation in the workplace lagged behind the science with a gradual change 
from neat mineral oil use to the more modern emulsions. The composition of clean 
MWFs is variable between companies and is continually reviewed in the light of 
improving science. Formulations typically contain a 5-7% content of oil (either mineral 
oil, semi synthetic or synthetic oil) in a water emulsion, with other chemical 
constituents to enhance the performance of the product, e.g. emulsifiers, anti-weld 
agents, corrosion inhibitors, extreme pressure additives, buffers (alkaline reserve) 
and biocides 256.  
In use, the fluid complexity is compounded by contamination with substances from 
the manufacturing process (such as tramp oils which refer to hydraulic oil or grease 
leaking from the machinery) and particulate matter from grinding and machining 
operations. Furthermore, water-based metalworking fluids support microbial growth, 
which introduces biological contaminants such as bacterial and fungal cells or cell 
components and their related biological by products such as endotoxins, exotoxins, 
and mycotoxins 257.  
MWFs are used in vast quantities worldwide. In 2007, the United States used 
approximately 420 000 metric tons of MWF, 305 000 metric tonnes were used in 
Western Europe, and 815 000 metric tonnes in the Asia/Pacific region 258. Annually in 
the USA, 1.2 million workers in machine finishing, machine tooling, and other 
metalworking and metal-forming operations are potentially exposed 257. The Health 
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and Safety Executive (HSE) estimates that in the UK there are 100 000 to 200 000 
people that are exposed to MWFs. Workers can be exposed to the fluids by 
breathing aerosols generated in the machining process, or through skin contact when 
they handle parts and equipment covered with the fluids 259.  
MWF is typically sprayed on to the moving parts of machinery, drains away and is 
collected in a reservoir, referred to as a sump, from where it is re-circulated. Some 
metal working machines employ stand alone small volume sumps, where as in large 
plants, many machines can be fed from a single shared sump (e.g. containing more 
than 200,000 litres of MWF) 260. Given the cost of MWFs, the larger reservoirs of 
MWF are typically kept for long periods (months to years) and changes to their 
composition are therefore more likely. The high water content of modern MWFs 
makes them highly susceptible to colonisation both by bacteria and fungi because of 
the combination of the correct requirements for microbial growth, including nutrient 
sources (from the MWF, from water used as a diluent and from dust, swarf and 
debris accumulating in sumps); environmental conditions conducive to microbial 
growth (temperature and aeration; ability to form biofilm on surfaces) and source of 
microbial inoculums (water, dust, swarf and debris). This is exacerbated by the length 
of time MWF is in use but modified by controls to reduce microbial colonisation, 
including MWF management and the addition of biocides where appropriate.  
Consequently, any MWF system in use potentially may have a dynamic population of 
microbial contamination. Typically MWFs are formulated at high pH (pH~9.0) but 
excessive growth of microorganisms can lead to increased acidity. Due to 
evaporative loss, the concentration of emulsion based MWFs can also change which 
impacts on their performance. The accumulation of metal fines and other chemical 
contaminants may lead to deterioration in the performance of a MWF, which 
therefore may need regular monitoring and adjustment 259 261.  
 
Health and Safety 
HSE provides guidelines on mist and fluid control, cleaning and management of 
sumps and bacterial control. Well maintained fluid contains less than 2% tramp oil, 
metal fines below 100 mg per litre of fluid, and less than 103 CFU/ml (1 000 colony-
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forming units per millilitre of fluid) 262. In the early 1990s in the UK, the occupational 
exposure standards (OESs) for highly refined mineral oil mists were derived from the 
work of the American Conference of Govermental Industrial Hygienists and were set 
at 5 mg/m3 for an 8h time weighted average and 10 mg/m3 for short exposures. 
These measurements refer only to the quantity of oil suspended in an air sample. 
However, as modern MWFs are more complex mixtures containing mainly water with 
multiple additives, it was concluded by the Health and Safety Advisory Committee on 
Toxic Substances that the previous OESs should not apply to modern MWFs 
including mineral oil derived MWFs. The committee concluded that due to the lack of 
evidence of an inhalation level that would not cause ill health, it was not possible to 
derive a new safety standard. In the absence of OESs, HSE developed a package of 
guidance regarding the assessment and control of personal mist exposure, good fluid 
management and correct training, in order to try and effectively manage health risks 
associated with exposure to MWFs 259 263. 
In the USA, in 1998, The National Institute of work Safety and Health (NIOSH) 
recommended that exposures to MWF aerosols be limited to 0.4 milligrams per cubic 
meter of air (thoracic particulate mass – particles that can penetrate the upper 
airways and enter the lungs) or 0.5 milligrams per cubic meter of air (total particulate 
mass), as a time-weighted average concentration up to 10 hours per day during a 40-
hour working week. The recommended exposure limit (REL) is intended to prevent or 
greatly reduce respiratory disorders associated with MWF exposure. It is 
acknowledged that some workers have developed adverse respiratory effects when 
exposed to MWFs at lower concentrations 257.  
In 2002 a survey lead by HSE, of 24 sites using MWF in the UK found that fluid 
management was found to be of a poor standard with high levels of bacteria, 
endotoxins and metal fines in sumps. Control of other factors such as water-mix fluid 
concentration was also poor. However, in general, occupational exposure to mineral 
oil MWF mist was controlled to <3 mg/m3 (8h time weighted average) and water 
mixed MWF mist to <1 mg/m3. Although these values did not necessarily represent 
best or safe practice, they were thought to be representative of the industry as a 
whole and were instituted as the new guidance values 259 263.  
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Disease associated with MWFs 
Until the middle of the 20th century, the primary route of personal exposure to MWFs 
was through the skin. Consequently, historically, the use of neat mineral oil as a 
MWF was associated with skin disease such as folliculitis (inflammation of the hair 
follicles), dermatitis, and skin cancer 260. These problems were found mainly on 
exposed areas, for example the neck, hands, arms and thighs. The association 
between exposure to mineral oils and squamous cell cancer of the skin, particularly 
the scrotum, has been well documented since the 1800s 264-266. The International 
Agency for Research on Cancer has concluded that hydrocarbon mineral oils used in 
metal machining are carcinogenic 267. At this time respiratory problems were not 
commonly reported and largely restricted to a rare lung condition called lipoid 
pneumonia, due to oil retention within the lung 268 269 
With the introduction of high speed machinery, significant exposures to MWFs can 
potentially occur via inhalation of the mist. This change in technology and the 
resultant change in the possible route of entry have turned public health attention 
toward potential effects on the digestive and respiratory systems. A number of 
papers have discussed the potential increased risk of cancer associated with 
exposure to MWF, especially to straight oils 270. Significant associations have been 
made between straight oil exposure and an increase risk of bladder, oesophageal, 
laryngeal, colon, rectal cancer and malignant melanoma 271-275 276 
Other researchers have noted association between soluble MWF and cancer of the 
larynx, oesophagus, skin, and brain, and noted a relationship between synthetic 
MWF and cancer of the oesophagus, liver, and prostate 274 276. The carcinogenicity of 
MWFs is beyond the remit of this thesis. 
Despite a move away from mineral oil based MWFs, dermatological problems remain 
prevalent, from both irritant and allergic contact dermatitis 277. Soluble metal working 
fluids are strong alkaline solutions (pH of approximately 9) and contain numerous 
additives and solvents. These solutions may cause irritant dermatitis by removing the 
natural protective oils from the skin, and directly damaging skin proteins. Allergic 
dermatitis is less common than irritant dermatitis, but allergic skin responses may 
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occur due to additives in MWFs and dissolved metal impurities such as chrome, and 
nickel 260.  
Over recent decades, the changing composition of MWFs has been accompanied 
with a change in the associated occupational disease profile. In addition to skin 
disease, the use of water-based MWFs has led to an increase in respiratory 
diseases, It has become evident that as well as dermatological conditions, outbreaks 
of respiratory disease have been reported particularly OA and EAA, but also 
bronchitis and humidifier fever. For those physicians specialising in occupational lung 
disease, the presence of individuals suffering from these conditions has illustrated 
the emerging problem. 
In 1983, Hendy et al. described one of the first reported cases of OA secondary to 
MWF in the UK 278. Subsequently in 1998, Robertson et al. wrote a case series of 
twenty five patients occupationally exposed to MWFs and who had been referred to 
an occupational respiratory clinic with work-related asthmatic symptoms 261. MWF as 
a potential cause of EAA amongst machinists was first identified by Bernstein et al. in 
1995. They reported a case series of six workers from an automobile manufacturing 
site, exposed to a synthetic MWF 279. In 1997, due an increasing awareness of 
outbreaks of respiratory ill health associated with MWF exposure, a workshop was 
set up to discuss eight clusters of EAA. They concluded that a risk exists for this 
granulomatous lung disease where water-based fluids are used and unusual 
microbial contaminants predominate. The workshop participants identified knowledge 
gaps regarding risk factors, exposure-response relationships, intervention efficacy 
and natural history, as well as surveillance needs to define the extent of the problem 
in this industry 280. The thesis will cover the association between MWFs and allergic 
respiratory disease in detail. 
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Aims of this research 
 
1. To better understand MWF-related health problems by firstly reviewing the 
findings from previous outbreaks.  
2. To analyse data from a large UK outbreak in order to develop guidance for 
use in future health investigations.  
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Chapter 1: Review of outbreak investigations of ill health 
associated with the use of Metalworking Fluids 
 
Introduction 
Although cases of OA and EAA due to MWF exposure had previously been 
described, the first major UK outbreak was investigated by HSE in June 2005.  This 
was at the Longbridge Powertrain plant, where engines were constructed for the car 
industry 260 281.  An investigation was triggered following the diagnosis of twelve 
individual cases of EAA in workers from this site. Extensive clinical, microbiological, 
immunological and hygiene studies were completed. Attention was focused on the 
use of water based MWFs and wash fluids (used to clean machined engine 
components). Out of a total workforce of 836, 87 workers (10.4%) met case 
definitions for occupational lung disease, comprising 19 cases of EAA, 74 cases of 
occupational asthma, and 7 cases of humidifier fever. Despite a very detailed 
outbreak investigation, the cause of the outbreak was never fully established. Results 
of air monitoring between May 2002 and October 2003 showed that concentrations of 
MWF in the air were generally below the HSE guidance value of 1mg/m3 259 263. In 
October 2003 the levels of mineral oil mist in air were between 1 and 4 mg/m3 with an 
average concentration of just above 1mg/m3. Although microbial 
contamination/endotoxin levels were low in the main shared MWF reservoirs, 
individual MWF sumps and component wash machine fluids were very heavily 
colonised.  Bacterial contamination was therefore implicated in the outbreak and the 
majority of the cases of EAA showed immune precipitin responses to these bacteria 
260. The occurrence of this large outbreak demonstrated that adherence to the 
Occupational Exposure Standard (5 mg/m3 for a 8-hour time-weighted average 
reference based on the measurement of oil mist) applicable in the UK at that time, 
did not prevent cases of respiratory disease 259 263.  
The results of the Powertrain investigation served to highlight the difficult area of ill 
health and occupational exposure to MWF, which led to the subject being formally 
discussed by the government Working Group on Actions to Control Chemicals 
(WATCH). Members of WATCH commented that previously published literature 
suggested a possible difference in the geographical distribution of cases of 
respiratory disease versus reported skin disease, attributable to MWFs 282. For 
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example, it was noted that Nordic countries had reported very little respiratory 
disease and more commonly reported skin disease (i.e. dermatitis). The UK and USA 
were the countries that had experienced large outbreaks of respiratory disease 
amongst staff working with water based MWF. It was asked whether this difference 
was attributable to the way that MWFs were managed or was a consequence of the 
way that occupational illness is investigated and reported in these countries. At a 
subsequent WATCH meeting (June 2007), recommendations were made to review 
published studies, papers and reports from around the world referring to outbreaks of 
disease amongst MWF workers 283. 
To enable a full assessment of the international scale and distribution of outbreaks it 
was important to review international published and non-published studies of ill 
health outbreaks attributable to work with water based MWFs. Data about the 
potential 'triggers' for these investigations of ill health, the methodology employed 
and the outcome of each investigation was summarised (see appendix 1). The 
objective was to seek explanations for the apparent differences in the reported 
prevalence of respiratory and skin disease between these countries. 
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Methodology 
To better understand the demographics of disease associated with MWFs a two 
phased approached was utilised. In the first stage a detailed literature search was 
carried out, to identify and review all previously published 'outbreak' investigations 
related to ill health associated with use of water mix MWFs. For the second stage, in 
an attempt to gain further information, contacts were made with European 
occupational ill health reporting networks.  
 
Literature review of published outbreaks 
Before commencing the literature searches an experienced team (consisting of two 
occupational lung disease specialists, two microbiologists and an immunologist) 
identified appropriate search terms in consultation with the HSE library information 
search team. These terms were divided into two groups (Table 3).  
Searches were carried out combining each term in list one with each term in list two. 
The searches were based upon proximity of these terms i.e. appearing in any order 
within the document abstract but no more than five words apart. The HSE library 
services then independently completed the search on OSHROM (HSELINE, 
NIOSHTIC, CISDOC, RILOSH and OSHLINE) databases, Embase, Medline, 
Healthsafe and Web of Science (Table 4), between 1990 (prior to the large scale 
introduction of water based MWF) and October 2008. 
A total of 1346 references were located and the titles and abstracts of these reviewed 
by relevant specialists within the team. Relevant references were identified and 
allocated to topic groups based on content and relevance to the review. Following 
this sift a total of 331 'relevant' studies were short listed and entered into Endnote 
reference database (Table 5). 
The selected publications were further sifted by the team to select studies that 
reported the outcome of investigation of ill health associated with MWFs (this 
included reviews of ill health related to use of MWFs). The inclusion and exclusion 
criteria used for this sift are summarised in Table 6. 
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The second sift resulted in a total of 40 studies that met the inclusion criteria and 
which documented incident investigations of respiratory and skin disease attributed 
to water based MWF. Each publication was read in detail and the background, 
methodology and results summarised. On closer inspection articles that no longer 
met the criteria laid down in Table 6 were excluded.  Some of the discarded articles, 
although not referring directly to an outbreak of ill health associated with MWF, were 
reviews of outbreak investigations, which summarised useful information.   
The final sift of the papers resulted in thirty-five relevant articles, twenty-nine 
concerning outbreaks of ill health attributed to MWF. Seventeen publications 
concerned outbreaks of respiratory disease only, four outbreaks of skin disease only 
and eight outbreaks of skin and respiratory disease. Review articles were also 
examined and those that referred to outbreaks of disease were used as supporting 
evidence. These details are summarised in Table 7.  
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Table 3: Summary of search terms  
List 1 List 2 
Asthma MWF 
Bronchitis Metalworking (near) fluid 
Breathing difficulties Metal (near) working (near) fluid 
Irritant (near) respiratory Cutting fluid 
Hypersensitivity (near) pneumonitis Sud (near) machine (near) metal 
Impaired (near) lung (near) function Coolant/s (near) machine (near) metal 
Extrinsic (near) allergic (near) 
alveolitis 
Slurry (near) machine (near) metal 
Respiratory (near) disease Soap (near) machine (near) metal 
Respiratory (near) problem Metal removal fluid/s 
Humidifier (near) fever Lubricant/s/lubrication 
Health Oil mist 
Outbreaks Machining (near) fluid 
Skin  
Dermatitis  
Reversible airway obstruction  
Investigation  
Epidemiological 
 
 
Table 4: Summary of publication databases searched 
Search engine No references 
found 
OSHROM (HSELINE, NIOSHTIC, CISDOC, RILOSH & 
OSHLINE) 
566 
Embase and Medline, 388 
Web of science 306 
Healthsafe 86 
Total 1346 
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Table 5: Summary of number of papers for each topic related to MWF 
Topic of reference No abstracts 
Immunology 35 
Microbiology 82 
Exposure studies 96 
Clinical investigations of lung disease 37 
Clinical investigations of skin disease 48 
Outbreak investigations of lung disease 57 
Outbreak investigations of dermatitis  21 
Review articles about MWF and ill health 60 
Review articles about specific respiratory conditions and 
MWF 
10 
Review articles about specific dermatological conditions and 
MWF 
10 
Review articles about 'general health' problems and MWF 16 
 
Table 6: Summary of criteria used to select incident investigations 
Criteria used to identify incident investigations of ill health associated with 
MWF  
 
Inclusion criteria 
Outbreaks had to involve more than one worker at a particular site 
Evidence that the workers suffering ill health had been exposed to MWFs 
Clinical studies that were precipitated by evidence of an outbreak 
 
Exclusion criteria 
Outbreaks of ill health associated with use of neat MWF oils were excluded 
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Table 7: Summary of the incident investigation studies  
Category No 
articles 
Not related to 
topic 
Outbreaks of lung disease  31 25 
Outbreaks of skin disease 12 12 
Simultaneous outbreaks of lung and skin 
disease 
8 8 
All outbreaks 35 29 
 
Other relevant publications 
  
Reviews about general ill health due to 
MWF 
3  
Reviews about lung disease outbreaks due 
to MWF 
3  
Reviews about dermatological disease due 
to MWF 
2  
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Data from national reporting schemes and other experts  
To identify further useful information about the relative incidence of respiratory and 
dermatological ill health associated with use of MWFs, government bodies, national 
reporting schemes, and experts were contacted.  
The American National Institute for Occupational Safety and Health (NIOSH) 
investigates symptoms or cases of disease thought to be occupational in origin. Their 
investigations are all published on their website and had been identified on the 
previous library based literature search 284. 
The PEROSH (Partnership for European Research in Occupational Safety and 
Health) website (with links to fifteen European institutes of Occupational Safety and 
Health in fourteen countries) was examined for content related to cases of ill health 
associated with MWF 285.  Direct contact with PEROSH staff was made, resulting in 
additional data from National reporting schemes in the UK (THOR), France (French 
national occupational disease surveillance and prevention network), the Netherlands 
(Nederland's Centrum voor Beroepsziekten), Czech Republic (the Czech Registry of 
Occupational Diseases), and Finland (from the Surveillance of Working Conditions 
and Health at the Finnish Institute of Occupational Health).  
The European Agency for Safety and Health at Work website was also examined for 
information on outbreak investigations or reported data on ill health associated with 
MWF 286. 
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Results 
General summary of the incident investigations of respiratory and skin disease 
at plants using metal working fluids 
The outbreaks showed a peak incidence between 1996-2000 (Figure 1). The date 
allocated is, where it could be identified, the date of diagnosis of the sentinel case, 
and where this was not available, the date on which the outbreak was recognised. In 
some cases there was a lag time (sometimes a few years) between initial case 
diagnosis and the investigation of the outbreak, and between the investigation of the 
outbreak and subsequent publication of investigation.  
 
Figure 1: Year of onset of outbreak of respiratory and skin disease 
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Twenty-nine outbreak investigations met the full criteria for inclusion in the review i.e. 
involved ill health in one or more workers from any particular site, with evidence of 
exposure to water based MWFs. Summary details for these are provided in the 
following figures. Most of the outbreaks reported respiratory disease, either in 
isolation, or in association with skin disease (Figure 2a). The majority of these 
originated in the United States (Figure 2b), most commonly in the car manufacturing 
or aerospace industry (Figure 3a), and predominantly in large workplaces (Figures 3b 
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and 3c). Seventeen publications concerned outbreaks of respiratory disease only, 
four outbreaks of skin disease only and eight outbreaks of skin and respiratory 
disease (Table 8) 
 
Table 8:  Summary of the published incident investigation outbreaks  
Disease(s) investigated  Number of  
published papers 
Locations of 
investigations 
 
Respiratory disease only 
 
17 
 
14 (USA) & 3 (UK) 
Skin disease only  4 4 (USA) 
Respiratory & skin disease 8 7 (USA) & 1 (Croatia) 
Total 29 
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Respiratory
Mixed
Skin
14%
28%
58%
UK
USA
Croatia
3% 10%
87%
Fig 2a
Fig 2b
Figure 2a and 2b: a) Proportion of outbreaks by type of ill health investigated; 
b) country of outbreak where ill related to use of MWF investigated 
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Figure 3a, 3b & 3c: a) Outbreak of ill health by type of industry using MWFs; b) 
outbreaks by numbers of exposed workers; c) outbreaks by total number of 
employees at plant 
Automobile
Aerospace
Others
28%
14%
58%
<100
100-250
>250
24% 29%
47%
Fig 3b
Fig 3a:
<500
500-1000
>1000
18%
27%
55%
Fig 3c
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Figure 4a, 4b & 4c:  a) Type of MWFs used by companies where outbreaks of 
illness occurred; b) Use of MWF sumps at companies where outbreaks of 
illness occurred c) Types of micro-organism identified at outbreaks of ill health 
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Outbreaks of ill health have been described with exposure to all types of water based 
MWFs (Figure 4a), and more commonly linked to machines with shared central 
sumps, rather than individual sumps (Figure 4b). Microbial contamination of MWFs 
was commonly found during outbreak investigations (Figures 4c).  Most commonly 
isolated were Gram-negative bacteria in different taxonomic groups (80% of all 
identified isolates). Although mycobacteria (irregular non sporing Gram positive rods) 
were reported as being isolated in 59% of outbreak investigations, they comprised 
only 3% of the identified isolates (Figure 5). 
 
Figure 5: Types of bacteria identified at outbreaks of ill health 
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Gram negative aerobic/ micro aerophilic rods & cocci
Gram negative facultative anaerobic rods
Vibrionaceae
Gram positive cocci
Endospore forming gram positive rods
Irregular, non spore forming gram positive rods
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Table 9:  Summary of incident investigations of respiratory ill health  
Year of 
initial case 
Country Industry Workforce Exposed 
workers 
MWF aerosol levels Type of MWF used Ref 
1983 UK Aeronautical NA NA Oil mist 0.66 mg/m
3
 Soluble/water mixed, neat 
261 278
 
1992 USA Automobile NA 16 NT Synthetic 
279
 
1994 USA Automobile (3 sites) NA NA NT Soluble 
287
 
1995 USA Automobile 1,592  
Oil mist mean 0.8 mg/m
3
, total 
particulate mean 1.0 mg/m
3
 (<REL) 
Synthetic 
1
 
1995 USA Automobile 1600 800 Oil mist < REL Synthetic, soluble/water mixed 
288
 
1996 USA Automobile NA 265 
3 PBZ > REL  
0.08-1.17 mg/m
3
 
Soluble/water mixed, semi 
synthetic 
289
 
1997 USA Aeronautical 1600 80 20/21< REL Soluble/water mixed 
290
 
1997 USA Firearms 1100 450 
39 samples for oil mist. Mean 0.66 
mg/m
3
 
Semi synthetic 
291
 
1997 USA Aeronautical 120 105 
 All < REL 
0.09-0.38 mg/m
3
 
Neat oil, soluble/water mixed, 
semi synthetic, synthetic 
292-294
 
1997 USA Automobile 1000 338 
5 out of 9 >REL 
0.33-1.29 mg/m
3
 
Soluble/water mixed, semi 
synthetic neat oil, 
295
 
1999 USA Automobile  (3 sites) 700 NA NT NT 
296
 
1999 USA Automobile 462 250 4 out of 70  REL Semi synthetic 
297
 
2000 USA Automobile 400 150 0.059-3.5 mg/m
3
 Semi synthetic 
298-300
 
2000 USA Automobile 2000 NA All but 1 < REL Semi synthetic 
301 302
 
2003 USA Automobile (3 sites) 942(mean) NA All < REL Semi synthetic 
303
 
2003 UK Automobile 836 NA Generally < HSE guidance Soluble/water mixed 
260 281
 
2005 UK 
Small component 
manufacture 
<50 21 NT Soluble/water mixed 
304
 
 
Note:  REL = recommended exposure limit set by NIOSH. 
*NIOSH recommends a REL MWF aerosol of 0.4 mg/m
3
 thoracic particulate (the proportion of the aerosol that penetrates below the larynx in the respiratory 
system) as a time weighted average (TWA) concentration for up to 10 hours per day during a 40 hour week. Measurement of total particulate is an acceptable 
substitute for measuring thoracic particulate and the NIOSH REL is 0.5mg/ m
3
 
257
.  
HSE guidance for MWF concentration in air: 1mg/m
3
 and for mineral oil mist in air: 3mg/m
3
 
259 263
. 
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Table 10:  Summary of respiratory conditions and immunology test in incident investigations of respiratory ill health  
Year of 
initial case 
Respiratory symptoms/diagnosis 
other than EAA and OA 
Cases of EAA Cases of OA Immunological tests Ref 
1983   13 
(+7 equivocal OA) 
NT 
261 278
 
1992  6 (diagnostic criteria not 
documented) 
 All 6 
+
ve
 
IP test to Pseudomonas 
sps 
279
 
1994  6 (D) confirmed by biopsy 
14 (P) cases 
 2 workers tested, -ve IP to 
standard commercial antigen 
panel (bac, fungi, avian) 
287
 
1995 12(OB), 6 (B), 3 (COPD), 10 (other) 
Out of 71 who self reported symptoms 
and were then assessed by a physician 
20 cases 
10 (D), 5 (P), 4 (Po) (+ 2 that 
were diagnosed by a physician 
but did not the meet diagnostic 
criteria) 
3 -ve IP to unused MWF, biocide or 
lysed  M. Chelonae. +ve IP to 
used MWF. 
1
 
1995 6 (OB) 7 (physician diagnosed) 12 All EAA cases 
+ 
IP test to used 
MWF, strongest +IP to 
Acineobacter. All EAA cases 
- 
ve 
IP test to M. chelonae, biocides 
and Xanthomas maltophilia 
288
 
1996  14 (physician diagnosis)  
+
ve IP test against M.chelonae 
289
 
1997 Of 84 (79% of exposed workers) who 
completed questionnaire: 
S: 57% of EX  ‘v’ 43% of UEX; 
TC: 29% of EX vs 13% of UEX; 
GA: 40% of EX vs 23% of UEX; 
SB: 30% EX vs 19% of UEX; 
C: 39% EX vs 26% of UEX. 
  NT 
290
 
1997 Of 515 Ex workers and 435 Uex 
Symptoms > EX than UeX 
SB: 11% of EX: v 5% of UeX 
C:  26% of EX v 11% of UeX 
  NT 
291
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1997 B:  2 cases 
 
38 cases, 16 of which are 
biopsy proven. (does not 
differentiate P/Po/D) 
  
292-294
 
1997 35 of 131 EX  questionnaire 
respondents had WR ‘v’ 4 of 131 
UNEX. 
1  NT 
295
 
1999  8 (physician diagnosed) 
(over 3 work sites) 
  IgG to Mycobacterium + other 
organisms 
296
 
1999 229 of 462 workers over 3 sites, one of 
which (dept 8700) was the source of 
complaints of ill health, responded to a 
questionnaire. 41 of 66 respondents 
from Dept 8700 had C ‘v’ 46 of 163 
respondents from other departments. 
 2 (+ 8 workers with 
an asthma like 
condition not 
diagnosed as OA) 
NT 
297
 
2000 3 (OB), 2 (RS), 1 (SB) 
 
30 (18 physician diagnosed and 
12 with criteria) 
14 NT 
298-300
 
2000  7 
3 (D), 2 (P), 2 (Po) 
 IL-8 levels  in exposed. 
+
ve IP (to M.chelonae + fusarium) 
>EAA than  non-EAA 
301 302
 
2003  7 (physician diagnosed)  NT 
303
 
2003 15 (OB), 7 (HF) 19(at least Po) 74 10/12 cases of EAA had +ve IP 
test to  1 microbe 
260 281
 
2005 6/8 (WR) 
2/8  (SS) 
1 (physician diagnosed)  +ve IP in 4/11 cases  to 
Pseudomonas sps 
304
 
  
Tests:         ND not detected; NT not-tested 
Symptoms:      C cough; GA generalised aches; SB shortness of breath; W wheeze; WR work related respiratory symptoms;  
                                           RS respiratory symptoms; SS 'flu like' systemic symptoms, S Sinus symptoms; TC tightness of  chest 
Respiratory diagnosis: B  bronchitis not necessarily occupational; HF  humidifier fever; OB occupational bronchitis; RS rhinosinusitis; UIP usual 
                                           interstitial pneumonitis,         
Description of cases:       D definite cases; P probable cases; Po possible cases; 
Exposure:      W entire workforce; EX exposed; UEX unexposed 
 49 
Table 11: Microbiological investigations in incident investigations of respiratory ill health  
Year of 
initial case 
Presence of micro-organisms Viability CFU/ml of MWF Viability in air CFU/m
3
 
 
Ref 
1983 
Klebsiella, Proteus, Bacillus, no fungi, Myc not 
mentioned 
NT NT 
261 278
 
1992 
Pseudo, Aspergillus, Staph, Rhodococcus, Bacillus. Myc 
in sputum. 
<10 CFU/ml (fungi) 
1.1X10
6
-1.3x10
6
/ml (bacteria) 
NT 
279
 
1994 NT NT NT 
287
 
1995 >100 different isolates incl. bacteria,  fungi + Myc NT NT 
1
 
1995 Several diff isolates incl. Bacillus, Pseudo + fungi + Myc ND 525 – 4200 CFU/m
3
 
288
 
1996 Myc was predominant microbe, also Pseudo + fungi 1.4x10
3
 – 1.0 x10
7 
CFU/ml 26-363 microbes/ft
3
 
289
 
1997 ND ND ND 
290
 
1997 Several different isolates incl. fungi + Myc <10
1
 to >3 x 10
7 
CFU/ml NT 
291
 
1997 
Several different isolates incl. Moraxella, fungi + Myc in 1 
sump only 
Mean 10
7 
CFU/ml Mean 388 CFU/m
3
 
292-294
 
1997 Several different isolates incl. Pseudo + fungi + Myc ND NT 
295
 
1999 Myc, Pseudo, Bacillus, fungi, yeasts Up to 10
7
 CFU/ml some > 9 424 CFU/m
3
 
296
 
1999 Gram –ve + fungi 6.3x10
5
 – 2.5x10
8
 CFU/ml NT 
297
 
2000 Several other isolates incl. Myc + fungi Up to 10
7 
CFU/ml NT 
298-300
 
2000 Myc + fungi NT NT 
301 302
 
2003 Myc ND ND 
303
 
2003 Acinebacter, Ochrobacter None in main sump NT 
260 281
 
2005 Fusarium, Pseudo, fungi 
50% samples < 100 CFU/ml, 
others 1.4 x 10
5 
– 8.2 x 10
6
 CFU/ml 
1.2x10
4
 – 2.1x10
7 
CFU/m
3
 
304
 
 
Tests:   Myc Mycobacterium chelonae; Pseudo Pseudomonas; CFU viable colony counts; ND not detected; NT not-tested; ml millilitre; m
3
 cubic 
metre of air 
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Table 12:  Summary of incident investigations of respiratory and skin disease  
Year of 
initial case 
Country Industry Exposed/total workers MWF type Aerosol MWF Ref 
1988 USA Automobile 152/NA* Soluble/water mixed 
Oil mist 7 PBZ 0.14mg/m
3
 – 
1.08 mg/m
3
 
305
 
1990 USA Aluminium ingots 150//NA ND NT 
306
 
1990 USA Roof bolts 55/66 Soluble/water mixed PBZ 0.16 – 1.06 mg/m
3
 
307
 
1998 USA Automobile NA/850 Straight + Semi synthetic 2/7 PBZ > REL 
308
 
1998 Croatia Automobile NA/ /NA Soluble/water mixed  
309
 
1999 USA Aerospace 204/345 
Soluble/water mixed 
+ Synthetic 
1/55 > REL 
310
 
2003 USA Steel bars and coils 50/NA 
Straight + Soluble/water 
mixed 
All 4 PBZ > REL 0.57 – 2.6 
mg/m
3
 
311
 
2005 USA Bicycle 30-40/520 Soluble/water mixed  
312
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 Table 13: Summary of incident investigations of respiratory and skin disease  
Year of 
initial case 
Respiratory 
symptoms 
OA Skin symptoms Microorganisms 
&  M. chelonae 
Microorganisms  
in MWF 
Ref 
1988 
NA 
(C + SB) 
NT 10/13 (R) NT NT 
305
 
1990 
6/78 
(acute WR) 
NT 
70% eye irritation 
44% skin irritation 
Predominantly gram +ve NA 
306
 
1990 8/37 (B) NT 14/37 (R) Mainly Pseudo sps 2.5x10
6
 – 2.5 x 10
8
 CFU/ml 
307
 
1998 
5/13 
(SB + Wh) 
NT 5/13 (R) NT NT 
308
 
1998 
18 of W 
(B/Pn) 
NT  NA/20 (SI) 
Several diff isolates incl. 
pseudo + yeast 
Average = 3x 10
5
 CFU/ml 
309
 
1999 
64/188 EX (SB) 
10/92 UEX (SB) 
1 (+ 8 A) 
63/188 EX(R) 
9/92 UEX (R)  
Bacillus sps + Pseudo sps 1/55 PBZ > REL 
310
 
2003 
12/35 interviewed 
(RS) 
NT 11/31 interviewed (R) 
Several diff isolates 
No fungi or Myc 
Up to 4.2 x 10
5 
EU/ml 
311
 
2005 2/12 (RS) NT 12/34 (R) NT NT 
312
 
 
Tests:      ND not detected; NT not-tested; NA not available 
Respiratory Symptoms:  C cough; SB shortness of breath; Wh wheeze; WR work related respiratory symptoms; RS respiratory  
symptoms; SS 'flu like' systemic symptoms 
Respiratory diagnosis: B bronchitis not necessarily occupational; HF humidifier fever; OB occupational bronchitis; A asthma, not proven to be work 
related; RS rhinosinusitis; UIP usual interstitial pneumonitis  
Skin symptoms:   R rash 
Skin diagnosis:   ID irritant dermatitis; AD allergic dermatitis; SI skin infection;        
Description of cases:    D definite cases; P probable cases; Po possible cases; 
Exposure:     W entire workforce, EX exposed; UEX  unexposed 
Other symptoms:  WR work related respiratory symptoms; RS respiratory symptoms; SS (flu like' systemic symptoms; OI ocular irritation 
Tests:      CFU viable colony counts; ND not detected; NT not-tested, ml millilitre; m
3
 cubic metre of air 
 
Note: No case of EAA reported in these studies and no immunological tests described. 
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Table 14:  Summary of incident outbreaks of skin disease only in date order  
Year of 
initial case 
Country Industry Exposed/total MWF type Aerosol MWF Ref 
1986 USA Hydraulic pumps 140/NA NA NT 
313
 
1995 USA Automobile NA/NA Soluble/water mixed Oil mist: 0.27-0.47 mg/m
3
 
314
 
2000 USA Air compressors NA /350 
Neat oil  
+Soluble/water mixed 
 + semi synthetic 
+Synthetic oil 
50% > REL 
315
 
2003 USA Automobile NA/NA 
Soluble/water mixed 
Semi-synthetic oil 
Synthetic oil 
NT 
316
 
 
 
Table 15: Summary of clinical investigations of incident involving skin disease only in date order  
Year of 
initial case 
Skin Microorganisms 
&  M. chelonae 
Ref 
1986 30/55 interviewed and examined (D)  NT 
313
 
1995 8/8 interviewed (R) Several gram –ve, no fungi 
314
 
2000 5/12 interviewed (R) Pseudomonas sps + Citrobacter sps 
315
 
2003 
57% exposed (R) 
0% unexposed 
Several isolates of bacteria and a yeast 
316
 
 
Exposure:          REL recommended exposure limit set by NIOSH at 0.4/mg m
3
 in 1999 for an 8hr TWA 
Specific skin symptoms:         D (dermatitis); ID (irritant dermatitis); AD (allergic dermatitis); SI (skin infection); R  (rash) 
Other symptoms:  WR (work related respiratory symptoms); RS (respiratory symptoms); SS ('flu like' systemic symptoms);  
                                                    OI (ocular irritation) 
Tests:                 NA (not available); ND (not detected); NT (not-tested) 
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Additional evidence provided by reporting schemes and experts 
The second phase of the review involved collecting information through the Health 
and Safety Laboratory’s (HSL’s) European and American network of contacts and by 
examining websites for national reporting data. Details from a range of countries 
were made available, including information, of varying detail from France, the 
Netherlands, Switzerland, Austria, Germany, Czech Republic, Italy, Spain, Finland 
and Canada. Through HSL contacts, unpublished data also was obtained for the UK 
from The Health and Occupation Reporting Network (THOR), and from other 
European occupational reporting networks. Data was received from the Czech 
Republic, the Netherlands, and Finland. The websites of Partners in the European 
Research into Occupational Safety and Health (PEROSH) 285 and the European 
Agency for Safety and Health at Work 286 were searched for information on outbreaks 
of ill health associated with MWF. 
 
USA 
No national reporting data could be identified from the USA. NIOSH have completed 
forty-one Health Hazard Evaluation (HHE) reports because of complaints of ill health 
associated with MWF. Between 1998 and 2006, NIOSH received a total of twenty-
three HHE requests concerning exposure to MWFs. The results of the twenty three 
NIOSH evaluations indicated that thirteen of the fifteen facilities where air samples 
were collected, had air concentrations of MWF mist above either the US REL of 0.5 
mg/m3 for total MWF particulates or 0.4 mg/m3 for the thoracic particulate mass (as a 
time-weighted average concentration for up to 10 hours per day during a 40-hour 
work week). Spirometry and medical record reviews revealed respiratory symptoms 
in thirteen of the facilities, skin symptoms in twelve, occupational asthma in three, 
and hypersensitivity pneumonitis in three. This collection of investigations showed 
almost an equal split between skin and respiratory disease. 
When comparing the NIOSH investigations, there was great variability in the extent to 
which these investigations were carried out. This concern was recognised by NIOSH 
and currently is under review. Some of these investigations were very extensive and 
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involved screening of the entire workforce, with detailed clinical investigations 
alongside exposure monitoring and microbiological and immunological tests. Some of 
the outbreaks originally investigated by NIOSH were also followed as a longitudinal 
studies with detailed mapping of MWF aerosol emissions and the application of 
diagnostic criteria for EAA 293 298. Other investigations involved small-scale sampling 
of the work force, with a limited clinical and hygiene investigation. These samples 
either consisted of workers randomly assigned for investigation or ill workers selected 
by the union and management. After questioning, those that stated they had 
symptoms were not always offered further evaluation. 
 
UK 
Within the UK, some cases of occupational disease are reported to The Health and 
Occupation Reporting Network (THOR). This is a research and information 
dissemination programme reporting on the incidence of occupational disease and 
work-related ill health. The programme consists of a group of closely linked national 
occupational health surveillance schemes dating back to 1989. Data is collected from 
a research network of over 2000 specialist physicians and specially trained General 
Practitioners throughout the UK. The data is collated, stored, analysed, reported and 
disseminated by the Occupational and Environmental Health Research Group at the 
University of Manchester. Chest physicians report cases of work-related respiratory 
disease to the Surveillance of Work-Related Respiratory Disease scheme (SWORD). 
Approximately 490 respiratory physicians throughout the UK participate in reporting 
occupational respiratory disease. Twenty one of these are 'core' reporters who report 
every month; the remainder are sample reporters who are sampled at random and 
report for one month only each year. Consultant dermatologists report work-related 
skin diseases to the Occupational Skin Surveillance scheme (EPIDERM). A reporting 
scheme for occupational physicians (OPRA 1996) also records occupational ill health 
317. 
THOR data shows, overall, much greater numbers of reported skin disease 
compared to respiratory disease caused by MWF exposure. Between 1993 and 2007 
there were six hundred and sixty six cases of contact dermatitis reported to 
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EPIDERM (Figure 6a and 6b) compared to two hundred and sixty three estimated 
cases of respiratory disease reported to SWORD (Figure 7a and 7b). It is recognised 
that due to the design of the scheme, these are likely to be underestimates of the 
total number of cases, although the relative proportion of skin and respiratory disease 
may be more accurate. This data suggests that skin disease attributed to exposure to 
MWF has a higher incidence than respiratory disease in the UK however because of 
the Powertrain outbreak, in 2004 the incidence of respiratory disease overtook that of 
dermatitis318. The impact of respiratory disease compared to skin disease is 
potentially more significant on a personal level and this information is not reflected by 
comparing incidence. 
Between 1996 and 2007 occupational physicians reported five actual (twenty seven 
estimated) cases of work-related respiratory disease attributed to metal working 
fluids to OPRA. Of these cases, 60% were diagnosed as occupational asthma, 20% 
inhalation accidents and 20% other respiratory disease (a diagnosis of chrome 
rhinitis). Occupational physicians reported ninety-two actual (598 estimated) cases of 
work-related contact dermatitis attributed to MWF. The most frequently reported 
industry sector for work-related contact dermatitis cases attributed to metal working 
fluids was manufacture of metal components, motor vehicles, and trailers 318.   
HSE runs a separate reporting scheme. The Reporting of Injuries, Diseases and 
Dangerous Occurrences Regulations 1995 (RIDDOR) places a legal duty on: 
employers, self-employed and people in control of premises; to report work-related 
deaths, major injuries or over-three-day injuries, work related diseases and 
dangerous occurrences (near miss accidents). The RIDDOR came into effect on 1 
April 1996. The Regulations only apply to England, Scotland and Wales (Northern 
Ireland will develop similar proposals at a later date). Reports are submitted to the 
health and safety enforcing authorities and the information used to target action to 
improve ill health prevention and control 319. 
HSE provides a list of reportable diseases and a corresponding list of causative 
agents. Only if an employee develops a disease linked to a corresponding activity is 
it reportable through RIDDOR. At the time of this research, occupational dermatitis 
caused by MWFs was a reportable condition and therefore employers were legally 
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obliged to report it through RIDDOR; this is not the case for EAA caused by MWF 
exposure 319. 
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Figure 6a & b: a) Work related dermatitis recorded in EPIDERM (1993-2007) 
attributable to MWFs b) Work related dermatitis recorded in OPRA (1996-2007) 
as attributable to MWFs 
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Figure 7a & b: a) Cases of work related respiratory disease recorded in SWORD 
(1989-2007) as attributable to MWFs b) types of work related respiratory 
disease recorded in SWORD (1989-2007) as attributable to MWFs 
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France 
Observatoire National des Asthmes professional (ONAP) involves a network of 
occupational and chest physicians who are asked voluntarily to report cases of 
occupational asthma. Between 1996 and 1999 they identified 2178 cases of OA. 
Papers reviewing their findings detail the most common causes of OA as flour, 
isocyanates and latex. MWF are not specified, however 343 cases of OA are under 
the causative category of “other” and 198 under “undetermined” 27.  
Documents from the National Research and Safety Institute for occupational 
accidents prevention in France (INRS) show that there have been eight reported 
cases of OA thought to be secondary to MWF between 1991 and 1999. It is 
recognised that this does not reflect the true number of affected workers. An estimate 
of the incidence in the entire exposed population is less than 10 cases per year but 
the validity of this estimate is poor. Dermatological disease in France is officially 
recorded at under 100 cases per year, although it is recognised that the true 
incidence of disease is likely to be 50-100 times that officially reported 320.  
Vincent Bonterre from the French national occupational disease surveillance and 
prevention network (RNV3P) responded to a request for information regarding 
reported MWF ill health. RNV3P collect data from thirty occupational disease 
consultation centres in university hospitals, where patients are referred for a 
potentially work-related disease. A generous data set was supplied concerning 
patients that were exposed to MWF and whose physician (GP or specialists) ask the 
occupational disease centres for advice to explore the work-relatedness. Bonterre 
noted that health surveillance in France is based on a statutory declaration system 
and encounters the same problem of underreporting seen in schemes involving 
insurance companies 321 322. 
Considering RNV3P 2001-2007 data relating to any disease, any “attributable cause” 
(Figure 8), and any type of MWF (without taking into account co-morbidities) there 
were 1014 reports concerning workers that have been exposed to MWF. These 
reports came for thirty occupational disease centres and included 924 men (mean 
age 43, SD=15) and ninety women (mean age 44, SD=12). There were 579 reports 
concerning skin disease and 151 reports concerning respiratory disease 321 322. 
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When analysing the subset of the data where MWF has been identified as the main 
exposure rather than just a co-exposure, there were 536 reports of either respiratory 
or skin disease. These were reported from twenty-four occupational centres and 
concerned 480 men (mean age 38, SD=12) and fifty-six women (mean age 42, 
SD=11). Ninety-six cases of respiratory diseases were documented, most frequently 
diagnosed as asthma (n=40), COPD (n=12) and hypersensitivity pneumonitis (n=5).  
Four hundred and forty cases of skin disease were noted, most frequently allergic 
contact dermatitis and irritant contact dermatitis. In seventy-three cases of contact 
dermatitis the underlying mechanism was unknown, and there were also four cases 
of urticaria. Seventy one percent of the patients (n=350) came from manufacturing 
industries (including metal working), sixteen percent (n=78) came from automobile 
repair and domestic product repair sectors 321 322. 
 
Finland   
Finland has a compulsory reporting scheme, where physicians are required to report 
every case of occupational disease to the Finnish Register of Occupational Diseases 
(FROD). In a recent study based on the FROD data, the incidence of skin disease in 
machinists (1.62 per 1000 person years) was about three-fold that of the total 
working population 323. Based on statistics collected by FROD and the patient 
register of the Finnish Institute of Occupational Health (FIOH) during 1992-2001, skin 
diseases were found to be the second most common occupational disease of 
machinists, after musculoskeletal injuries, accounting for twenty seven percent of all 
occupational diseases. A cross sectional study was completed to investigate the 
frequency of skin and respiratory symptoms using telephone interviews to question 
757 machinists and eighty four controls in sixty four- sites using MWF. Suuronen et 
al. 2007, found that one in five of the interviewed machinists had symptoms of 
recurring or prolonged hand or forearm dermatitis in the previous year. This was an 
increase of five-fold compared to the office-based controls 323. 
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Figure 8: Numbers of respiratory (R) and skin disease (D) cases associated 
with exposure to MWFs between 2001-2007 in France  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Government statistics reported that between 1992 and 2001 there were thirty 
reported cases of allergic respiratory disease (mainly asthma) in machinists. This 
translates to an incidence of 0.2 cases per 1000 persons per year, which is 
approximately the same as in the total working population 324 325. This was not 
reflected in a nationwide follow up study on asthma incidence by occupation 
however, where an elevated risk of adult onset asthma in machinists and related 
workers compared to administrative staff was demonstrated 326. In telephone 
interviews by Jaakkola et al. 2009, thirty one percent of machinists reported suffering 
from a recurring or prolonged respiratory symptom within the past year. Compared to 
the office workers, the machinists had a 2.5-fold risk of respiratory symptoms and a 
5-fold increase risk in upper respiratory symptoms. It was noted that machinists 
 
Key: 
0: no link between exposure and disease 
1: link between MWF exposure and the disease is weak or doubtful 
2: possible or direct but not essential link between MWF exposure and disease 
3: direct and essential link between MWF exposure and disease 
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working in areas where the aerosol level was above the mean level of 0.17 mg/m3 
were at increased risk (OR  2) of nasal and throat symptoms, cough, wheezing, 
shortness of breath, chronic bronchitis and current asthma. Workers with a history of 
at least fifteen years exposure to MWF experienced increased throat symptoms, 
cough and chronic bronchitis. The workplace assessment identified considerable 
variation in exposure control measures. One third of the machinery was equipped 
with functional local ventilation and enclosure. Gloves for dermal protection were not 
always used, and many were not of material optimal for protection against MWF 324 
325. 
Detailed exposure assessments were conducted in ten machine shops measuring air 
concentrations of ingredients and contaminations of MWF and inhalable dusts.  The 
mean concentration of oil mist was 0.14 (range <0.010-0.60) mg/m3 compared to the 
recommend limit of below 5 mg/m3. The concentration of microorganisms was low. 
All measured aerosol levels, including aldehydes, were below the Finnish 
occupational exposure limits. The authors concluded that improvements in 
occupational hygiene to maintain the air contamination well below the recommended 
limits and protect workers from exposure were needed 324 327. 
 
Czech Republic 
Urban, P. from the Czech Registry of Occupational Diseases provided information on 
the reported occupational diseases caused by MWF in the Czech Republic between 
2003 and 2008 (Figure 9a). The design of their reporting scheme was not clear, but 
over the four-year period there were twelve reported cases of allergic rhinitis, 
seventeen of allergic asthma, one hundred and twenty three cases of allergic contact 
dermatitis, one hundred and seventeen cases of irritant contact dermatitis and two 
cases of acne reported. The incidence of disease was relatively constant across the 
time period suggesting that major outbreaks of ill health had either not occurred or 
not been reported 328. 
 63 
0
2
4
6
8
10
12
14
16
2000 2001 2002 2003 2004 2005 2006 2007 2008 total
Year
C
a
se
s 
o
f 
d
is
ea
se
unspecified respiratory disorder
COPD
Occupational asthma
Contact dermatitis
0
20
40
60
80
100
120
140
2004 2005 2006 2007 2008 Total
Year
N
u
m
b
er
 o
f 
ca
se
s
allergic rhinitis
allergic asthma
allergic contact dermatitis
irritant contact dermatitis
acne
Fig 9a:
Fig 9b:
C
a
se
s 
o
f 
d
is
ea
se
C
a
se
s 
o
f 
d
is
ea
se
N
u
m
b
er
 o
f 
ca
se
s
N
u
m
b
er
 o
f 
ca
se
s
Figure 9a & b: a) Occupational disease attributable to MWFs reported (2003-
2008) in the Czech Republic; b) Occupational disease attributable to MWFs 
reported (2000-2008) in Holland 
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Netherlands 
In the Netherlands, a small number of cases of ill health attributed to MWFs were 
reported. Between 2000 and 2008 ((Figure 9b) twelve cases of contact dermatitis 
were reported, two cases of COPD or asthma, and one of unspecified respiratory 
disease. Again, the exact nature and purpose of the reporting scheme is not clear 329. 
 
Switzerland 
In Switzerland, the metal working industry is reported to be the main cause of work-
related skin disease. According to data from the Swiss National Insurance 
Organisation (SUVA), about seventeen cases of skin disease due to exposure to 
MWFs are reported per year. Over the past ten years, this has constituted 
approximately eighteen percent of all cases of work-related skin disease. SUVA data 
identified four cases of respiratory disease associated with exposure to MWF each 
year. Approximately half of these were cases of OA, a quarter were disease of the 
upper respiratory tract, and a quarter due to bronchitis 330.  
 
Austria 
There are an estimated 270,000 people involved in the Austrian metal working 
industry, and approximately 95,000 are reported to come regularly into contact with 
MWF. Data from the Austrian Social Insurance for Occupational Risks (AUVA) 
recognized about ten cases of skin disease per year from the industry class ‘Metal 
production and machining’. Identifying the substances responsible for these 
conditions is not possible based on the data provided in the AUVA statistics. 
Approximately five cases of respiratory disease are also recognized each year in the 
same industry class with 80% of this accounted by upper respiratory tract disease 
and 20% as OA 330. 
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Germany 
Between 1887 and 2007 the Hauptverband der Gewerblichen 
Berfusgenossenschaften (HBVG) institution(s) were the leading association 
representing the interests of the 25 trade institutions. The commercial trade 
associations are the carries of statutory accident insurance for companies in the 
German private sector and their employees. Reporting of occupational disease is 
through HVBG, although the exact methods and requirements, and the proportion of 
the working population that HVBG cover is unclear 331.  
In 2005 there were 53,576 notifications of occupational disease to HVBG . Data from 
HVBG suggests that the number of confirmed cases of skin disease caused by MWF 
was on average four hundred and twenty three per year. The number of cases of 
disease of the respiratory tract, linked with exposure to MWF, was twelve per year 
330. 
A study was also identified of skin disease in a large metal working concern, 
employing 10,000 employees producing mainly roller bearings. MWF exposure was 
predominantly due to water miscible MWFs, and occupational related skin disease 
was common. In the exposed workers who had regular health monitoring, 48% 
suffered from irritant dermatitis and 6.9% had allergic dermatitis 332. 
 
Italy 
No national reporting data from Italy was identified. A study of skin disease in MWF 
workers by Papa et al. in 2000, which included one hundred and fifty metal workers 
occupationally exposed to metals and metalworking fluids (MWFs). This 
demonstrated an excess of minor skin disorders in exposed workers (18.6%), when 
compared to a control group (2%). The prevalence of major skin disorders was 
similar between the two groups (6.6% versus 5.4%) 333.  
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Spain 
Orrilos et al. 2006, based in Catalonia (Spain), implemented a voluntary surveillance 
system whereby selected physicians, including occupational and respiratory 
specialists and general practitioners were asked to report cases of occupational 
respiratory disease. The results of this survey were compared to those of the official 
compulsory reporting of insurance companies. It was found that the voluntary 
surveillance had a much higher detection rate of disease and that the official system 
seriously under reported in Catalonia. The voluntary scheme identified 174 cases of 
OA in a twelve-month period. None of these were identified in the report as being 
caused by MWF but twenty four percent were caused by undefined chemicals/agents 
35. 
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European overview 
The overall numbers of reported cases of respiratory and skin disease that have 
been attributed to work with MWFs is summarised in Figure 10. 
Figure 10: Relative proportion of respiratory and skin disease attributable to 
MWF reported by different countries  
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Discussion 
Principal findings 
This review identified twenty-nine previously published ill health outbreaks, with a 
peak incidence between 1996 and 2000. Outbreaks were most commonly of 
respiratory cases, with or without cases of skin disease, often in large American 
automobile plants. No clear aetiology for respiratory disease has been established, 
although microbial contamination of MWF, most often from bacteria, was commonly 
demonstrated during outbreaks. 
Due to the lack of published 'outbreak investigation' studies from Europe, a second 
phase of the review included data from European reporting schemes where 
information on ill health related to MWF was available. This was successful in 
providing some data from the UK, France, Germany, Austria, Switzerland, Holland, 
Czechoslovakia, and Finland.  Each country had a different reporting scheme, some 
voluntary, for example France and some compulsory, for example Finland. It was 
suggested that all methods employed were at risk of under reporting and due to the 
inequality in the information acquired from each country it is difficult to draw direct 
comparisons.  What can be noted is that dermatological disease is generally more 
commonly reported than respiratory disease. 
 
General limitations 
Given the comprehensive nature of the outbreak literature review, it seems unlikely 
that published outbreaks will have been missed. The conclusions which can be 
drawn from the published outbreak investigations, are generally limited due to the 
cross-sectional nature of the studies and may be biased towards a 'surviving 
population'. This may lead to an under-estimate of cases, not including those workers 
who previously left employment due to work-related illness. Some of the outbreak 
investigations have attempted to minimise this by collecting longitudinal data, and by 
reviewing previous sickness absence records. Environmental investigations during 
outbreaks may also be limited in usefulness if improvements have been instigated in 
the workplace prior to sample collection. Again, some investigations had attempted to 
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allow for this by studying historical records of oil mist levels, sump contamination, 
and biocide usage when available.  
The geographical comparisons that could be made in this study were severely limited 
by the paucity of published European outbreaks and the lack of a United States 
national reporting scheme for occupational ill health. Any comparisons made 
therefore, require examination of data from different sources, limiting their validity. 
Although we were able to gain valuable reporting data from a range of European 
countries, their reporting schemes were variable in design making comparisons 
difficult. We were not able to find national reporting data for certain European 
countries.  
 
Geographical comparisons of outbreaks 
The majority of outbreaks of MWF-related ill health have been reported from 
America, most commonly in large automobile manufacturing industry. It is not 
possible to tell from the literature review whether the high number of outbreaks from 
the United States is representative of a wider problem in that country, or relates to 
other factors such as reporting bias. One possible explanation to consider for such 
geographical differences in the incidence of reported MWF outbreaks is differences 
in socio-economics – that is countries consuming the most MWFs may simply have 
more disease. This seems unlikely to be the full explanation as the number of 
reported outbreaks per country is not proportional to the country’s consumption of 
MWFs. In 2007 the United States used approximately 420 000 metric tons of MWF 
compared with 305 000 metric tonnes in Western Europe and 815 000 metric tonnes 
in the Asia/Pacific region 334. 
Given the industrial sector most commonly implicated in outbreaks, comparison of 
global car production can also provide some insight to this. Data from 2002 listed the 
top five car manufacturers as Japan (8.6 million), followed by Germany (5.1 million), 
the United States (5.0 million), France (3.3 million) and South Korea (2.7 million) . 
For comparison, the UK produced 1.6 million cars in 2002 which was seventh overall 
in the world 335. The lack of published outbreaks from the other four highest car 
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manufacturers, particularly Japan and Germany, suggests that the relationship 
between usage and outbreaks is not simply the answer.  
Comparisons of MWF exposure for workers in different countries is hampered by a 
lack of standardised methodology for measuring MWFs, but recommended exposure 
limits do vary. In the US, NIOSH recommended exposure limits (RELs) for MWFs are 
0.5 mg/m3 for total MWF particulates as a time-weighted average (average exposure 
over a specified period of time) concentration for up to 10 hours per day during a 40-
hour working week 257. Exposure monitoring in US outbreaks have shown variable 
results, with cases of respiratory ill health occurring above and below these exposure 
limits. At the time of the large UK (Powertrain) outbreak, average personal exposures 
to mineral oil mist were 1.3 mg/m3, well below the (now withdrawn) UK occupational 
exposure standard (OES) of 5 mg m3 for a 8-hour time-weighted average 260. More 
recent surveys from Finland and Sweden have found much lower average exposure 
levels of MWFs, in the region of 0.2-0.4 mg/m3, and it has been suggested that this 
may be a possible explanation for the lower incidence of respiratory disease in these 
countries 325 327 336. This level of exposure is in keeping with the American 
Conference of Governmental Industrial Hygienists recommended threshold limit 
value for mineral oils of 0.2 mg/m3 337.   
Another possible factor to explain the high number of reported outbreaks from the US 
is the ease by which investigations may be initiated, the resources available for these 
investigations and the routine publication of their findings. This is likely to vary 
between different countries and is certainly not the case in the UK. The author is 
aware of other UK MWF outbreaks that occurred, but which have not been formally 
investigated in detail and therefore are not reported in the literature 338. The National 
Institute for Occupational Safety and Health (NIOSH) carried out 76% of the US 
investigations and is part of the Centres for Disease Control and Prevention (CDC) a 
department of Health and Human Services. NIOSH is a non-regulatory investigative 
body that responds to requests to investigate workplace hazards. NIOSH is not an 
enforcement agency and has a distinct role from the Occupational Safety and Health 
Administration (OSHA) whose main mission is setting and enforcing standards 284. 
NIOSH is well resourced and has a policy of making all health investigation reports 
publicly available. Such Health Hazard Evaluations (HHE) are relatively easy to 
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trigger, only requiring three staff members to formally express concern regarding 
health in the workplace. The exact nature of the evaluation is dependent on the 
nature of the complaint and type of workplace. For US MWF outbreaks this has 
varied from simply reviewing occupational health records, to 'in depth' workplace 
studies collecting detailed medical, microbiological, immunological and hygiene data. 
Differences in diagnostic approach may be necessary depending on the type of 
outbreak investigation and may relate to a countries healthcare system, with 
variability in the availability of invasive biopsies, or complex radiological tests such as 
gallium scans. This lack of a standardized approach makes comparisons of 
outbreaks within the US and between the US and Europe difficult. 
 
Risk factors for disease during outbreaks 
A number of respiratory outbreak investigations have examined demographic data for 
affected and non-affected workers, but no consistent risk factors for MWF-related ill 
health have been established. Fox et al. compared thirty-four demographic risk 
factors between cases of EAA and controls, but found no significant differences for 
age, gender, race, past smoking, family history, or a range of occupational factors 1. 
Similarly in the Powertrain outbreak, no differences in smoking history, demographic 
characteristics, or the length of employment was observed between cases and 
controls 260. However, in contrast to this, Hodgson et al. found that workers with EAA 
were older and more frequently non-smokers when compared to the rest of the 
workforce 294. Current cigarette smokers are known to be less likely to develop EAA 
from any cause, which may affect the incidence of EAA in different workforces with 
variable smoking prevalence 339. 
Personal mist exposures may vary markedly between workers due to a wide range of 
factors. These include differences in work task, usage of enclosed systems, 
availability of exhaust ventilation and usage of compressed air 336. The relationship 
between exposure and respiratory disease is certainly not straightforward and 
findings have again been conflicting. Trout et al. were able to demonstrate a dose-
response relationship between oil mist exposure and the development of EAA, for 
low, medium and high exposure category jobs 298-300. In contrast to this, Hodgson et 
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al. found no clear association between qualitative exposure measurements and case 
definitions using logistic regression models 294. Fox et al. found no significant 
difference in oil mist exposure levels between EAA cases and controls 1 and Park et 
al. 175 did not find that cross-shift peak flow decrements were related to exposure 
category .  
Another factor to consider in outbreaks is the type of water-based MWF used in the 
workplace. A previous study of Canadian apprentices identified exposure to synthetic 
MWFs to be a significant risk factor in the development of airway responsiveness (a 
feature of asthma), where as this was not the case for soluble MWFs 340. Amongst 
cases of EAA, Fox et al. also found increased odds ratios for exposure to certain 
MWFs, two of which were synthetic 1. Our results however, identified respiratory 
outbreaks associated with all types of modern MWFs, being relatively evenly split 
between water mix mineral, semi-synthetic, synthetic fluids, or a combination of fluid 
types. Respiratory outbreaks were more commonly associated with MWF systems 
with common rather than individual sumps, but it is difficult to interpret the relevance 
of this without knowing whether this simply reflects the normal pattern of usage of 
MWF by large industry.  
In MWF associated respiratory disease, exposures are complex and the specific 
agent causing disease is yet to be identified. In specific cases, bronchial challenge 
testing has confirmed that particular MWF ingredients, for example, alkanolamines, 
pine oil reoderant and colophony are asthmagens 261 278 341 342. Exposure to microbial 
contaminants is however suspected to be the most likely cause of EAA, which would 
be in keeping with the aetiology of many other types of EAA. This is also supported 
by immunological responses found during outbreak investigations and limited 
challenge studies, where responses have been associated with used but not unused 
MWF 1 260. The review of the microbiological findings from the outbreaks clearly 
demonstrated that microbial contamination of MWF was common, most frequently 
with bacteria. More than 80 different bacterial species were cultured from samples 
taken during the outbreaks, the largest group being Gram-negative aerobic rods, i.e. 
Pseudomonas and related genera. Other taxonomic groups of Gram-negative 
bacteria have also been reported, as well as Gram-positive rods and cocci. The 
bacteria isolated largely reflect the environmental niche generally occupied by these 
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microorganisms, i.e. soil and water-borne bacteria, highly adaptable and with 
unexacting nutritional requirements. These bacteria are rarely pathogenic in 
immunocompetent individuals, but contain material in their cell walls (such as 
lipopolysaccharide) capable of stimulating the human immune system and enhancing 
the body’s response to allergens 343. 
Hot tub lung is a recognized granulomatous condition, which is thought to be a form 
of EAA caused by exposure to aerosolized Mycobacterium avium complex organisms 
contaminating hot tub water 344. Opportunistic mycobacteria have also been found as 
a contaminant in a number of MWF outbreaks 289 and have therefore been suggested 
to be the aetiological agent responsible for MWF EAA. More recently, French 
researchers have demonstrated a significantly higher number of precipitin arcs to 
Mycobacterium immunogenum (as measured by electrosyneresis) in 13 workers with 
MWF EAA, as compared to 12 exposed asymptomatic controls (8/13 having positive 
arcs). The authors have suggested that this is evidence of causation and that a cut 
off of five arcs has 77% sensitivity and 92% specificity for diagnosing MWF EAA. 
This study however further highlights the difficulties of establishing immunological 
causation in EAA, as 8/13 of the cases also had positive arcs to a bacterium in the 
MWF and 4/13 had positive arcs to a fungus. In addition, one of the asymptomatic 
exposed controls had 12 arcs to Mycobacterium immunogenum, which was as strong 
a response as seen in the EAA cases 345. It is clear that large outbreaks of EAA have 
occurred in workplaces with minimal 294 or absent mycobacterial contamination 260. 
Strong further evidence that Mycobacterium immunogenum is not the causative 
agent in all MWF EAA outbreaks, was seen in the UK Powertrain outbreak, where no 
mycobacterial DNA was found, none of the workers showed positive precipitin 
responses to Mycobacterium immunogenum and two positive specific challenges 
were demonstrated to used MWF that did not contain these organisms 260. 
Fungal contamination has frequently also been found during MWF respiratory 
outbreaks, only slightly less commonly than bacteria. Few studies have specifically 
investigated immune responses to fungal contaminants, although this was not felt to 
be relevant in the aetiology of the Powertrain outbreak.  
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Comparison of different types of health outbreak 
In terms of comparing types of outbreaks, the majority of these have been of 
respiratory ill health, either alone or in combination with skin disease. The small 
number of reported skin outbreaks limits the conclusions that can be made and this 
may reflect the different clinical consequences of developing skin or respiratory 
disease. It seems likely that an outbreak investigation is more likely to be instituted 
following concerns over less common or more serious health problems (such as 
inability to tolerate the workplace from breathlessness in asthma or alveolitis), than 
from concerns relating to skin rashes and eczema. For NIOSH studies it should be 
noted that the focus of an investigation in terms of which disease is looked for, may 
simply reflect the type of complaint that originally prompted it, e.g. worker concerns of 
breathlessness may lead to an investigation designed to record asthma and 
alveolitis, without routinely also recording dermatitis. Outbreaks that have reported 
both types of illness, however, have generally found skin disease to be more 
prevalent.  
Comparisons are also limited by differences in the type of investigation carried out for 
different types of health outbreak. For the mixed disease outbreaks, the 
investigations have generally relied on recording symptoms, where as those for 
respiratory outbreaks have tended to be much more involved, requiring detailed 
diagnostic tests. However, some differences can be noted for example respiratory 
disease outbreaks (70%) more commonly occurred in automobile plants than was the 
case for mixed outbreaks of respiratory and skin disease (50%). The exposed 
population was typically higher in the respiratory outbreaks (247 workers), versus 
that in the mixed outbreaks (140 workers).  
Respiratory outbreaks were associated with all types of modern water containing 
MWFs used in isolation as well as in combination. This pattern was not the same for 
skin outbreaks, where only one of the three outbreaks in which the MWF type was 
documented, was associated with a single type of MWF. It is of note that of those 
outbreaks involving skin disease (+/- respiratory disease) associated with a mixed 
MWF exposure, each of the 4 types of MWF (including neat oil) are used in at least 
50% of the outbreaks.  
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No clear differences were seen between the types of outbreak in terms of MWF 
system, with all outbreaks being more commonly associated with the use of shared 
rather than individual sumps. Bacterial contamination of MWF was consistent in 
approximately three-quarters of all types of outbreak, where as fungal contamination 
was found approximately four times as frequently in respiratory outbreaks as the 
other types. A marked difference in the presence of opportunistic mycobacteria was 
also found between the types of outbreak, being present in over half of the 
respiratory outbreaks, but none of the skin or mixed outbreaks. In some cases this 
reflected its absence, where as in others this simply reflected the level of 
investigation completed.  
 
Data from European reporting schemes 
Data from European reporting schemes was gathered through personal contacts and 
review of online sources. Although it was possible to obtain useful data from a limited 
number of European countries with reporting schemes, this may not be 
representative of the wider European picture. It should also be noted that the data 
from different reporting schemes is not easily comparable due to a lack of 
standardisation between countries. The reporting of work-related ill health to such 
schemes may be a legal requirement (e.g. as in Finland), or voluntary (e.g. THOR 
reporting in the UK and ONAP in France). The diagnostic certainty required for 
reporting an illness may also vary, with some requiring it to be more likely than not 
work-related (e.g. UK), where as other schemes require a much more certain 
diagnosis, particularly where linked to compensation schemes (e.g. Finland, Austria 
and Germany). This may be a particular issue for diagnosing respiratory disease 
related to MWF exposure, where no single aetiological agent has been identified and 
asthma and alveolitis may both occur in the same workplace. Accurate case 
reporting may also be difficult in outbreaks where case definitions have been used 
and have identified some individuals with both occupational asthma and alveolitis 260. 
Patients ultimately diagnosed with EAA in outbreaks have often been previously 
treated for recurrent chest infections, due to the non-specific clinical features of this 
illness. It is likely therefore that this condition is particularly under-reported. Details on 
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occupational disease in Spain and Canada were taken from temporary voluntary 
physician reporting schemes. 
Accepting the above limitations it is clear that MWF respiratory and dermatology ill 
health are reported in the United States, UK and mainland Europe. For the small 
number of European countries with reporting schemes, it can be seen that 
dermatological disease is generally more commonly reported than respiratory 
disease. This may not be surprising, given that the significant respiratory diseases 
(OA and EAA) are allergic in nature, where as skin responses may be either allergic 
or irritant in aetiology. Data from France, Switzerland, Austria and Holland show that 
although total numbers may vary, skin disease is reported approximately 2-4 times 
more often than respiratory disease. In the UK, reporting of occupational ill health 
can be via the RIDDOR scheme, which is largely the legal responsibility of 
employers, or through THOR, which is a voluntary UK sampling scheme aimed to 
gather data on occupational disease from the physician. The THOR data from over 
the past 10-15 years shows that prior to the Powertrain outbreak 260, dermatologists 
reported approximately 5 times as much MWF skin disease each year than 
respiratory physicians reported respiratory disease 317. More recently however, there 
has been a downward trend in reporting of skin disease amongst dermatologists and 
a large peak of reporting of respiratory disease following the UK outbreaks. It is 
difficult to compare reporting from the different specialist groups and to know whether 
these trends reflect a change in disease, a change in reporting practice, or increasing 
awareness of disease 317. 
Data from compulsory reporting to the Finnish registry shows an eight-fold higher 
incidence of skin disease than allergic respiratory disease in MWF workers. The 
prevalence of reported MWF OA in Finland was similar to that in the general 
population, which contrasts with Finnish research findings from cross-sectional 
studies which have found a high prevalence of respiratory symptoms in exposed 
workers, even in fairly clean work environments 323 324. A Finnish study 323 suggested 
that skin disease may also be under-reported to FROD, which may reflect patients 
not seeking medical attention, or skin complaints not being identified at primary 
health care units. The diagnosis of irritant contact dermatitis is based on clinical 
assessment, as there are no gold standard diagnostic tests 323. Allergic contact 
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dermatitis is demonstrated by patch testing. Therefore if a patient presents with 
dermatitis it can be diagnosed clinically regardless of the response to skin testing. 
This is in marked contrast to the diagnosis of OA, which is based on confirming the 
diagnosis of asthma, onset of symptoms after entering work and association between 
symptoms and work. Work as the cause of disease must be proven by significant 
work-related changes in peak expiratory flow, similar to the usual diagnostic method 
in the UK. In addition to this, however, an IgE mediated allergy to an agent at work 
needs to be identified. If either or both of these are lacking, a positive response to a 
specific bronchial challenge test may be required. Both testing of IgE mediated 
allergy and bronchial challenge test are difficult without knowledge of the actual 
allergen causing MWF OA 327. MWF is a complex mixture of ingredients and each 
brand of MWF is slightly different. It is rarely possible to test workers with every 
conceivable potential allergen and it may be difficult to accurately reproduce the work 
environment, particularly where challenges are only performed with pristine MWFs. 
The level of diagnostic rigor required is therefore greater than in the UK, where 
challenges are rarely performed and this may be part of the explanation for lower 
rates of OA seen in Finland. 
The reporting data from German insurance schemes shows a very different picture, 
with a thirty-five-fold higher reporting of dermatitis relative to respiratory disease. 
Without a detailed knowledge of the German reporting scheme, these figures are 
difficult to interpret. It seems likely that again this may partly be explained by 
differences in the diagnostic requirements of their 'insurance based' system (e.g. the 
requirement for specific inhalation challenges in asthma). 
 
Comparison with other studies 
To our knowledge, this review is the first to comprise an in depth review of published 
outbreaks of MWF related ill health and to include data from European reporting 
schemes where there has been few published incident outbreak investigations. The 
findings of this study regarding outbreaks are in keeping with those from a NIOSH 
MWF-associated hypersensitivity pneumonitis (EAA) workshop, which was held in 
1997 280. This followed eight clusters of disease in the American automotive industry 
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and recognised reversible disease, which occurred despite oil mist exposures within 
guidance limits. This workshop reviewed the existing evidence from outbreaks of 
EAA and identified a range of significant knowledge gaps, including risk factors for 
disease, exposure-response relationships, intervention efficacy and the natural 
history of disease. Over the last 10-12 years, despite a great deal of further research 
in relation to large outbreaks of occupational respiratory disease, many of these 
questions remain unanswered. This is particularly true for the timing of outbreaks and 
the aetiology of EAA and asthma. These issues are complex and a range of factors 
limits the conclusions that may be reached by studying outbreaks of disease. These 
include resource issues, difficulties with the complexity of workplace exposures and 
evolving improvements, which may be implemented within the workplace during data 
collection.  
Many of the detailed outbreak investigations have focused on EAA and it is clear that 
this has only occurred with the more modern water containing MWFs. These fluids 
readily support microbial growth and there is some evidence to implicate this 
contamination in the aetiology of respiratory disease. However, a consistent link 
between exposure and disease has not been found, with some outbreaks occurring 
despite relatively low exposure levels 292.  Improvements in workplace hygiene have 
often followed respiratory outbreaks, often by cleaning machines, changing fluids, 
and improving general and local exhaust ventilation. There is some limited evidence 
from longitudinal studies that this approach, linked with worker education, has 
allowed a significant proportion of workers with EAA to safely return to work 292. 
Established UK guidelines for OA 42 50 highlight the importance of early case 
identification and removal of the worker from further harmful exposure. There is some 
case series evidence to support this for EAA also, where removal of affected 
individuals from further MWF exposure has often been associated with a good 
clinical recovery, with marked improvements in radiology and physiology 279 292 302 303. 
It therefore follows that early case identification by health surveillance and outbreak 
investigation should be advocated for all MWF exposed workers and that they should 
be adequately educated about the health risks. 
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Conclusion 
The main finding of this review has been the lack of a standard approach to outbreak 
investigations. This limits the useful conclusions which can be gained from 
comparing data from outbreaks, which is further hindered by the lack of uniformity 
between national reporting schemes. Although microbial contamination was 
commonly found, no unifying cause could be identified amongst outbreaks. 
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Chapter 2: Systematic review of the diagnostic criteria used in 
previous outbreaks of extrinsic allergic alveolitis associated with 
metal working fluids 
 
Introduction 
In clinical practice, a diagnosis of EAA is often only suspected following the 
identification that a symptomatic patient is in an at-risk exposure group, or following 
the typical high resolution CT (HRCT) features of EAA being found in a patient with 
unexplained interstitial lung disease 346. Due to the non-specific presentation of the 
disease clinical diagnosis is often not straightforward and no single diagnostic test 
exists for EAA of occupational or environmental causes 215 347. This has led to the 
development of a number of general diagnostic criteria for EAA 203 210 215 246 348 349, all 
relying on a varying combination of: clinical assessment, suitable exposure, abnormal 
lung physiology, the presence of specific precipitating IgG antibodies in blood tests, 
radiology and the demonstration of a lymphocytic alveolitis on bronchoalveolar 
lavage or granulomas on lung biopsy. Confirmatory evidence may also come from 
symptomatic, physiological and radiological deterioration with workplace exposure 246 
350 and rarely specific inhalation challenges may also be performed with nebulised 
antigen 351. 
For OA clear diagnostic guidelines have been developed and are freely available on 
line 41 112. Workers suspected of having OA should be referred early to a physician 
with an interest in this disease and objective confirmation for UK MWF workers still in 
employment is usually made by demonstrating work-related changes in airway 
calibre by recording serial peak flow measurements. Other useful objective tests for 
OA may include serial assessments of airway responsiveness and in a small number 
of cases workplace or laboratory inhalation challenges 41 112 352. Due to the complex 
mixture of MWFs and the fact that their composition evolves with usage, no specific 
blood IgE or skin prick test is commercially available to demonstrate sensitisation. 
As described in chapter one, between 1990 and Oct 2008 there has been 25 
documented outbreaks of respiratory disease, particularly OA and EAA, associated 
with exposure to MWFs. The majority have occurred in the USA between 1992 and 
2003 1 279 287-301 303, affecting workers manufacturing metal components, often for 
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motor vehicles. During outbreak investigations of large workplaces several hundred 
workers may need to be screened for work-related symptoms by questionnaire, with 
symptomatic workers requiring detailed diagnostic testing. If many workers are 
affected with the same condition in the same workplace it may not be diagnostically 
necessary for all workers to have invasive tests (such as lung biopsies) and 
epidemiological or clinical case definitions may be agreed 1 260 281 288 294 300 303. 
Difficulties exist in processing such large numbers of individuals, particularly given 
the unpredictable nature and timing of outbreaks. 
Following the Powertrain outbreak in Birmingham 260 281, it was suggested by WATCH 
and agreed by HSE, that a standard UK approach to outbreak investigations should 
be developed. Development of this involved a review of the EAA case definitions 
used in previous outbreaks and formally planning the response for future outbreaks 
following a multidisciplinary modelling scenario. 
The aim of this part of the project was to review the respiratory case definitions used 
in previously published MWF investigations, in an attempt to adopt approved 
standards for future UK outbreaks.   
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Methodology  
 
As part of a formal literature review designed to identify published MWF outbreaks, a 
research team, comprising two clinical staff, two microbiologists and an 
immunologist, agreed the search terms that are shown in table 14. Library searches 
for paper abstracts that included a word from list 1 and a word from list 2 were 
conducted in OSHROM (HSELINE, NIOSHTIC, CISDOC, RILOSH and OSHLINE) 
databases, Embase, Medline, Healsafe and Web of Science. Papers documenting 
diagnostic criteria or case definitions for respiratory ill health were then identified and 
reviewed. 
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Results 
 
The first description of a US outbreak of MWF HP was published in 1995, based on 
workers investigated in 1992 279. Bernstein et al. named the condition machine 
operators lung and the investigation followed the recognition of a cluster of 
respiratory ill health among 6 out of 16 workers exposed to soluble MWFs, 
manufacturing car parts. In this outbreak, no case definitions were developed, as 
each case was investigated in detail. Clinical diagnoses were established based on 
improvements in work-related symptoms, chest x-ray appearances and lung function, 
following cessation of exposure.   
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The Kenosha diagnostic criteria 
 
A separate outbreak of 34 cases of EAA in MWF exposed workers occurred in a 
large US engine manufacturing plant (Kenosha outbreak 1995-6), leading to the 
Wisconsin Division of Health carrying out an investigation and case-control study 1. In 
the opinion of the authors, existing HP diagnostic criteria developed for all causes, 
were not ideally suited to the MWF environment given the lack of a clear etiological 
agent and the commonality of some of the symptoms of HP with MWF bronchitis. To 
allow a case-control study to investigate risk factors for developing HP they 
developed seven diagnostic criteria to allow case definitions (table 16). These were 
designed to facilitate an epidemiological study of workers already diagnosed with 
possible HP and not for a systematic plant-wide survey of all workers.  
 
It should be noted that of the 34 workers previously clinically diagnosed with HP in 
the outbreak, only 20 (59%) met the epidemiological case definition of being at least 
a possible case. Of these, 10 were definite cases, 5 probable cases and 5 possible 
cases. The authors also acknowledged that their criteria had been developed by 
themselves for the purpose of the study and had not been validated elsewhere.  
 
 
Table 16: The Kenosha diagnostic criteria 
 
1. Physician diagnosis of hypersensitivity pneumonitis  
2. Onset of at least two pulmonary symptoms (cough, wheeze, chest 
tightness, shortness of breath), and at least one systemic symptom (fever, 
weight loss) after July 15, 1995   
3. Recurrence of pulmonary or systemic symptoms after 3 or more day 
avoidance  
4. Restrictive pattern on spirometry not due to obesity 
5. Impairment of pulmonary diffusing capacity less than 80% predicted 
6. Interstitial or reticulonodular pattern on chest X-ray or CT 
7. Biopsy evidence of non-caseating granulomas 
 
Definite case, 6 or 7 criteria; probable case, 5 criteria; possible case 4 criteria. 
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Wisconsin diagnostic criteria 
 
A further set of diagnostic criteria (table 17) were developed to investigate another 
US outbreak, which occurred between March 1996 and May 1997, in a Wisconsin 
automobile manufacturing plant 288. It can be seen from table 17 that the diagnostic 
criteria for this outbreak were broadened to include OA and industrial bronchitis, as 
well as HP. 
 
Table 17: Wisconsin diagnostic criteria 
 Required 
features 
Supportive 
features 
Hypersensitivity pneumonitis 
 Workplace-related cough, dyspnea, chills, 
fever; or insidious onset of malaise, weight 
loss, or progressive dyspnea 
 Serum precipitins to MWF or microorganisms 
isolated in MWF 
 Chest X-ray: infiltrates in a reticulonodular or 
interstitial pattern; occasionally normal 
 Pulmonary function: restrictive abnormality with 
decreased diffusing capacity; occasionally 
normal 
 Lung biopsy: non-caseating granulomas 
 
X 
 
 
 
X 
 
X 
X 
 
 
X 
Occupational asthma  
 Workplace-related cough, shortness of breath, 
chest tightness, or wheezing 
 Pulmonary function: obstruction with 
reversibility with normal diffusing capacity or 
bronchial hyperresponsiveness, using 
methacholine challenge 
 Chest x-ray: hyperinflation or atelectasis 
 
X 
 
X 
 
 
 
 
 
 
X 
Industrial bronchitis 
 Workplace-related cough and sputum 
production 
 Pulmonary function: negative methacholine 
challenge and normal spirometry, unless 
complicating disease such as COPD present 
 
X 
 
X 
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The HP criteria were broadly similar to those developed for the Kenosha outbreak, 
but more relaxed and with the first criteria of physician diagnosis removed. Although 
no detail as to how these were developed or selected is given in the article, it seems 
likely that this reflects the two different styles of outbreak investigation. In the 
Kenosha outbreak, cases had been investigated by a number of different centres; 
whereas all of the cases in the Wisconsin outbreak were investigated at the author’s 
centre. 
Around the same time (1996-1998), concerns regarding an outbreak of HP in an 
Indiana plant, manufacturing car climate control components, lead to a NIOSH 
(National Institute for Occupational Health and Safety) survey of the workforce, 
comprising a notes review and questionnaire 289 . No single case definitions were 
used in this survey and the authors stated that diagnoses were based on symptoms, 
exposure history and results of clinical tests including radiology, lung biopsies and 
lung function testing. 
 
Development of Hypersensitivity Pneumonitis Diagnosis Index 
A further US outbreak of HP in MWF exposed workers began in 1997, in a 
Connecticut factory that produced precision parts for the aerospace industry 292-294. 
This followed the identification of a cluster of cases of HP having been identified by a 
single clinician. All workers from the plant were then invited to be examined at the 
University of Cincinnati Occupational and Environmental Medicine Unit, where they 
underwent a standard clinical assessment of history, examination, spirometry before 
and after work, a chest x-ray, a thin-section CT of the chest, a gallium scan and full 
lung function tests. Workers suspected of having HP after these tests were then 
offered invasive tests in the form of transbronchial or thoracoscopic lung biopsies for 
confirmation. Clinical diagnosis of HP required symptoms consistent with the 
disease, including at least one systemic symptom and one respiratory complaint, in 
association with a positive biopsy. In addition to this, the workplace was screened 
with a cross-sectional survey, using a combination of three previously developed 
questionnaires. The first of these was designed for HP, enquiring about the presence 
of three respiratory and three systemic symptoms, their frequency (rarely, 
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sometimes, usually) and their work-relatedness i.e. whether they improve away from 
work at weekends (symptoms get better or do not). In addition to this, a separate 
questionnaire was used to record current asthma symptoms, physician diagnosis and 
frequency of medication. A third questionnaire was also used to document the work-
relatedness of chest symptoms. Questionnaire based case definitions were then 
developed for HP and OA (table 18).    
 
Table 18: Questionnaire case definitions Connecticut outbreak 
 Required 
features 
Hypersensitivity pneumonitis 
 At least one chest symptom (coughing, wheezing, 
dyspnea with exertion) 
 At least one systemic symptom (arthralgias, chills and 
feverishness) 
 Symptoms frequency of usually or usually/sometimes 
 
X 
 
X 
 
X 
 
Occupational asthma (loose definition) 
 One chest symptom  
 Improvement away from work 
 
X 
X 
Occupational asthma (tight definition) 
 Three or more chest symptoms  
 Improvement away from work 
 
X 
X 
 
Although the sensitivity and specificity of these criteria are not documented, an 
attempt to examine the validity of the questionnaire case definitions was made. This 
demonstrated that seven of ten biopsy proven HP cases did fulfil the above case 
definition for HP, but that a much looser case definition was needed to include all ten 
cases. In order not to have missed any of the ten biopsy-proven cases, all workers 
reporting that they experienced at least one respiratory or systemic symptom 
“sometimes” or “usually” would have had to be included and further investigated. 
Using a different model, with tighter HP questionnaire case definitions that only 
included workers reporting at least three respiratory or systemic symptoms “usually”, 
only 30% of the biopsy-proven cases would have been identified. The authors also 
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noted a significant cross-over of the questionnaire case definitions, with 60% of the 
HP clinical cases also fulfilling their looser definition for OA. 
The investigation of this outbreak led to the recognition by the authors of the need to 
develop less invasive diagnostic criteria for HP than the Kenosha criteria, in an 
attempt to avoid the cost and morbidity of transbronchial and open lung biopsies 293. 
Using regression models, clinical data from biopsy-proven cases and non-cases was 
compared and a non-invasive Hypersensitivity Pneumonitis Diagnostic Index was 
developed (table 19). The results of the index were similar in output to the Kenosha 
case definitions, resulting in definite, probable or possible cases, depending on 
number of positive criteria. In this model, the previous physician diagnosis of 
hypersensitivity pneumonitis was removed as was the need for invasive tests. In 
place of these criteria, others were added: listening for lung crackles and taking a 
blood sample from the patient to assess inflammatory markers (ESR). The index also 
included performing an extra radiological test, a radioisotope gallium scan. The 
authors do not state why this scan was included in their case definitions although it 
may simply have been a routine part of their institutions assessment of the activity of 
interstitial lung disease. The authors went on to attempt to validate the index with 
other workers from the outbreak and compared case definitions made by this index, 
with cases diagnosed by slightly modified Kenosha criteria. The modifications made 
were minor and made the definition more inclusive. They included adding chills, 
sweats and fatigue to the constitutional symptoms in criteria 2, adding ground glass 
to the CT appearances in criteria 6 and modifying criteria 7 to allow any 
histopathology consistent with HP (see table 19).  
When case definitions were compared for 61 workers, there was a good level of 
agreement between the Kenosha criteria and the HP Diagnostic Index (kappa = 
0.766 +/- 0.093), although they did not identify identical patients. Four patients who 
met the case definition by the HP Diagnostic index did not meet the Kenosha criteria 
and the reverse was true for two other patients.  
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Table 19: Hypersensitivity Pneumonitis Diagnostic Index criteria  
1. Onset of at least one work-related systemic symptom (extreme fatigue or 
myalgias/body aches) and two work-related respiratory symptoms (cough, 
dyspnea, chest tightness, or wheezing) after January 1, 1995. That is, these 
symptoms occurred repeatedly during the work week and subsided when the 
patient was out of work (over long weekends, vacations, or medically restricted 
from work): One point 
2. Dry crackles (typically at the bases) detected on lung auscultation: One 
point   
3 Restrictive spirometry (FVC < 80% predicted and FEV1/FVC > 70%) while 
symptomatic, not due to obesity: One point 
4. Evidence of decreased diffusion capacity while symptomatic: 
One point for DLco (single breath) 60-80% of predicted, or an increase of the 
A-a oxygen gradient to > 16 mmHg 
Two points for DLco < 60% of predicted, with or without an increased A-a 
gradient  
5. Increased erythrocyte sedimentation rate while symptomatic:  
(≤ 15 mm/hr = No points, 16-60 mm/hr = One point, > 60 mm/hr = Two 
points)  
6. High resolution chest CT scan chest X-ray interpreted as consistent with 
hypersensitivity pneumonitis by an expert reader: One point  
7. Gallium scan of lung parenchyma interpreted by the nuclear medicine 
service as being consistent with hypersensitivity pneumonitis: One point 
Possible hypersensitivity pneumonitis (HP) is denoted by a score of 3; probable HP is 
denoted by 4-5; and definite HP by 6 or more. 
 
Ohio outbreak 
In 2001 three machinists from a US automobile brake manufacturing facility in Ohio 
were hospitalised with HP, prompting an investigation of the records for the rest of 
the workforce by NIOSH 298-300. Symptomatic workers were investigated by local 
health-care providers and cases were identified from their medical records. The 
diagnostic criteria for OA and HP used are shown in table 20. 
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Table 20: NIOSH diagnostic criteria for Ohio outbreak  
  Required 
features 
Hypersensitivity pneumonitis 
 One or more work-related respiratory symptoms (cough, 
dyspnea, wheezing, or chest tightness) 
 One or more systemic signs or symptoms (fever, chills, 
extreme fatigue, myalgia, or night sweats) 
 Infiltrate on CXR or HRCT 
 Abnormal spirometry (either an obstructive or restrictive 
pattern) 
 
X 
 
X 
 
X 
X 
 
Occupational asthma  
 One or more work-related respiratory symptoms (cough, 
dyspnea, wheezing, or chest tightness  
 Absence of systemic signs or symptoms 
 No infiltrate seen on CXR or HRCT 
 Spirometry consistent with reversible airway obstruction 
(an obstructive pattern with ≥12% improvement in FEV1 
after administration of inhaled bronchodilators ) 
 
X 
 
X 
X 
X 
 
The diagnostic criteria used here by NIOSH both for OA and HP are again slightly 
different to those used in other US investigations. In this outbreak the case definitions 
were based purely on symptoms, radiology and spirometry, without the need for 
blood tests, bronchoscopies, lung biopsies or gallium scans. Again it is likely that this 
choice in part reflected the type of investigation, based on reviewing notes and in part 
the need to avoid expensive invasive tests.  
In 2002 NIOSH were involved in another workplace investigation following an index 
case of hypersensitivity pneumonitis in a toolmaker, working for a company 
manufacturing automatic transmissions and transmission components 301 302. In this 
investigation, medical notes of symptomatic workers were reviewed and the Kenosha 
hypersensitivity pneumonitis case definitions were utilised. A short symptom 
questionnaire was also administered to part of the workforce but this was purely to 
facilitate an immunological study.  
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Michigan State diagnostic criteria 
Three further outbreaks of HP were identified from cases in 2003-2004, following an 
investigation in Michigan by Michigan Occupational Safety and Health Administration 
(MIOSH) of three separate plants manufacturing automobile parts 303. This followed 
the identification of seven cases of HP, either from reports to the Michigan State 
Occupational Disease surveillance system, or referrals to the Division of 
Occupational and Environmental Medicine at Michigan State University. In this case, 
general diagnostic criteria for HP were used, which had previously been developed 
for HP of any aetiology (table 21). 
 
Table 21: Michigan State diagnostic criteria for hypersensitivity pneumonitis 
Major Criteria 
 Symptoms compatible with HP 
 Evidence of exposure to appropriate antigen by history or detection 
in serum/or BAL antibody 
 Findings compatible with HP on CXR or HRCT scan 
 BAL lymphocytosis (if BAL performed) 
 Pulmonary histological changes compatible with HP 
 Positive “natural challenge” (reproduction of symptoms and 
laboratory abnormalities after exposure to the suspected 
environment) 
Minor criteria 
 Bibasilar rales 
 Decreased diffusion capacity 
 Arterial hypoxemia (rest/exercise) 
 
Diagnosis is confirmed if the patient fulfils four major criteria and two minor criteria 
and other diseases with similar symptoms are ruled out. 
These criteria were originally designed for clinical diagnosis with follow up, rather 
than epidemiological case definitions in cross-sectional surveys. They are therefore 
more stringent than some of the criteria specifically designed for MWF outbreaks and 
allow an assessment of whether abnormalities improve away from work and then 
recur with re-exposure. With these criteria an exposed MWF worker with symptoms, 
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a typical CT scan and abnormal lung function, would still need either an invasive test 
(bronchoscopy or lung biopsy) or a positive “natural challenge” to be diagnosed with 
HP. Of the seven cases described in this outbreak, all fulfilled four of the major 
criteria but only five also fulfilled the requirement of two minor criteria. 
 
Diagnostic criteria used for Powertrain outbreak 
In 2003-4 a large outbreak of respiratory ill health was identified in a UK car engine 
manufacturing plant 260 281. This outbreak was investigated in detail, using a phased 
approach. In Phase 1 all (836) employees were provided with a screening 
questionnaire, enquiring about 11 respiratory and nasal symptoms. In Phase 2 
symptomatic workers with at least one respiratory or nasal symptom, or reporting 
weight loss were invited for further assessment. This comprised a detailed self-
completed questionnaire, spirometry, phlebotomy and a clinical opinion with an 
experienced occupational respiratory physician. Those with possible occupational 
asthma were also asked to perform serial peak flow measurements. In Phase 3 
further detailed clinical assessments were performed including allergy tests, 
radiology, assessment of bronchial responsiveness to methacholine, full lung function 
and bronchoscopy.  The case definitions for HP (table 22) were adapted from the 
criteria used in the Kenosha outbreak (table 16); case definitions were also 
developed for OA and humidifier fever. By comparing table 16 and table 22, it can be 
seen that criteria 1,3,4,6,7 for HP were slightly adapted and more inclusive than 
those described in the original Kenosha outbreak; modifying the physician diagnosis 
criteria; redefining the work-related criteria for symptoms; allowing a broader 
spectrum of compatible CT appearances and adding a less invasive test 
(bronchoscopy with alveolar lavage) to the biopsy criteria. The investigators in this 
study also accepted EAA cases with four or more of the seven criteria i.e. the 
outbreak included possible, probable and definite cases of EAA. This study also 
noted an overlap between case definitions, with eight workers meeting the criteria for 
EAA and OA. 
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Table 22: Diagnostic criteria used for Powertrain outbreak 
Disease Criteria for case definition 
Extrinsic allergic 
alveolitis  
(at least 4 of the 7 
criteria must be 
met) 
1. Physician diagnosis of EAA (probable or definite) 
2. Onset of at least two pulmonary symptoms (cough, 
wheeze, chest tightness, shortness of breath), and one 
systemic symptom (fever, weight loss)  
3. A history of symptoms improving regularly on days 
away from work and deteriorating on return to work   
4. Restrictive pattern on spirometry FVC <80%, 
FEV1/FVC > 70% 
5. Pulmonary carbon dioxide transfer factor < 80% 
predicted 
6. CXR or CT scan showing interstitial, reticulonodular or 
mosaic pattern  
7. Biopsy evidence of non-caseating granulomas and/or 
lymphocytosis on bronchoalveolar lavage 
Occupational 
asthma  
Diagnostic peak expiratory flow record in 2003-5  
(ie OASYS score ≥2.67 and/or a mean day interpreted 
difference between work and rest days of ≥16 l/min) 
Humidifier fever Onset of disease after December 2002 and a physician 
diagnosis based on: 
 Recurrent symptoms of a flu-like illness worst on 
first day of exposure after a break 
 No weight loss or radiological infiltrates 
 No long-term restrictive lung disease 
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Discussion  
Main findings 
This review identified six different case definitions for EAA, four for occupational 
asthma and one each for humidifier fever and industrial bronchitis. In all but one of 
these, no information was presented as to how the case definition had been 
developed or validated 1 260 288 294 300 303. Only one paper was identified where the 
performance of different disease case definitions was compared 293. 
 
Limitations  
This study comprised a comprehensive and systematic review of the literature based 
on search terms agreed by a multidisciplinary team with experience of investigating 
MWF outbreaks, assisted by an experienced library search team. Despite this it is 
possible that the review may have missed certain other outbreaks, particularly if the 
nature of the paper was not clear from the abstract review, or the outbreak was 
published in a language other than English. In addition it is possible that there have 
been other MWF case definitions published since October 2008, although the 
authors are not aware of any in the recent literature. 
 
Comparison with other studies 
A number of difficulties arise in developing an approach to investigating MWF 
outbreaks. The first of these are logistical as they are usually unexpected and have 
to be investigated with little time to plan in order to minimise further harmful 
exposures. It may be difficult to differentiate workers with HP and OA from those with 
similar symptoms due to irritant bronchitis, humidifier fever, or unrelated viral 
infections. No internationally agreed gold standard diagnostic criteria exist for HP 207 
or OA of any cause 112 353, which therefore makes comparisons of the performance of 
MWF case definitions very difficult. The situation is particularly difficult for MWF 
associated EAA, as a case definition needs to allow for workers with very different 
presentations of disease including typical sub-acute EAA, as well as those with 
slowly progressive interstitial disease identical to idiopathic fibrosis 293. The value of 
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utilising a positive biopsy consistent with HP as a gold standard during outbreaks of 
HP 287 294 354 is limited by a number of factors, including interpretation of 
histopathology, false negative rates, cost and patient acceptability 293. 
The most commonly used MWF-EAA case definitions utilised in outbreaks have been 
those published by Fox et al. in 1999, which were used in their original or modified 
format in 4 outbreaks 1 260 293 301. In their original paper the authors acknowledged a 
major limitation to their study was that this case definition had been created for their 
case-control study without prior validation. In terms of performance, when applied to 
22 workers with clinically diagnosed MWF-EAA, these criteria only identified 45% of 
them as definite EAA cases. 
One set of MWF-EAA criteria (the HPDI) have been developed by statistical analysis 
of outbreak data, with some attempt at validation and comparison with another EAA 
case definition 293. Despite this, since their publication in 2002, they have not been 
utilised in subsequent reported US or UK outbreaks 260 303. The HPDI includes a 
criteria based on the results of a gallium scan, which may limit its usefulness if this 
test is not routinely performed in the assessment of possible HP 207.  
In one further MWF outbreak, HP diagnostic criteria were utilised, that had previously 
been developed for EAA of any cause 246.The level of clinical certainty required to 
diagnose a single isolated case of EAA, is clearly different to that required when a 
number of similar cases have been diagnosed from the same workplace. These 
criteria were not developed from outbreak data and are comparatively stringent in 
terms of fulfilling the case definition. This was highlighted in the outbreak report they 
were utilised in, as 2 of the 7 HP cases did not actually meet the full case definition 
that required two minor criteria. There is also some limitation for these criteria in 
MWF-EAA, as opposed to farmers or bird fanciers lung, as aetiological exposures 
are more complex, with no standardised serum or BAL antibody available. In terms of 
satisfying the four major criteria, a symptomatic MWF worker during an outbreak, with 
crackles, a CT showing classical HP and a reduced gas transfer would still need 
either an invasive test, or re-exposure to demonstrate deterioration during a “natural 
challenge”. The authors acknowledged the limitations of these criteria and also 
checked their cases by applying three other diagnostic criteria, one for farmers lung 
210 and two developed for EAA of any cause 203 215. No detail of the comparison of the 
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performance of these criteria was provided however and according to a recent 
review, three of the four criteria utilised in this study 203 210 246 have not been 
previously validated 207.  
The final set of criteria utilised in their study for EAA represent an evidence-based 
prediction rule, developed based on clinical differences between patients with 
suspected ILD, who did or did not have EAA as their final diagnosis 215. The 
significant predictive factors for EAA included exposure to a known cause of HP, 
positive serum precipitins, recurrent episodes of symptoms, lung crackles, symptoms 
4-8 hours after exposure and weight loss. These factors were then combined in to a 
model, to allow a calculation of how likely EAA was to be the underlying cause for 
any patient presenting with possible ILD. This prediction rule was therefore designed 
to differentiate EAA and non-EAA in sub-groups of hospital patients with ILD, as 
opposed to identifying MWF-EAA amongst symptomatic workers in an outbreak.  
Whether this type of prediction rule could be of value in MWF outbreaks requires 
further study.  
It has been estimated that over 1 million US workers are exposed to MWF during 
machining processes 355 and the associated health concerns of increased risk of 
occupational lung disease, as well as dermatitis and cancer, remain relevant to all 
MWF exposed workers worldwide. Although no more recent US outbreaks have been 
identified, it is not possible to tell whether this relates to an absence of outbreaks, an 
absence of outbreak investigations, or an absence of related publications. An 
outbreak of MWF-EAA has however recently been published in French automobile 
workers 345, although no case definitions were reported. Cases of MWF related 
occupational lung disease also continue to be reported to UK surveillance schemes 
and between 2010 and 2012, they were the 4th most common cause of OA 4. Recent 
Scandanavian cross-sectional studies of MWF exposed workers have also reported 
an excess of respiratory symptoms and asthma, even at relatively low average 
exposure levels 325 327.  
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Conclusion 
Despite numerous previous outbreak investigations, there are no gold standard 
diagnostic criteria for MWF-related respiratory ill health. Although many different 
criteria have previously been utilised, they have usually been developed for a specific 
type of investigation, often by adapting existing criteria, and with little or no validation. 
In some cases these criteria would not be suitable for UK investigations due to the 
nature of the test included 293. 
There is a clear need to develop a standardised approach to facilitate clinical 
investigations of future UK outbreaks of respiratory ill health in MWF-exposed 
workers. Further research work is needed to establish reasonable, acceptable and 
validated case definitions for these investigations.  
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Chapter 3: Expert panel identification of definite cases of EAA 
associated with exposure to metal working fluids at the Powertrain 
site 
 
Introduction 
The detailed literature reviews in the previous chapters summarise the features of 
previously published outbreaks of MWF-related ill health, serving to highlight both a 
lack of consistency in approach to outbreak investigation and a lack of evidence-base 
for case definitions of extrinsic allergic alveolitis. 
In 2003-4, a large outbreak of respiratory ill health occurred at Powertrain, in the 
Longbridge car engine manufacturing plant in Birmingham 260. This outbreak is 
discussed in detail in chapter 1. At the time of the outbreak investigation, 10.4% of 
the total Powertrain workforce met the case definitions for occupational lung disease, 
this included 19 cases of extrinsic allergic alveolitis and 7 cases of humidifier fever 260 
281. During the investigation, all of the clinical data collected was entered in to an 
SPSS database containing up to 400 data points on over 800 workers. This database 
could potentially be used to compare questionnaire responses etc from those 
workers with and without EAA, in order to assist in future diagnosis of workers with 
MWF associated disease. The validity of this work was dependent on identifying a 
group of workers with definite EAA. The aim of this chapter was therefore to review 
the records of those Powertrain workers initially suspected of having EAA or a related 
condition and unambiguously clarify which workers definitely had EAA. 
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Methodology  
In the absence of a single standardised diagnostic test to establish the diagnosis of 
MWF associated EAA, an ‘Expert Panel’ of occupational respiratory consultants was 
utilised. The ‘Expert Panel’ reviewed the available medical information, including 
follow-up data after exposure had ceased, in order to identify which workers could be 
clinically diagnosed as definite cases of EAA. 
 
Case Selection 
During the Powertrain outbreak investigation, a three-phased approach was applied 
to the entire workforce. The study population for this project comprised all workers 
recorded as having suspected EAA and/or humidifier fever, following assessment by 
the Powertrain clinical team at Birmingham Chest Clinic (Phase 3 of the 
investigation). 
 
Preparation of clinical information 
Clinical notes, radiology and computer records were made available and reviewed. A 
clinical summary was prepared for each case, based on this recorded clinical 
information and the data documented during the outbreak investigation. This included 
symptoms, radiology reports, physiology, immunology, cyto/histopathology and the 
clinical course of each workers illness. Hard and/or digital copies of all available 
radiology were also sourced for the panel meeting. Data was collected during a 
number of visits to Birmingham Chest Clinic over a several month period. 
 
Selection of Expert Panel 
The Expert Panel comprised five physicians, all founder members of the Health and 
Safety Executive sponsored national Group of Occupational Respiratory Disease 
Specialists (GORDS), and all with a current or previous clinical interest in EAA. The 
panel included two members (Professor Burge and Dr Robertson) who had both 
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been involved in the initial Powertrain outbreak investigation and clinical follow-up of 
affected workers at Birmingham Chest Clinic. The third member (Professor Pickering) 
had taken part in the Powertrain outbreak investigation, but not the clinical follow-up 
of affected workers. The fourth and fifth members (Professor Hendrick and Dr 
Barber) had not participated in the Powertrain investigation or follow-up of workers.  
 
Expert Panel Meeting 
The Expert Panel meeting was held at East Lodge on January 13-15th 2010. Dr 
Burton presented clinical data to the Expert Panel on each case, with the addition of 
summary data projected in a Powerpoint presentation. Hard copies of chest X-rays 
and CT scans for each case were made available for viewing on light boxes, with 
digital copies of radiology available to view projected on to a separate screen.  
Following the presentation of each case, there was discussion by the five members 
of the Expert Panel, and they were each asked their clinical opinion as to whether 
they felt they would be confident to diagnose EAA. Each member was only allowed to 
give one of the following opinions: 
 Definite case of EAA  
 Possible case of EAA 
 Definitely not EAA 
The Expert Panel was not provided with any information during the meeting relating 
to whether each case had met the case definition of EAA used during the outbreak 
investigation. A definite clinical case of EAA (i.e. sufficient to give this diagnosis to a 
patient in clinic) required at least four of the panel members to agree. Similarly a 
‘definitely not a case of EAA’ (i.e. EAA excluded) required four panel members to 
agree. Any other combination of votes was taken as the patient being a possible 
case of EAA.  
In addition to the clinical opinion statement, an Expert Panel Score (range 0-100%) 
was calculated for each case, representing how likely it was that this represented 
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EAA. This was calculated based on the total of five scores, one given by each panel 
member, where a vote of: 
 Definite EAA = 20 
 Possible EAA = 10 
 Definitely not EAA = 0 
 
Reproducibility 
In order to assess the reproducibility of the Expert Panel opinion, the panel re-
reviewed ten randomly selected cases, blinded to their initial opinion. Results from 
the first and second opinion were compared. Reproducibility of the Expert Panel 
Score was calculated using the concordance correlation co-efficient. 
 
Expert Panel opinion and modified Fox case definitions  
The Expert Panel opinion was compared graphically with the outcome of the case 
definition that had been used at the time of the Powertrain outbreak (modified Fox 
criteria).  
 
Comparison with interleukin-2 
Although the Expert Panel opinion was taken as the gold standard for a diagnosis of 
EAA, the Expert Panel Score was compared to a key cytokine (interleukin-2), 
responsible for T-cell activation in EAA. This data had previously been collected as 
part of a separate research project during the Powertrain investigation and was not 
available to the Expert Panel.   
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Ethical Approval 
Ethics approval was granted by the Birmingham Ethics Committee, as an 
amendment to the existing Ethical approval for the Powertrain Research project.  
 
 103 
Results 
Participants 
Following interrogation of the Powertrain database 37 workers were identified for the 
study.  
Figure 11: The number of patients seen at each phase of the Powertrain 
outbreak and the selection criteria for Expert Panel review 356 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phase 1. 11 point screening questionnaire
N = 808/836
Phase 2. Detailed questionnaire 108 questions, 
spirometry and blood sampling.
N =510
Phase 2. Findings compatible with EAA 
and/or humidifier fever.
N = 101
Phase 3. Clinical review and testing a t 
Birmingham Chest Clinic
N = 78
Clinical suspicion of EAA 
and /or humidifier fever
N = 37
Expert panel review
N = 14 definite cases of EAA
Phase 3. linical revie  and testing at 
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Table 23: Expert Panel results for the 37 workers reviewed, showing the panel 
EAA opinion, calculated panel score and original Powertrain outbreak case 
definition 
ID Panel opinion Panel case? Panel score % Powertrain case? 
1 YYYYY Definite 100 Probable 
2 YYYYY Definite 100 Definite 
3 YYYYY Definite 100 Probable 
4 PPNNN Possible 20 Possible 
5 YYYYY Definite 100 Possible 
6 YYYYY Definite 100 Probable 
7 PPPPP Possible 50 No 
8 YYYYY Definite 100 Probable 
9 NNNNN No 0 No 
10 YYYYY Definite 100 Probable 
11 PPNNN Possible 20 Probable 
12 YYYYY Definite 100 Definite 
13 YYYYY Definite 100 Definite 
14 PNNNN No 10 No 
15 NNNNN No 0 No 
16 NNNNN No 0 No 
17 NNNNN No 0 Possible 
18 PPPNN Possible 30 Probable 
19 PPPPP Possible 50 No 
20 PPPPN Possible 40 Possible 
21 PPNNN Possible 20 No 
22 NNNNN No 0 No 
23 PNNNN No 10 Probable 
24 YYPPN Possible 60 No 
25 PPPPP Possible 50 No 
26 YYYYY Definite 100 Possible 
27 YYYYY Definite 100 Definite 
28 PPPNN Possible 30 No 
29 NNNNN No 0 No 
30 NNNNN No 0 No 
31 NNNNN No 0 No 
32 YYYPP Possible 80 Possible 
33 YYYYY Definite 100 Probable 
34 NNNNN No 0 No 
35 YYYYY Definite 100 Definite 
36 PPPPP Possible 50 No 
37 YYYYY Definite 100 Probable 
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It can be seen from Table 23 that in the opinion of the Expert Panel, 14 workers were 
definite cases of EAA, 12 were possible cases of EAA and 11 were definitely not 
cases of EAA. For all of the 14 definite cases of EAA, there was full agreement by all 
five members of the panel, i.e. a panel score of 100%. Possible cases had a range of 
Expert Panel Scores between 20-80% and definitely not EAA cases a range of 
scores between 0-10%. 
Table 24: Reproducibility of panel opinion for EAA cases 
Case Panel opinion 1 Panel opinion 2 
1 Definite case 
(YYYYY = 100%) 
Definite case 
(YYYYY = 100%) 
2 Definite case 
(YYYYY = 100%) 
Definite case 
(YYYYY = 100%) 
3 Definite case 
(YYYYY = 100%) 
Definite case 
(YYYYY = 100%) 
4 Definitely not a case 
(NNNNN = 0%) 
Definitely not a case 
(PNNNN = 10%) 
5 Possible case 
(PPPPP = 50%) 
Possible case 
(YYPPN = 60%) 
6 Definitely not a case 
(NNNNN = 0%) 
Definitely not a case 
(NNNNN = 0%) 
7 Possible case 
(PPPPP = 50%) 
Possible case 
(PPPPN = 40%) 
8 Possible case 
(PPPNN = 30%) 
Possible case 
(PPPNN = 30%) 
9 Definitely not a case 
(NNNNN = 0%) 
Possible case 
(PPNNN = 20%) 
10 Definite case 
(YYYYY = 100%) 
Definite case 
(YYYYY = 100%) 
 
The reproducibility of the Expert Panel opinion was good and the results are shown 
in Table 24. The final opinion only varied in one case on repeat testing, with a 
definitely not a case of EAA becoming a possible case. The four definite cases re-
reviewed remained definite cases. For the Expert Panel Score, the concordance 
correlation coefficient was 0.98, with a mean difference of 5% (range 0-20%). 
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Comparison with interleukin-2 
There was a significant positive correlation between the serum levels of a cytokine 
interleukin 2 (IL-2) and the Expert Panel Score (figure 12). The Pearson correlation 
coefficient was 0.51 (p=0.004). 
 
Figure 12: Scatter plot showing correlation between IL-2 and Expert Panel 
Score 
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Comparison of Expert Panel Opinion and Powertrain Case Definitions 
When the diagnostic criteria utilised in the Powertrain outbreak (modified Fox criteria) 
260 are reviewed for the 14 definite Expert Panel EAA cases, it can be seen that they 
were all classified as possible (n=2), probable (n=7), or definite (n=5) EAA cases 
(Figure 13). During the outbreak, any case scoring 4 (probable case) or above, on 
the modified Fox criteria was documented as being a case of EAA. All 14 of the 
definite cases identified by the expert panel had met the case definition of EAA at the 
time of the outbreak. 
It is possible to map the modified Fox criteria scores against the Expert Panel Score, 
for each of the 37 workers (Figure 14). This demonstrates the range of Expert Panel 
clinical opinion for each level of the outbreak diagnostic criteria scores. It can be 
seen that, of the 37 workers reviewed by the expert panel, cases who met the 
‘possible EAA’ criteria at the time of the outbreak (a score of 4), had a range of 
Expert Panel Score between 0-100%, and for ‘probable cases’ in the outbreak (a 
score of 5), the range of Expert Panel Score was 10-100%. Those who had a 
‘definite EAA’ diagnosis at the time of the outbreak (a score of 6 or above), all 
received an Expert Panel Score of 100%. 
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Figure 13: Original case definitions (modified Fox criteria) used in Powertrain 
outbreak for the 14 workers with definite EAA as per Expert Panel opinion 
(score of 6 = definite, 5 = probable, 4 = possible case)  
 
 
Figure 14: Comparison of Modified Fox scores and Expert Panel Scores for the 
37 workers (Modified Fox case definition with score of 6 = definite, 5 = 
probable, 4 = possible case) 
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Discussion 
Principal Findings 
An Expert Panel of five occupational lung disease consultants from the GORDS 
group, reviewed the clinical case histories of 37 workers who had been suspected of 
having EAA due to MWF exposure during the Powertrain outbreak investigation. 
Information presented to the panel included summaries of work-related symptoms 
and the results of any diagnostic tests performed, including lung function, chest 
radiology, blood tests, alveolar lavage and lung biopsies. Data was provided from the 
initial Powertrain investigation and from subsequent follow-up visits at Birmingham 
Chest Clinic.  
The 14 definite cases as defined by the Expert Panel had all been diagnosed as EAA 
using the modified Fox criteria at the time of the outbreak, but not all had been 
classified as ‘definite EAA’ i.e. had not necessarily received a score of 6 or more. 
Additional to those 14 workers confirmed as having EAA by the Expert Panel, the 
Birmingham group had diagnosed a further 5 workers with EAA at the time of the 
outbreak and another one case subsequently. These 6 workers were not considered 
to be definite cases of EAA by the Expert Panel.  
 
Study limitations 
Due to the lack of a single diagnostic test for EAA, the condition is usually diagnosed 
on clinical grounds, based on the results of a range of diagnostic tests. We therefore 
retrospectively reviewed the outbreak investigation and clinical data for 37 workers 
suspected of having EAA in Phase 3 of the Powertrain outbreak investigation and 
used the clinical opinion of five UK occupational respiratory disease specialists as a 
gold standard diagnosis. The Expert Panel review was designed to mirror clinical 
practice, reviewing available clinical information, and discussing diagnosis between 
clinicians who had and had not been involved in each workers clinical care and 
follow-up. No information was provided to the panel regarding how each worker had 
been classified during the Powertrain outbreak, however two panel members had 
been involved in the medical care of the workers. The main output from the panel 
was to divide workers in to two groups, dependent on whether they had definite EAA 
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or not, to allow comparison between these groups. We therefore adopted a stringent 
requirement of at least four out of five panel members to agree a worker definitely 
had EAA, in order to ensure this classification was as close to a clinical gold standard 
diagnosis as possible. The opinion of the panel was also translated in to a score, 
which showed good reproducibility and was significantly positively correlated with a 
blood test marker of T-cell activation. The results of T-cell activation were not 
available at the time of the panel meeting.   
Many cytokines have been linked to the pathogenesis of EAA for example IFN – γ 
357, IL – 17 358 359, IL- 12, IL – 18 TNF – α 360, IL – 5, IL  - 1β 361 and IL – 2 362. IL – 2 is 
used to demonstrate correlation with the panel score because this was measured by 
the original group investigating the Powertrain outbreak and therefore the data was 
available. It has not been demonstrated that this interleukin in the marker of choice 
and it is not an accepted gold standard for monitoring T-cell activation. 
Clearly the opinion of the Expert Panel was based on the data presented to them, 
data collected during the investigation of an unexplained outbreak and subsequent 
outpatient visits, rather than from the results of a carefully designed research study. 
EAA is a variable disease and logistical issues within the NHS may have determined 
the timing of the tests, this is likely to have affected the predictive value of certain 
diagnostic investigations. Important examples of this include outpatient CT scanning 
and gas transfer estimates, where there may have been a several week interval 
between requesting the test and it being performed, potentially allowing time for a 
symptomatic worker to recover. Clearly the value of any diagnostic test in a variable 
disease is likely to be greatest if it is performed at the time of a worker having 
symptoms, which may not always be possible in an NHS outpatient setting.  
There was also some missing data, as not all workers had been judged to require the 
full range of tests, and some workers were lost to clinic follow up. The workers rated 
as “possible cases” of EAA by the Expert Panel therefore are likely to represent a 
mixed group, with some truly indeterminate cases,and some with insufficient clinical 
information. Due to the retrospective nature of the panel review, diagnosis could only 
be based on the results of the tests that had already been performed i.e. the Expert 
Panel were unable to request extra tests or further question the patients. 
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The Expert Panel only reviewed cases where a doctor in the Birmingham Chest 
Clinic had previously suspected EAA or humidifier fever, during Phase 3 of the 
Powertrain outbreak investigation. In this highly selected group of 37 workers, there 
was unanimous agreement for 14 definite cases of EAA. It is entirely possible 
however that there were more actual cases of EAA in the outbreak, who were not 
identified in the earlier phases, or who did not take up the invitation to attend hospital 
appointments.  
At the time of the outbreak, there were initially thought to be, based on clinical 
opinion alone, 24 cases of EAA. At the time of publication, this was reduced to 19 by 
using the modified Fox criteria. Emerging data after the time of publication confirmed 
an extra case that met the criteria, bringing the total to 20. This is reflected in graph 3 
by 20 points with a modified fox score of 4 or above.  
 
Comparison with other studies 
EAA is now a well recognised complication of exposure to water containing MWF. In 
some outbreaks the investigators have relied on diagnosis by a physician 279 289 296. In 
1995, Bernstein reported a case series of six workers from an automobile-
manufacturing site who were evaluated and treated for respiratory disease between 
April and September of 1992. This was the first documented outbreak of MWF 
related EAA. No diagnostic criteria were used, just clinical assessment including 
appropriate investigations. Rose et al. and Hodgson et al. relied heavily on a biopsy 
showing changes consistent with EAA for a diagnosis 287 294. Other outbreak 
investigations have adopted a diagnostic criteria 1 260 288 302 303, the validity of these 
criteria are discussed in chapter 2. Other investigations have used a combination of 
diagnostic methods, in report HETA 2001 0303 2893 some cases of EAA were 
physician diagnosed and others were diagnosed based on a diagnostic criteria 299. 
As far as is evident, no outbreak investigation has previously used an expert panel 
case review in order to decide on definite diagnosis of EAA. The use of an expert 
panel is time consuming and potentially costly and may be difficult to arrange in an 
emerging outbreak setting. However it was felt that, given the lack of gold standard 
test or specific validated diagnostic criteria, the consensus diagnosis of a group of 
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expert occupational respiratory physicians would provide the best available diagnosis 
of definite EAA.  
In the 14 cases of definite EAA diagnosed by the expert panel there was total 
agreement among the panel members, creating a panel score of 100%. However in 
the cases when EAA was thought to be possible but not definite, there was an expert 
panel score range 20-80%. Clearly, even in the retrospective review of clinical cases, 
discrepancy still occurred between experts. This mirrored the findings of work by 
Baldwin et al. and Turner et al. who looked at OA and agreement in diagnosis 
between experts 363 364. In both studies, there was significant variation in diagnostic 
opinion. Baldwin et al provided physicians with 35 peak flow records from workers 
under investigation for suspected OA including details of nature of work, inter-current 
illness, drug therapy, predicted PEF, rest periods, and holidays. Simple plots of PEF 
and the Oasys-2 generated plots were available. Experts were advised that 
approximately 1 hour was available to review the records and were asked to score 
each record for evidence of asthma and occupational effect, these scores were 
expressed as a percentage.  Cases were divided in to 2 groups depending on the 
scores, 0-50% and 51-100%.  For occupational effect, median kappa values were 
0.83 (range 0.56–0.94) for the two groups. For asthma, median kappa values were 
0.58 (0–0.67). It was concluded that considerable variation in agreement was seen in 
expert interpretation of occupational PEF records which may lead to inconsistencies 
in diagnosis of OA 363.  
Turner et al. sent summaries of possible OA cases to 104 occupational and 
respiratory physicians, to identify differences in diagnoses between the specialties.  
Raters assigned likelihood scores (0–100%) of OA based on case histories (phase 1) 
and on histories plus investigative procedures (phase 2). The difference between 
mean overall scores was 2.1% (52.1% occupational physicians; 50.0% respiratory 
physicians) in phase 1 (95% CI −2.6 to 6.8, p=0.37). In phase 2, mean overall scores 
were 46.1% (occupational physicians) and 41.5% (respiratory physicians); the 
difference in mean overall scores was 4.6% (95% CI −3.5 to 12.5, p=0.27). However, 
despite mean overall scores between the groups being similar, on a case by case 
basis, the OA scores showed limited agreement within each group of (occupational 
or respiratory) physicians. Raters with General Medical Council registration ≥1986 
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were found to be more likely to give a positive occupational asthma diagnosis. In 
phase 2, male raters were more likely to label cases as OA than female raters (RR 
4.5, 95% CI 3.3 to 6.0) 364.  
Diagnosis by the expert panel was based on clinical review of data, as this was the 
chosen gold standard of the research team. Other teams have chosen different 
methods as their gold standard, and different levels of acceptable certainty in the 
diagnosis. When the Birmingham team, investigating Powertrain used the modified 
Fox criteria, they agreed to count even possible EAA 260. However, as the aim of our 
research is to identify a group of workers with definite EAA in order to compare and 
contrast their clinical findings, it was important to take a more stringent approach. 
 
Study Implications 
EAA has traditionally been described to have an acute, subacute and chronic form. In 
the acute form, respiratory and systemic symptoms tend to occur 4 -8 hours after 
exposure and persist for up to 12 hours. In these patients the history is often clearer, 
especially if exposure to a known antigen is present. In other patients the disease 
takes a more insidious, progressive form, with non specific symptoms such as 
worsening dyspnoea on exertion 201 207. In some workers with subacute EAA, 
constitutional flu-like symptoms such as fever, myalgia, malaise and weight loss are 
more predominant than respiratory symptoms 293. The variable face of EAA means it 
can be difficult to identify the disease, in some cases leading to delayed diagnosis.  
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Conclusion 
In an outbreak setting, it is not possible to have the wealth of follow up data that was 
available to the Expert panel. However by studying the cases that the panel defined 
as definite EAA and comparing them to those that were not, it may be possible to 
retrospectively isolate clinical differences that could aid diagnosis of ‘definite EAA’ in 
future outbreaks of EAA associated with MWF. 
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Chapter 4: Sensitivity and positive predictive value of questionnaire 
responses in the Powertrain outbreak of metal working fluid – 
extrinsic allergic alveolitis 
 
Introduction 
Expert panel opinion may be considered gold standard for the diagnosis of the 
multifaceted disease that is EAA, however the practicality of this is clearly limited. In 
the case of individual patients, clinical review of the patient and investigative results, 
perhaps with discussion in a multidisciplinary meeting, would usually be sufficient to 
establish a working diagnosis. In the setting of a large outbreak of respiratory disease 
in a MWF exposed population, the feasibility of a full clinical review of every worker 
would be restricted. In such scenarios, screening questionnaires have been utilised 
to identify workers with potential occupational respiratory problems. Little is 
understood about the predictive value of particular screening questions in this 
situation, both for occupational asthma or EAA.  
For OA, it has been possible to examine the performance of questionnaire responses 
against specific inhalation challenge results, for patients referred to tertiary centres, 
although this is likely to be different in an outbreak situation.  Malo et al. found that 
wheezing at work occurred in 88% of subjects with OA and was the most specific 
symptom. Nasal itching at work, and improvement in symptoms at weekends and on 
vacations were also significantly associated with the presence of OA 365. 
Similarly, Lacasse et al. investigated which symptoms best predicted EAA in referrals 
to specialist centres. They concluded that dyspnoea, recognised exposure to known 
EAA inciting antigen, cough, recurrent episodes of symptoms and weight loss carried 
the highest predictive values ranging from 98% to 42% respectively 215. 
The first phase of the Powertrain outbreak investigation was completed in May 2004 
when 808 of the 836 workers completed a 'self reporting' symptom questionnaire, 
including 11 screening questions. A further, more extensive questionnaire was 
completed by those workers recording a respiratory or nasal symptom, or weight 
loss. The results of the questionnaires and further follow up data were entered in to 
an SPSS database. 
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The aim of this chapter was to compare the questionnaire responses of those 
workers who had a definite diagnosis of EAA, as decided by the expert panel 
(chapter 3) and those workers who did not. By calculating the sensitivity and positive 
predictive value of each question, the usefulness of the individual questions in 
identify cases of MWF-EAA in an outbreak setting could be established thus 
highlighting those questions that should be included in future questionnaire surveys. 
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Methodology 
During the outbreak investigation at the Powertrain site, workers who complained of 
at least one respiratory or nasal symptom or weight loss during the initial screening 
questionnaire were invited to take part in phase 2 of the investigation. The phase 2 
assessment included a detailed questionnaire (appendix 2), spirometry and blood 
tests undertaken at the factory site during June 2004. The phase 2 questionnaire 
involved 108 questions on worker and workplace demographics, shortness of breath, 
cough, ocular, nasal and throat symptoms, past illnesses, asthma symptoms, and flu 
like symptoms. An initial clinical opinion was then provided based on the 
questionnaire responses and spirometry results. 
Based on the results of phase 2 assessments, employees with symptoms suggestive 
of occupational disease were identified and invited to enter phase 3. 161 workers 
were seen for more detailed investigation at Birmingham Chest Clinic, this included 
pulmonary lung functions, chest x-rays, methacholine challenge tests (for bronchial 
hyperreactivity), skin prick tests for common environmental allergens, and HRCT. 
In phase four, case definitions for EAA and OA were applied to identify cases that 
met predefined objective criteria with onset of disease after January 2003. The case 
definition groups were not mutually exclusive which resulted in workers potentially 
being assigned to more than one group. Those workers who, at phase 3 were 
suspected to be suffering from EAA were discussed by the expert panel and a 
definitive diagnosis of definite EAA, possible EAA or not EAA was made.  
All results from phase 1-4 of the investigation, follow up data and the findings of the 
Expert Panel were entered in to an SPSS database. This database was used to 
compare the questionnaire responses of workers with definite EAA, as defined by the 
expert panel, and those workers without definite EAA. With this information, the 
sensitivity and positive predictive value of each screening question was calculated. 
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Due to the design of the outbreak investigation, the calculated specificity and 
negative predictive value of questionnaire items would be artificially high, due to 
workers without an individual symptom being less likely to have continued in to the 
later phases. It is not possible to say therefore, whether a worker without a specific 
symptom was actually suffering from undiagnosed EAA, which could have potentially 
been identified based on physiology or radiological changes in later phases. For this 
reason, these values have not been calculated. 
Table 25: Sensitivity and positive predictive value  
Term Definition 
Sensitivity The proportion of actual positives which the question correctly 
identified as such (i.e. the percentage of patients with definite 
EAA who answer positively to the question). 
Positive 
Predictive 
Value 
Positive predictive value is the proportion of subjects with 
positive test results who are correctly diagnosed (i.e. the 
percentage of patients who answer positively to the question that 
have EAA).  
 
All responses to the Phase 1 questionnaire were used due to the binary nature of 
their answer i.e. yes or no. The first 18 questions of the phase 2 questionnaire are 
regarding the worker demographics and the responses provide continuous data, for 
example ‘On average, how many hours do you work in a week?’ These questions 
and those similar have not been included in the results as it is not possible to 
calculate the sensitivity and positive predictive value. The responses to the phase 2 
questionnaire are subdivided in to shortness of breath, cough; ocular, nasal and 
throat symptoms; past illnesses, asthma symptoms, and flu like symptoms. 
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Results 
This is a results summary, see appendix 2 and 3 for full details. 
Phase 1 screening questionnaire 
Table 26: Phase 1 responses 
Question: In the last 18 months have you 
had any... 
Sens% PPV% 
1 wheeze or chest tightness 93 4 
2 treatment for chest 100 8 
3 woken at night with cough or tightness 100 5 
4 episodes of breathlessness 93 5 
5 time off with chest disease 100 13 
6 tightness/breathlessness post exercise 93 4 
7 difficulty breathing 93 7 
8 eye irritation 64 3 
9 stuffy nose 64 2 
10 soreness of nose, lips or mouth 43 3 
11 unexplained weight loss 79 25 
The phase 1 questionnaire was the initial survey of the workforce, aiming to identify 
any worker who may be suffering from a respiratory problem. The question with the 
greatest positive predictive value was Qu 11: In the past 18 months, have you had 
any unexplained weight loss? with a PPV of 25%. 
Both Qu 2: Have you taken any treatment for your chest? and Qu 5: Have you had 
any time off work with any chest illness? refer to previous medical illness related to 
chest disease in the preceding 18 months. Both questions have a sensitivity of 100%, 
showing all workers with EAA, as defined by the expert panel, had had either 
treatment or time off due to chest disease before the investigation took place. They 
have a positive predictive value of 8% and 13% respectively, which suggests that 
there were high numbers of workers with significant respiratory symptoms other than 
those diagnosed with EAA.  
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Qu7: Have you developed difficulty breathing? is a very broad respiratory question 
and would be expected to detect most cases of EAA. This is illustrated with a 
sensitivity of 93%. However, as it is also a common symptom of most respiratory 
disease so the positive predictive value is only slightly raised at 7%. 
Questions 8-10 refer to ocular, nasal and oral symptoms. These are not symptoms 
usually associated with EAA and therefore showed low positive predictive values of 
3, 2 and 3% respectively.  
Phase 2 screening questionnaire 
Table 27: Shortness of breath (SOB) 
Question: On your worst day in the last 
12 months... 
Sens%  PPV% 
20 SOB hurrying on flat or walking up hill 100 6 
21 SOB walking with peers 100 11 
22 Stop for breath walking on own on flat 93 22 
23 SOB washing and dressing 64 39 
25 SOB waking 50 13 
26 SOB during day 100 11 
27 Woken from sleep SOB 71 18 
28 SOB worse at beginning of week 8 7 
29 SOB worse at end of week 79 16 
30 SOB no different through week 25 2 
31a SOB better on days away from work 85 9 
31b SOB same on days away from work 15 2 
31c SOB worse on days away from work 0 0 
32a SOB better on holiday 85 7 
32b SOB same on holiday 15 3 
32c SOB worse on holiday 0 0 
34 SOB at present 86 8 
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Questions 20 –23 ask about shortness of breath at decreasing levels of exertion, 
from hurrying on level ground or walking up a slight hill, to washing and dressing. As 
the disability through breathlessness increases, the sensitivity of the question 
decreases but the positive predictive value increases. For Example, Qu 20 On your 
worst day in the last 12 months, did you get SOB when hurrying on level ground or 
walking up a slight uphill?  has a sensitivity of 100 % and a positive predictive value 
of 6% but Qu 23 On your worst day in the last 12 months, were you short of breath 
washing or dressing? has a sensitivity of 64 % and positive predictive value of 39%.  
The time of day that a worker is most affected by their breathlessness was 
investigated by questions 25 – 27. Of the three questions, the one with the greatest 
positive predictive value is Qu 27 On your worst day in the last 12 months, were you 
woken from your sleep? (sensitivity of 71% and positive predictive value of 18%).  
Qu 28 On your worst day in the last 12 months, was your breathlessness worse at 
the beginning of the working week? has a sensitivity of 8 % and a positive predictive 
value of 7% and Qu 29 On your worst day in the last 12 months, was your 
breathlessness worse at the end of the working week? had a sensitivity of 79 % and 
a positive predictive value 16%. These values show that more cases of EAA felt short 
of breath at the end of the week compared to the beginning, and more of the 
respondents complaining of worse shortness of breath at the end of a week rather 
than the beginning had EAA. 
Qu 31a On days away from work, is your breathlessness better?  and Qu 32a On 
holidays is your breathlessness better? are both questions aiming to identify whether 
the worker is less short of breath when not at work. These questions validate each 
other’s answers, by confirming that workers are less short of breath away from the 
workplace, having almost identical sensitivities (85%) and positive predictive values. 
Interestingly, the positive predictive value of these questions, 9% and 7% 
respectively, is approximately half that of Qu 29 (16%), despite all three questions 
referring to the temporal relationship of the shortness of breath. This suggests that 
workers at Powertrain who identified deterioration in their breathing through a 
working week are more likely to have EAA than those who only notice an 
improvement when away from work/on holiday. 
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Table 28: Cough and sputum 
Question Sens% PPV% 
35 Cough 93 4 
38 Cough on waking 62 7 
39 Cough during day 92 5 
40 Woken by cough 43 8 
41 Cough worse at beginning of week 7 6 
42 Cough worse at end of week 50 9 
43 Cough same all week 43 3 
44a Cough better away from work 69 7 
44b Cough same away from work 23 2 
45a Cough better on holidays 69 5 
45b Cough same on holidays 23 3 
45c Cough worse on holidays 0 0 
46 Cough up sputum 86 5 
47 Sputum 3 months per year 77 6 
48 Sputum 3 months per year for 2 yrs 34 3 
50 Sputum on waking 62 7 
51 Sputum during day 71 6 
52 Sputum worse at beginning of week 0 0 
53 Sputum worse at the end of week 43 8 
54 Sputum no different throughout week 43 4 
55a Sputum better away from work 46 5 
55b Sputum worse away from work 38 4 
56a Sputum better on holiday 62 6 
56b Sputum same on holiday 23 3 
 
The question regarding cough and sputum with the highest sensitivity was the 
opening question, Qu 35: Do you cough? with a sensitivity of 93%. Because of the all 
encompassing nature of the question it has a low positive predictive value of 4% as 
many of the workers responding positively to this question had conditions other than 
EAA resulting in a cough. 
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Deterioration in symptoms throughout the working week and improvement away from 
work/on holiday, as seen in the shortness of breath questions, are echoed but not as 
extreme in the cough and sputum question responses. A positive response to Qu 41: 
Is your cough worse at the beginning of the week? has a sensitivity of only 7% and a 
positive predictive value of 6%. Qu 42: Is your cough worse at the end of the week? 
has a much higher sensitivity of 50% and slightly higher positive predictive value of 
9%. A higher sensitivity (69%) but similar PPVs of 7% and 5% respectively can be 
seen in Qu 44a Is your cough better away from work? and Qu 45a Is your cough 
better on holiday? This suggests that patients with EAA are less likely to complain of 
temporal changes in cough rather than shortness of breath but if anything, they 
notice improvement away from work/on holiday rather than notice deterioration 
throughout a working week. 
As regards to the sputum production in Powertrain workers, the question with the 
greatest sensitivity is the opening question, Qu 46 Do you cough up phlegm (sputum) 
from your chest? (sensitivity 86%). Sputum production is not specific to EAA and this 
is reflected in the low positive predictive value (5%). For those workers with EAA who 
do expectorate, the responses demonstrate an increased production at the end of the 
week compared to the beginning of the week. Qu 52: Is your phlegm production 
worse at the beginning of the week? and Qu 53 Is your phlegm production worse at 
the end of the week? Show sensitivities of 0% and 8% and positive predictive values 
of 0% and 43%. These values indicate that none of the EAA cases produced more 
sputum at the beginning of the week. 
In summary, 100% of the EAA cases had shortness of breath, 93% had cough and 
86% had sputum. All 3 of these symptoms are relatively common in the general 
population at Powertrain so the positive predictive value is low ranging from 5% for 
sputum production to 9% for shortness of breath. A temporal relationship associating 
these symptoms to work was most evident with shortness of breath being described 
as worse at the end of a working week in 79% of definite EAA cases, with a PPV of 
16%.
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Table 29: Ocular and nasal and throat 
Question: In the past 12 months have you 
had... 
Sens% PPV% 
58 2 x episodes of eye irritation or 
watering 
64 4 
60a Eyes better away from work 36 3 
60b Eyes same away from work 29 4 
60c Eyes worse away from work 0 0 
61a Eyes better on holiday 43 4 
61b Eyes same on holidays 21 3 
61c Eyes worse on holidays 0 0 
62 Blocked or stuffy nose 79 3 
64a Nose better away from work 36 3 
64b Nose same away from work 43 3 
64c Nose worse away from work 0 3 
65a Nose better on holiday 64 0 
65b Nose same on holiday 14 2 
66c Nose worse on holiday 0 0 
66 Dry or sore throat 71 3 
68a Throat better away from work 50 4 
68b Throat same away from work 21 2 
68c Throat worse away from work 0 0 
69a Throat better on holiday 57 4 
69b Throat same on holiday 14 2 
69c Throat worse on holiday 0 0 
 
The questions with the highest sensitivities are the two lead questions, Qu 58: In the 
past twelve months have you had more than two episodes of irritation or watering of 
the eyes? (64%), Qu 62: In the past twelve months have you had more than two 
episodes of blocked or stuffy nose? (79%) and Qu 66: In the past twelve months 
have you had more than two episodes of a dry or sore throat? (71%).These 
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sensitivities indicate that a high proportion of workers with EAA suffered with ocular, 
nasal and throat symptoms. However, the PPVs range from 3-4% suggesting that the 
symptoms are common throughout the workforce who completed phase two of the 
questionnaire. What is apparent is that workers with definite EAA consistently denied 
symptoms being worse out of work and generally felt that their ocular, nasal and 
throat symptoms were worse at work. 
Table 30: Past illness 
Question Sens% PPV% 
71 Previous chest illness 50 4 
72 Treatment for chest 79 15 
73 Lymphoma 0 0 
74 Weight loss 64 9 
 
In the past illnesses section of phase two, the question with the highest positive 
predictive value is Qu 72: Are you taking any treatment for your chest?  This 
indicates that 79% of the definite cases of EAA were already taking treatment for 
chest disease at the time of the outbreak. It is not possible to know whether those 
patients had been diagnosed with EAA and were consequently taking appropriate 
treatment. In many cases, EAA is initially misdiagnosed as conditions such as 
infection or asthma, and this was certainly noted to be the case for some workers 
when preparing the clinical reviews for presentation to the expert panel (chapter 3).  
The positive predictive value of this question is 15%, suggesting that 85% of the 
workers who responded positively to this question were not in the 14 that were 
ultimately diagnosed as having definite EAA, thus demonstrating a high burden of 
other chest disease within the population. 
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Table 31: Asthma 
Question Sens% PPV% 
75 Previous asthma diagnosis 43 8 
In the last 12 months... 
76 Chest tightness or breathing difficulties 100 5 
79 Chest or breathing difficulties on 
waking 
50 8 
80 Chest or breathing difficulties during 
day 
93 6 
81 Woken from sleep by chest or 
breathing 
50 10 
82 Chest or breathing worse at beginning 
of week 
0 0 
83 Chest or breathing worse at the end of 
week 
75 14 
84 Chest or breathing same throughout  
week 
25 2 
85a Chest or breathing better away from 
work 
77 8 
85b Chest or breathing same away from 
work 
23 2 
85c Chest or breathing worse away from 
work 
0 0 
86a Chest or breathing better on holidays 92 8 
86b Chest or breathing same on holidays 8 1 
86c Chest or breathing worse on holidays 0 0 
 
100% of the workers with definite EAA suffered with chest tightness or breathing 
difficulties, although a PPV of PPV 5% suggests that a large proportion of the other 
workers also complained of these symptoms. As regards the temporal relationship, 
this follows the same pattern as that demonstrated with the shortness of breath, 
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cough and sputum questions, with a 92% of the EAA cases stating an improvement 
during holidays (PPV 8%), 77% stating an improvement away from work (PPV 8%) 
and 75% complaining of worsening symptoms throughout the working week. The 
progression of symptoms throughout the week has the highest PPV, 14%.  
Question: In the past 12 months have you 
had... 
Sens% PPV% 
87 Wheezing or whistling (WW) 86 5 
90 WW on waking 54 8 
91 WW during the day 86 7 
92 Woken from sleep by WW 54 13 
93 WW worse at beginning of week 7 10 
94 WW worse at end of week 57 13 
95 WW same throughout week 23 2 
96a WW better away from work 62 8 
96b WW same away from work 23 2 
96c WW worse away from work 0 0 
97a WW better on hols 77 8 
97b WW same on hols 8 1 
97c WW worse on hols 8 1 
 
The temporal association of wheeze mirrors that identified by earlier respiratory 
symptoms. Waking at night due to difficulty in breathing or a tight chest (sensitivity 
50% PPV 10%) or wheeze (sensitivity 54% PPV 13%) in the previous 12 months was 
documented by at least half of the cases of definite EAA. This compares to 100% of 
the cases when asked in phase one if in the past 18 months, they had woken at night 
with a cough or chest tightness? This is a symptom traditionally associated with 
asthma rather than EAA. 
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Table 32: Flu 
Question: In the past 12 months have you 
had... 
Sens% PPV% 
98 Recurrent flu like symptoms 62 4 
99 Fever 38 5 
100 Shivering 38 5 
101 Tiredness 62 4 
102 Weakness 62 5 
103 Joint/muscle pains 54 4 
106 More freq after particular job 25 17 
107a Flu at beginning of week 15 11 
107b Flu at the end of the week 31 11 
107c Flu same throughout week 17 1 
108a Worse back at work after weekend 46 13 
108b Worse back at work after holiday 46 11 
 
Phase two questionnaire illustrated that flu like symptoms in general are common in 
workers with and without definite EAA. Qu 106: Do these symptoms occur more freq 
after doing a particular job? aims to associate the flu like symptoms to a particular 
activity.  Although this question is not particularly sensitive, in that only a quarter of 
the workers with EAA felt that they had flu like symptoms that occurred more 
frequently after doing a particular job, the positive predictive value was relatively high 
at 17%.  
Qu 107-108, look more generally at the association between work and flu like 
symptoms, rather than a specific activity. The style of the questions is slightly 
different than that seen in previous sections of phase two. Qu 107a asks ‘Do these 
symptoms occur at the beginning of the working week?’ rather than whether they are 
worse at the beginning of the week. The temporal relationship is not as clearly 
evident as seen previously with the respiratory symptoms. Qu 108 refers to a 
worsening of flu like symptoms when returning to work after a weekend break or 
holiday (sensitivity 46% PPV 11% and 13%). This question maybe included due to 
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the typical increase in symptoms after a return to work post break seen in humidifier 
fever. 
When analysing a work health survey for responses typical of workers with EAA, the 
PPV of the question would be an important factor to consider. Those questions with 
the highest positive predictive value are listed in Table 2.  
 
Table 33: Questions in the Powertrain questionnaires with the highest positive 
predictive value 
Question 
number 
Question 
Positive 
predictive 
value (%) 
Phase 
one:11 
In the past 18 months, have you had any unexplained 
weight loss? 
25 
Phase 
two: 22 
On your worst day in the last 12 months, did you have 
to stop for breath walking at your own pace on level 
ground? 
22 
Phase 
two: 23 
On your worst day in the last 12 months, were you 
short of breath washing or dressing? 
39 
Phase 
two: 27 
Are you woken from sleep by your breathlessness? 18 
Phase 
two: 29 
Is your breathlessness worse at the end of the 
working week? 
16 
Phase 
two: 72 
Are you taking any treatment for your chest? 15 
Phase 
two: 106 
Do these symptoms (recurrent flu like symptoms) 
occur more freq after doing a particular job? 
17 
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Discussion 
Main Findings 
This study aimed to identify the most useful questions for recognising MWF-EAA 
during an outbreak. By comparing the questionnaire responses of those workers with 
definite EAA to the responses of those workers without definite EAA, the sensitivity 
and positive predictive value of each question was calculated.  
Three of the phase one eleven screening questions had 100% sensitivity; all the 
MWF-EAA cases had had time off work due to chest problems, treatment for chest 
conditions and had been woken with cough or chest tightness in the preceding 
eighteen months. The positive predictive values of these questions for EAA however 
were variable however, ranging from 5-13%. Question 11 of phase one asked ‘In the 
past 18 months, have you had any unexplained weight loss?’ had a lower sensitivity 
of 79% but a higher PPV of 25%. 
During Phase 2 of the Powertrain outbreak, a very detailed questionnaire was 
utilised, with over 100 questions. As regards respiratory symptoms, 100% of the EAA 
cases had shortness of breath and difficulty breathing or chest tightness, 93% had 
cough and 86% had sputum and wheeze. All of these symptoms are relatively 
common in the general population at Powertrain, so the positive predictive values are 
low ranging from 5% to 9%. A temporal relationship associating these symptoms to 
work was most evident with shortness of breath being described as worse at the end 
of a working week in 79% of definite EAA cases, with a PPV of 16%. The question 
with the highest PPV (39%) was Qu23: On your worst day in the last 12 months, 
were you short of breath washing or dressing? This suggests that although shortness 
of breath when hurrying on level ground or walking up a slight hill had a low PPV of 
6%, the greater the disability, the greater the proportion of positive respondents 
having definite EAA. 
Phase two questions relating to eyes, nose and throat had low PPV, which maybe 
expected as these are not symptoms typical to EAA. They were however common 
symptoms in the workforce in general. The question relating to flu like symptoms with 
the most significant PPV was that referring to increasing symptoms following 
completing certain task within the work place (PPV 17%). 
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Limitations 
The limitations in this chapter largely relate to its design, in terms of interrogating an 
existing database from an investigation of an unexplained health outbreak, with no 
facility to collect further data. The questionnaires were designed as part of an 
evolving outbreak investigation, not as part of a research study. A possible limitation 
is that only one constitutional symptom (unexplained weight loss) was included in the 
Phase 1 screening questions. It is possible therefore that some cases of MWF-EAA, 
for example those suffering recurrent flu-like symptoms in the absence of weight loss 
or respiratory symptoms, will have been classed as asymptomatic and not invited to 
take part in Phase 2 of the study. Consequently, they would have remained 
undiagnosed by the investigative team and their disease would not be included in the 
findings. It is possible to look at positive predictive value and sensitivity (as these 
calculations look at those workers with definite EAA, as defined by the expert panel), 
but it is not accurate to look at negative predictive value and specificity as we cannot 
guarantee that other additional workers at Powertrain did not have EAA that went 
unidentified by the researchers and so the total number of workers without EAA 
cannot be calculated. 
The response rate for this outbreak investigation was high, although not 100 percent.  
808 of 836 workers completed the first phase of the screening questionnaire. In the 
second phase, the detailed questionnaire was completed by 454 of the 481 
symptomatic workers. Both questionnaires were self-reporting and as a consequence 
not all were completed in their entirety. As the questionnaire responses were used by 
the investigating team to identify potential cases of occupational lung disease, 
missing data obviously leads to the potential of cases being over looked. 
The number of definite EAA cases in the analyses is the number diagnosed as 
definite cases by the expert panel. The limitations in the Expert Panel can therefore 
also be applied to any further analysis using the definite 14 cases as a reference 
point. The true number of cases of EAA caused by MWF exposure at the Powertrain 
site can never actually be calculated for certain and the limitations of the 
methodology of using an expert panel as a gold standard for diagnosis is discussed 
in Chapter 3. At expert panel review, there were other workers judged to be possible 
 132 
cases of EAA, some of whom were lacking definitive investigation results, and others 
were lost to follow up.  
Symptoms enquired about in phase one were often the subject of questions in phase 
two, and the sensitivity and PPV values were not always consistent. In phase two, 
workers were asked whether, in the previous 12 months they had experienced 
waking at night due to difficulty in breathing or a tight chest (sensitivity 50% PPV 
10%) or wheeze (sensitivity 54% PPV 13%). Unlike the 100% sensitivity seen in 
phase one, only half of the cases of definite EAA responded positively to the phase 
two questions.  The difference could be accounted for the extra 6 months covered by 
the phase one question. Nocturnal waking is a symptom traditionally associated with 
asthma rather than EAA.  
Question 11 of phase one asked ‘In the past 18 months, have you had any 
unexplained weight loss?’ This received a positive response from 11 of the 14 
definite cases, producing a sensitivity of 79%. 1 in 4 of the workers reporting weight 
loss in phase one went on to be diagnosed with MWF-EAA by the expert panel (PPV 
25%). Question 74 of phase two asked ‘Have you lost weight since January 2003?’ 
received a positive response from only 9 of the definite EAA cases and a much lower 
PPV (sensitivity 64% PPV 9%). 33 workers who did not receive the diagnosis of EAA 
responded positively to the phase one question and 92 to the phase two question 
regarding weight loss. The reason for almost 3 times as many non EAA cases, but 
less of the EAA cases, reporting weight loss in phase two of the questionnaire is not 
evident. It is possible that this relates to improvements in the workplace between the 
questionnaires or the phrasing of the question.  
 
Comparison with other work 
Comparison with the findings from other studies is limited by a lack of 
standardisation, in terms of type and extent of investigation and exact method of 
symptom identification. In the Powertrain outbreak, initial screening of the workforce 
found that symptoms were common with 60% of workers reporting at least one 
respiratory symptom and a further 18% having eye or nasal symptoms. This is in 
keeping with previously published outbreaks in large workplaces which have been 
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reviewed in detail in Chapter 1. For example, in a large automobile factory where 
there had been 8 reported cases of EAA, Trout et al. 299 found symptom prevalence 
to be 74% for unusual shortness of breath, 72% for wheezing and whistling, 68% for 
chest tightness, 51% for fever or sweats, and 34% for chills or shivering. In another 
study, HETA 99-0177-2828, in 1999, 43% of workers exposed to MWFs complained 
of unusual tiredness of fatigue 310.  
Eye, nose and throat symptoms are commonly reported in MWF outbreaks, and in 
Phase 1 of Powertrain nasal stuffiness was the most commonly reported symptom. 
Although these symptoms are not traditionally associated with EAA, they were 
reported by approximately two-thirds of workers with MWF-EAA. Their positive 
predictive value however was low and this may reflect a non-specific response in the 
workplace to high levels of fume or dust, or other allergic responses to MWF 
allergens.  For identifying subjects with OA, Vandenplas et al., found that the most 
useful questionnaire items in tertiary centres were wheezing at work, nasal and eye 
irritation 365. The high prevalence of nasal and eye symptoms in the Powertrain 
workforce suggests that they would not be discerning questions in an outbreak 
setting. 
The findings from our study can be compared with general EAA research findings 
outside of MWF outbreaks. Lacasse et al. reported a range of symptom prevalence 
for 116 patients with EAA, predominantly farmers and bird fanciers 215. He found 
breathlessness (98%) and cough (91%) to be the commonest symptoms of EAA, but 
unlike our study, found a much lower prevalence of chest tightness and wheezing 
(31-35%). In the Powertrain study, 79% of workers with EAA reported unexplained 
weight loss in Phase 1 (64% in phase two), this was higher than in Lacasse’s report 
where the corresponding figure were 42%. However the number of EAA cases 
describing shivering/chills was very similar with 38% in the Powertrain outbreak and 
34% reported by Lacasse et al and Trout et al  215 299. 
In addition to recording the presence or absence of symptoms, it is also usual for 
questionnaires to enquire about the work-relationship of symptoms, often by asking 
whether symptoms improve at weekends or on holidays 294. A number of existing 
general diagnostic criteria for EAA include variability in symptoms as a case criterion, 
but there is little published research relating to how exactly to ask about work-
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relatedness. In the Powertrain outbreak, questions regarding respiratory symptoms, 
especially shortness of breath that was worse at the end of the working week, had a 
greater positive predictive value than questions relating to symptoms that improved 
on weekends and holidays. A difference in symptom intensity associated with days at 
or away from work was not identified for constitutional symptoms, where the question 
with the highest PPV was for symptoms after a particular work task. The reasons for 
this variation are not clear from this study, although variation in working patterns, 
differences in disease phenotype, and confounding factors such as humidifier fever 
may be relevant. Because of these factors, some groups have removed the 
requirement for work-relatedness in their diagnostic criteria. For example, during the 
investigation of a large outbreak of EAA in Connecticut, the temporal patterns of 
symptoms were ignored, as it was believed that the variable nature of the disease 
and the long working hours of the employees rendered the work relatedness of 
symptoms unreliable 294. 
 
Implications 
When analysing questionnaire data from an outbreak of MWF-EAA, certain questions 
were found to have a relatively high PPV for EAA. Recent weight loss, extreme 
shortness of breath including nocturnal symptoms, breathlessness worse at the end 
of the working week and flu like symptoms associated with particular work tasks are 
all symptoms that should be noted with a high level of suspicion. These questions 
and also whether the worker is being treated for chest disease presently should be 
included in any screening questionnaire designed to detect MWF-EAA in an outbreak 
setting.  
When discussing work relatedness of symptoms, physicians should be aware that 
simply asking if symptoms improve while away from work, may not be sufficient and 
that patients should also be asked how their symptoms change throughout the 
working week. Due to the potential difficulties in establishing a temporal relationship, 
some researchers have decided to dispense with the need for this in their diagnostic 
criteria. 
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Conclusion 
This study illustrates the difficulties in developing a questionnaire for use in MWF 
outbreak investigations where symptom prevalence is high compared to actual cases 
of disease, and individuals with occupational asthma and alveolitis need to be 
accurately and rapidly identified to avoid further harm. This chapter has highlighted a 
number of simple questions which have a higher PPV for MWF-EAA and could, in 
conjunction with other diagnostic procedures, form the basis of future outbreak 
investigation survey.   
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Chapter 5: Development and validation of evidence-based case 
definitions for extrinsic allergic alveolitis due to metalworking fluid 
exposure 
 
Introduction  
After reviewing the outbreaks of MWF EAA and further discussing the different 
diagnostic criteria used to define EAA, it became clear that there is no consistent, 
evidence based diagnostic criteria available for use in an outbreak scenario. The 
majority of criteria have utilised some combination of symptoms, lung function, 
radiology, blood tests and/or biopsies. 
Fox et al. investigated the US Kenosha outbreak of MWF EAA which occurred 
between 1995-97 1. They were the first to develop and publish case definitions for 
EAA for the purposes of their study, although these had not been validated prior to 
their usage. Their seven point diagnostic criteria was based on (one point for each), a 
previous physician diagnosis of EAA, at least two respiratory and one constitutional 
symptom, a recurrence of symptoms after a three or more days break from work, 
restrictive spirometry, a reduced gas transfer, abnormal radiology, and granulomas 
on lung biopsy. It was these criteria in a slightly modified form that were later used in 
the Powertrain investigation 260.  
Dangman et al. developed an evidence-based non-invasive hypersensitivity 
pneumonitis (EAA) diagnostic index (HPDI) for outbreak investigations, in part to 
avoid the morbidity and expense of lung biopsies, which had been previously used 
for case definition in other outbreaks 293. They also recognized the clinical variability 
of EAA, and noted that EAA may present as chronic fibrotic lung disease, mimicking 
idiopathic pulmonary fibrosis or sarcoidosis. They compared data by logistic 
regression from 16 cases of biopsy proven EAA, with that from 14 workers thought 
least likely to have EAA. This found that workers with EAA had more symptoms, 
higher ESRs, lower gas transfers, higher alveolar-arterial oxygen gradients, lower 
vital capacities, more abnormal HRCTs, and more abnormal gallium scans, than 
those without EAA 293. In practice in the UK, as alveolar-arterial oxygen gradients and 
gallium scans are not routinely available, the HPDI is not a useful tool. 
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By using the definite cases of EAA, as defined by the Expert Panel, the sensitivity 
and PPV of the questions making up phase one and two of the Powertrain 
investigation have been calculated (chapter 4). This provided insight in to which 
questions would be useful in future outbreaks of respiratory ill health associated with 
MWF and have provided the basis of further analysis of the database, in order to 
formulate an evidence based diagnostic criteria for use in an outbreak setting of 
MWF associated EAA. 
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Methods 
Comparison of Expert Panel definite EAA cases versus cases reviewed but not 
diagnosed as definite EAA versus cases not review by expert panel 
Chapter 5 divides workers into, those reviewed by the panel and diagnosed with 
definite EAA (n=14), those reviewed by the panel and not diagnosed with EAA 
(n=23), and those not reviewed by the panel i.e. those not considered in phase 3 to 
warrant further investigation for EAA or humidifier fever. This differs from chapter 4, 
which divides workers in to just two groups, those with definite EAA and without 
definite EAA, so grouping the latter two groups together. Between the three groups, 
comparisons are made regarding basic demographics, responses to the eleven 
phase 1 screening questions, the major symptoms recorded in the phase 2 
questionnaire, lung function test results, blood test results, radiological findings, and 
histopathology and statistical analysis. Continuous data was compared using Student 
t-tests and categorical data was compared using Fisher’s Exact tests.  
 
Case definition development 
Utilising the clinical differences found during the comparison between those workers 
reviewed by the expert panel with and without definite EAA, and with knowledge of 
existing EAA diagnostic criteria, a new diagnostic case definition (MWF EAA Score) 
was developed. This was designed to fit as closely as possible with the Expert Panel 
opinion, whilst remaining clinically valid and inclusive. The new scoring system was 
then applied to the Powertrain workers, and compared with the Expert Panel Score. 
Suitable cut offs for definite, possible and definitely not EAA were chosen, to best 
match the opinion of the Expert Panel.  
The performance of the MWF EAA Score and other published case definitions were 
compared by applying each of the case definitions to the 37 Powertrain workers 
reviewed by the panel. Performance was assessed by comparing the proportion of 
workers correctly identified as definite, possible and definitely not EAA, against 
Expert Panel opinion. Cohen kappa scores for agreement between the Expert Panel 
and the different case definitions for definite EAA cases were also calculated. 
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Validation of MWF EAA Score 
In an attempt to externally validate the MWF EAA Score, the scoring system was 
also applied to all available previously published case reports of workers developing 
definite EAA due to MWF exposure.  
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Results 
 
Demographics of workers reviewed by Expert Panel 
 
Workers with EAA were on average slightly older, had a shorter employment history 
prior to the Powertrain outbreak, and were less likely to be current smokers than the 
other groups. These demographic factors were not statistically significantly different 
however, and there were no significant gender or atopy differences. The high level of 
atopy in the workers who had skin prick tests, but were not reviewed by the Expert 
Panel for suspected EAA, is likely to be explained in part by their having this test as 
part of investigation for possible allergic occupational asthma.  
 
Table 34: Comparison of demographics for workers who were or were not 
reviewed by the Expert Panel  
Demographic Reviewed by Expert Panel (N=37) 
 definite EAA           not definite EAA 
Not 
reviewed 
(n=473) 
Mean age (SD) 47 (8) 43 (8) 45 (9)  
Male 86% 91% 84% 
Smoker 7% 26% 25% 
Atopic 38% 35% 50% (n=118) 
Year first 
employed 
1996 1992 1992 
(n=464) 
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Analysis of Phase 1 screening questionnaire responses 
Responses to the Powertrain Phase 1 screening questionnaire responses can be 
compared between workers with definite EAA, workers reviewed but not thought to 
have EAA, and the remaining workforce, this data is shown in table 4. 
Table 35: Comparison of Phase 1 screening questionnaire responses for 
workers who were or were not reviewed by the Expert Panel (*significant 
p<0.05)  
Question Reviewed by Expert Panel 
(N=37) 
 definite EAA         not 
definite EAA 
Not 
reviewed 
(N=771) 
Episodes of wheeze or chest 
tightness 
93% 87% 40% 
Chest treatment  100%* 39%* 19% 
Woken with cough or chest 
tightness 
100% 74% 31% 
Episodes of breathlessness 93% 78% 28% 
Time off with chest illness 100%* 32%* 11% 
Chest tightness or breathlessness 
after exercise 
93% 87% 36% 
Difficulty with breathing 93% 64% 19% 
Eye irritation 64% 39% 40% 
Stuffy nose 64% 83% 61% 
Soreness of nose/lips/mouth 43% 44% 28% 
Unexplained weight loss  79%* 9%* 4% 
 
For workers with suspected EAA reviewed by the Expert Panel, the largest difference 
in terms of symptom prevalence between those with and without definite EAA was 
seen for unexplained weight loss. Significant differences were also seen for previous 
chest treatment, and previous time off with chest illness. 
 
The positive predictive values of questionnaire responses are shown in Table 36. In 
the first column these relate to the likelihood of respondents answering yes to each 
question, later going on to be clinically suspected of having EAA when assessed at 
Birmingham chest clinic (i.e. and therefore being reviewed by Expert Panel). 
Similarly, the second column shows the likelihood of workers answering yes to each 
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question, later being considered definite cases of EAA by the Expert Panel review, as 
previously discussed in chapter 4. It can therefore be seen that 1 in 4 workers who 
on initial screening reported unexplained weight loss, and 1 in 8 workers who 
reported having had time off with chest problems, went on to be diagnosed as a 
definite case of EAA.  
 
Table 36: Positive predictive value (ppv) of Powertrain screening questions 
Screening question ppv 
clinical 
suspicion EAA 
ppv 
definite 
EAA 
Have you had any episodes of 
wheeze or chest tightness? 
10% 4% 
Have you taken any treatment for 
your chest? 
14% 8% 
Have you woken at night with a 
cough or chest tightness? 
12% 5% 
Have you had any episodes of 
breathlessness? 
12% 5% 
Have you had any time off work 
with any chest illness? 
20% 13% 
Have you developed chest 
tightness or breathlessness after 
exercise? 
11% 4% 
Have you developed difficulty with 
breathing? 
15% 7% 
Have you had irritation or watering 
of the eyes? 
5% 3% 
Have you had a stuffy nose? 6% 2% 
Have you had any soreness of the 
nose, lips or mouth? 
7% 3% 
Have you had any unexplained 
weight loss? 
30% 25% 
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Analysis of Phase 2 questionnaire responses 
Table 37: Comparison of Phase 2 detailed questionnaire responses for workers 
who were or were not reviewed by the Expert Panel (* p<0.05) showing the 
prevalence of self-reported symptoms 
Question Reviewed by Expert Panel (N=37) 
definite EAA                  not definite 
EAA 
Not 
reviewed 
(N ~ 473) 
Cough 93% 87% 55% 
WR cough 77% 70% 31% 
Progressive cough 50% 50% 13% 
Wheeze 86% 70% 42% 
WR wheeze 77% 57% 21% 
Progressive 
wheeze 
57% 41% 10% 
Chest tightness 100% 87% 43% 
WR chest 
tightness 
86% 61% 25% 
Progressive CT 64% 48% 10% 
Shortness of 
breath 
MRC 2 
MRC 3 
MRC 4 
MRC 5 
 
100% 
100% 
93%* 
64% 
 
83% 
70% 
39%* 
22% 
 
42% 
20% 
7% 
2% 
WR SOB 92% 57% 27% 
Progressive SOB 79% 38% 10% 
Recurrent flu 62% 74% 39% 
WR flu 50% 43% 11% 
Progressive flu 29% 17% 7% 
 
When the prevalence of the main symptoms from the Phase 2 questionnaire is 
compared between the groups of workers (Table 37), the majority of symptoms were 
more common in the workers who were reviewed by the Expert Panel i.e. those with 
suspected EAA. This reflects the design of the Powertrain investigation, where those 
workers with symptoms in Phase 2, were invited to attend Birmingham Chest Clinic 
for further tests in Phase 3. It can also be seen that the prevalence of work-related 
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and progressive wheeze, chest tightness and shortness of breath were higher in 
workers judged to have definite EAA by the Expert Panel (although these differences 
did not reach statistical significance), as opposed to those judged not to have definite 
EAA. The high prevalence of symptoms is to be expected, as the Expert Panel only 
reviewed workers with clinically suspected EAA, based on their having reported 
compatible symptoms during the outbreak investigation.  
All of the definite EAA cases reported shortness of breath on exertion, with the 
majority suffering from severe breathlessness of MRC Grade 4 or 5. MRC Grade 4 
breathlessness (having to stop for breath when walking at your own pace on level 
ground) was significantly more prevalent amongst workers with definite EAA than 
workers without definite EAA.   
In terms of constitutional symptoms, recurrent flu-like symptoms were more 
commonly reported in workers reviewed by the expert panel but not diagnosed with 
definite EAA than those with definite EAA, where as the reverse was true for work-
related and progressive flu-like symptoms. It is likely that this reflects the distinction 
between workers with EAA, whose constitutional symptoms worsened through the 
working week, and workers with humidifier fever whose symptoms improved through 
the working week. Although not statistically significantly different, the largest 
difference in symptom prevalence was for progressive flu-like symptoms i.e. workers 
with flu-like symptoms that became progressively worse over the working week. 
 
Analysis of Phase 2 respiratory physiology 
In addition to symptom prevalence, similar comparisons can also be made for the 
results of the respiratory physiology tests. The majority of workers in Phase 2 
performed simple spirometry in the workplace, resulting in measurements of FEV1, 
FVC, and FEV1/FVC ratio. Although mean per cent predicted values for both FEV1, 
and FVC did not differ between those with and without definite EAA, mean levels 
were significantly lower in both of these groups as compared to the rest of the 
workforce. Again this is to be expected by the nature of patients selected for Expert 
Panel review. The mean FEV1/FVC ratio was similar between all three groups. 
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Table 38: Comparison of physiology for workers who were or were not 
reviewed by the Expert Panel (* p<0.05) 
Lung function Reviewed by Expert Panel (N=37) 
definite EAA          not definite EAA 
Not 
reviewed 
(N=473) 
FEV1 % pred 84% 85% 98% 
FEV1 < 80% pred 29% 35% 12% 
FVC % pred 85% 91% 105% 
FVC < 80% pred 21% 26% 5% 
FVC < 70% pred 14% 9% 1% 
FEV1/FVC  81% 80% 78% 
Tlco % pred 68%* 80%* N/A 
Tlco < 80% pred 79% 56% N/A 
Tlco < 60% pred 29%* 0%* N/A 
Kco 1.43* 1.71* N/A 
 
More detailed respiratory physiology was only performed in workers with suspected 
occupational lung disease, with measurements of carbon monoxide gas transfer 
(Tlco) and transfer co-efficient (Kco) performed in the hospital respiratory function 
unit. Mean percentage values for both of these were lower in the group of workers 
with definite EAA versus not definite EAA, and having a gas transfer less than 60% 
predicted was only seen in the former group. 
 
Analysis of Phase 2 blood tests 
Blood tests were also performed in a large number of workers as part of the Phase 2 
investigation. Workers with definite EAA had significantly higher mean levels of 
neutrophils and total white blood counts, as compared to workers reviewed by the 
Expert Panel but without definite EAA . No significant differences were seen for the 
other types of white blood cells, such as lymphocytes or eosinophils. Serum levels of 
alpha 1 antitrypsin (an acute phase protein with a half-life of 4.5 days) were 
measured in 31/37 workers reviewed by the Expert Panel, with mean values being 
significantly higher in the definite EAA group. The other inflammatory mediator 
measured in the Powertrain investigation was another acute phase protein, c-reactive 
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protein (CRP), which has a much shorter half-life of 5-7 hours. This was only 
measured in 18 Of the Expert Panel reviewed workers and although this did not 
reach statistical significance, was higher in four workers with definite EAA, than in 14 
workers without definite EAA. No significant differences were seen for the results of 
the other blood tests measured, immunoglobulin G or M, or serum ACE. 
 
Table 39: Comparison of blood test results for workers reviewed by the Expert 
Panel, who did and did not have EAA (* p<0.05) 
Blood test Definite EAA Not definite EAA 
CRP – mg/L 11 (13) 4 (3) 
WBC – x109/L 8.1 (2.0)* 6.64 (1.5)* 
Neutrophils – x109/L 5.9 (2.5)* 4.1 (1.3)* 
Lymphocytes – x109/L 2.1 (0.8) 2.2 (0.6) 
Eosinophils – x109/L 0.2 (0.1) 0.18 (0.1) 
IgG – g/L 9.5 (3.0) 11.4 (1.9) 
IgM –g/L 1.1 (0.7) 1.1 (0.5) 
ACE – U/L 31 (25) 38 (14) 
Alpha -1 antitrypsin –mmol/L 1.4 (0.11)* 1.21 (0.15)* 
 
 
Analysis of Phase 3 investigations 
In Phase 3 of the Powertrain investigation, workers with suspected EAA were 
investigated as clinically indicated. Further tests included chest radiology, CT scans, 
bronchoscopy with alveolar lavage lymphocyte counts, and transbronhial or surgical 
lung biopsies. Table 9 shows the results of these further tests, with the prevalence of 
positive results for those with and without definite EAA. The figures in brackets show 
that not all workers had all tests.  
Workers with definite EAA were more likely to have abnormal chest X-rays, CT 
scans, and BAL lymphocytosis, than those without definite EAA. These differences 
were only statistically significantly different for CT changes and positive biopsies in 
this small group.  
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Table 40: Comparison of radiological findings, bronchoalveolar lavage 
lymphocyte counts and lung biopsy results in workers reviewed by Expert 
Panel (*p<0.05) 
Symptom Definite EAA 
 
Not definite EAA 
CXR nodularity, alveolar 
infiltrate interstitial change 
54% (7/13) 29% (4/14) 
CT nodularity, ground 
glass, mosaic change or 
interstitial fibrosis 
86% (12/14)* 32% (6/19)* 
BAL lymphocytes 
 20% 
78% (7/9) 40% (2/5) 
Biopsy compatible with 
EAA 
62% (8/13)* 0% (0/5)* 
 
 
Development of diagnostic criteria from Powertrain data 
Utilising the clinical differences between those workers with and without definite EAA 
as defined by the Expert Panel review and the relative positive predictive value of 
each of the diagnostic elements from previously published MWF diagnostic criteria, it 
was possible to develop diagnostic criteria from the outbreak data. This is shown in 
Table 41, where the highest score from each of the five sections is applied, and then 
added together up to a maximum of 41 points. It would have also been possible to 
use a combination of questions to try and predict the diagnosis of EAA, for example 
by using logistic regression analysis, although this was not carried out for this thesis.  
Each of the sections is based on the usual groupings in other diagnostic criteria, 
comprising respiratory and constitutional symptoms, with abnormalities of lung 
function, radiology, clinical examination, biopsy and blood test results. Only those 
diagnostic elements that were collected in the Powertrain outbreak have been 
included.  
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The weighting of each score in each section is based on the positive predictive value 
of being a definite EAA case, whilst having that feature, in workers with a clinical 
suspicion of EAA. An example of this is that 14 out of 21 workers with unexplained 
weight loss went on to be diagnosed with definite EAA by the Expert Panel, i.e. a 
positive predictive value of 67%. This is then divided by ten, and rounded up or down 
to the nearest whole number, equating to a score of 7 in the diagnostic criteria. The 
content of each section has been selected with the intent of best separating the 
workers who were and were not thought to definitely have EAA by the Expert Panel. 
Table 41: MWF EAA Score during MWF outbreaks based on weighting scores 
by positive predictive value  
Respiratory symptoms 
Work-related cough/wheeze/sob/chest tightness 
Stopping for breath when walking at own pace on level ground 
Previous time off work with any chest illness 
 
  
 +4 
 +6 
 +7 
Constitutional symptoms 
Recurrent flu-like symptoms worse at the end of the working week 
Unexplained weight loss 
 
 
 +5 
 +7 
Physiology 
FVC < 80% predicted 
FVC < 70% predicted or Tlco < 80% predicted 
Tlco < 60% predicted 
 
 
 +3 
 +5 
 +10 
Radiology/clinical examination 
Abnormal CXR (diffuse ground glass or nodularity) 
Abnormal HRCT (ground glass, nodularity, mosaic, or UIP fibrosis)   
Fine end-inspiratory crepitations on auscultation 
 
 
 +6 
 +7 
 +7 
Evidence of inflammation 
Neutrophilia > 7 or CRP  10 
BAL lymphocytosis  20% 
Lung biopsy typical of EAA (granulomatous or UIP) 
 
 +5 
 +8 
 +10 
Maximal score  
 41 
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The calculated and total MWF EAA Score for each of the 37 workers is shown in 
Table 42. The first 14 workers were those felt to be definite EAA cases (EAA) by the 
Expert Panel (EP), and their MWF EAA scores ranged between 27-41. The next 12 
workers were cases of possible EAA (Poss), having scores between 7-30. The final 
11 workers were not thought to have EAA by the Expert Panel (Not), and had scores 
between 3-18. 
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Table 42: MWF EAA scores for the 37 workers reviewed by the Expert Panel 
EP Respiratory Constitutional Physiology Radiology/ex Inflammation Total 
EAA 7 7 10 7 5 36 
EAA 7 0 10 7 10 34 
EAA 7 7 3 7 8 32 
 
EAA 
7 7 5 7 10 36 
EAA 7 7 5 0 8 27 
EAA 7 7 5 7 10 36 
EAA 7 7 10 7 8 39 
EAA 7 5 5 7 8 32 
EAA 7 7 5 7 10 36 
EAA 7 7 5 7 5 31 
EAA 7 7 5 7 10 36 
EAA 7 7 10 7 10 41 
EAA 7 7 0 7 8 29 
EAA 7 7 5 7 10 36 
Poss 7 7 5 7 0 26 
Poss 4 3 5 7 5 21 
Poss 4 7 3 6 8 28 
Poss 6 7 5 0 0 18 
Poss 4 0 5 0 0 9 
Poss 6 7 5 7 5 30 
Poss 7 0 0 0 0 7 
Poss 7 5 0 0 0 12 
Poss 7 3 0 7 0 14 
Poss 7 7 5 0 0 19 
Poss 0 0 5 7 8 20 
Poss 4 7 5 0 5 21 
Not 0 0 3 0 0 3 
Not 4 0 5 7 0 16 
Not 6 0 5 7 0 18 
Not 4 5 5 0 0 14 
Not 4 0 0 0 0 4 
Not 7 0 0 0 0 7 
Not 6 0 0 0 0 6 
Not 0 0 5 0 0 5 
Not 6 0 0 0 0 6 
Not 4 0 5 6 0 15 
Not 7 5 0 0 5 17 
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There was a good level of correlation between the derived MWF EAA score, and the 
Expert Panel score, with a Pearson correlation coefficient of 0.85 (p<0.01). 
 
Figure 15: Graph comparing Expert Panel score and MWF EAA score for 37 
patients considered by Expert Panel 
 
Comparison of Expert Panel Opinion and MWF EAA Score 
By using suitable cut offs of MWF EAA Scores, that were defined manually, (definite 
case > 26, possible case 19-26, and definitely not a case < 19), it is possible to show 
agreement (shown in bold) with the Expert Panel opinion in 30/37 (81%) of cases 
(Table 43). The performance of the MWF EAA diagnostic criteria against the Expert 
Panel opinion, can then be compared to the performance of other published 
diagnostic criteria, which have categorized workers in to similar groups (shown in 
Tables 44 - 47.)  
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Table 43: Comparison between MWF EAA case definitions, versus Expert Panel 
opinion (81% agreement) 
 
 
 
 
It can be seen from Tables 44 - 47, that the proportion of correctly classified workers 
was 65%, 59%, and 43% for the three other published case definitions utilized 1 260 
293.  
Table 44: Comparison between modified Fox case definitions (as used in 
Powertrain Outbreak) 260, versus Expert Panel opinion (65% agreement) 
 
Table 45: Comparison between original Fox criteria (as used in Kenosha 
outbreak) 1, versus Expert Panel opinion (59% agreement) 
 
 Expert panel opinion 
 
MWF EAA 
Score 
 Definite Possible Not a case 
Definite 14 2 0 
Possible 0 5 0 
Not a case 0 5 11 
 Expert panel opinion 
 
Modified 
Fox score 
 Definite Possible Not a case 
Definite/probable 12 2 1 
Possible 2 3 1 
Not a case 0 7 9 
 Expert panel opinion 
 
Original 
Fox score 
 Definite Possible Not a case 
Definite/probable 10 2 0 
Possible 3 2 1 
Not a case 1 8 10 
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Table 46: Comparison between Hypersensitivity Pneumonitis Diagnostic Index 
case definitions 293, versus Expert Panel opinion (43% agreement) 
 
 
In addition, it is possible to compare the Cohen kappa levels of agreement between 
the Expert Panel definite cases, and the definite cases as rated by other case 
definitions (Table 47).  
 
Table 47: Levels of agreement between outbreak case definitions of definite 
EAA cases versus Expert Panel opinion 
Outbreak (year published) Cohen kappa agreement with 
Expert Panel definite cases 
Zacharisen 1998 (Wisconsin) 288 0.44 (moderate) 
Fox 1999(Kenosha) 1 0.68 (substantial) 
Hodgson 2001 (Connecticut) 294 0.34 (fair) 
Dangman 2002 (HPDI) 293 0.55 (moderate) 
Weiss 2002 (Ohio) 300 0.49 (moderate) 
Gupta 2006 (Michigan) 303 0.68 (strong) 
Modified Fox 2007 (Powertrain) 260 0.71 (strong) 
MWF EAA Score 2010 0.94 (very strong) 
 Expert panel opinion 
 
HPDI 
score 
 Definite Possible Not a case 
Definite/probable 6 1 0 
Possible 5 1 2 
Not a case 3 10 9 
 154 
Validation of MWF EAA Score from Published Case Reports of EAA Due to 
MWF exposure 
In addition to comparing the MWF EAA score with the opinion of the Expert Panel’s 
review of UK Powertrain cases, it is also possible to apply the criteria to fifty other 
previously published American cases of EAA due to MWF exposure (Table 48- 56). 
Table 48: MWF EAA Scores for Bernstein cases 1995 279 
Case Respiratory Constitutional Physiology Radiology/ex Inflammation Total 
1 4-7 7 5-10 7 0-10 23-41 
2 4-7 5 10 6-7 0-10 25-39 
3 4-7 0 5-10 6-7 0-10 15-34 
4 4-7 0-5 10 0-7 0-10 14-39 
5 4-7 0 0-10 0-7 0-10 4-34 
6 4-7 7 10 6-7 0-10 27-41 
 
 
Table 49: MWF EAA Scores for Trout cases 1996 289 
 
Case Respiratory Constitutional Physiology Radiology/ex Inflammation Total 
1 4-7 5 3 7 10 29-32 
2 4-7 0 5 7 0-10 16-29 
3 4-7 0 10 7 0-10 21-34 
4 4-7 0 0-10 7 10 21-34 
5 4-7 7 5 7 0-10 23-36 
6 4-7 0 5 7 10 26-29 
7 4-7 0 3 7 0-10 14-27 
8 4-7 5 5 7 0-10 21-34 
9 4-7 0 5-10 7 10 26-34 
10 4-7 5 5 7 10 31-34 
11 4-7 0 5-10 7 0-10 16-34 
12 4-7 0 3 7 10 24-27 
13 4-7 5 5 6-7 10 30-34 
14 4-7 0 5 7 10 26-29 
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Table 50: MWF EAA Scores for Rose cases 1996 287 
Case Respiratory Constitutional Physiology Radiology/ex Inflammation Total 
1 7 7 5 7 10 36 
2 4-7 7 5 6-7 10 32-36 
3 4-7 5 10 7 10 36-39 
4 4-7 5 5 7 10 31-34 
5 4-7 5 0-10 7 10 26-39 
6 4-7 0 10 6-7 10 30-34 
7 4-7 7 5 7 10 33-36 
 
 
Table 51: MWF EAA Scores for Zacharisen case 1998 288 
Case Respiratory Constitutional Physiology Radiology/ex Inflammation Total 
1 7 5 5 6-7 10 33-34 
 
Table 52: MWF EAA Scores for Fox cases 1999 1 
Case Respiratory Constitutional Physiology Radiology/ex Inflammation Total 
1 4-7 5-7 5 7 0-10 21-31 
2 4-7 5-7 10 7 10 36-41 
3 4-7 5-7 5 6-7 0-10 20-36 
4 4-7 5-7 10 6-7 10 35-41 
5 4-7 5-7 5 6-7 0-10 20-36 
6 4-7 5-7 10 6-7 0-10 25-41 
7 4-7 5-7 10 6-7 10 35-41 
8 4-7 5-7 5 7 10 31-36 
9 4-7 5-7 5 7 0-10 21-36 
10 4-7 5-7 5 6-7 0-10 20-36 
 
Table 53: MWF EAA Scores for Hodgson cases 2001 294 
Case Respiratory Constitutional Physiology Radiology/ex Inflammation Total 
1 7 5 5 0-7 10 27-34 
2 0-7 0-7 10 0-7 10 20-41 
3 7 0-7 0 0-7 10 17-31 
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Table 54: MWF EAA Scores for Weiss case 2002 300 
Case Respiratory Constitutional Physiology Radiology/ex Inflammation Total 
1 7 0-7 5-10 7 0-10 19-41 
 
 
Table 55: MWF EAA Scores for Trout case 2003 301 
Case Respirat
ory 
Constitutional Physiology Radiology/ex Inflammation Total 
1 7 5 3 7 7 29 
 
Table 56: MWF EAA Scores for Gupta case 2006 303 
Case Respiratory Constitutional Physiology Radiology/ex Inflammation Total 
1 7 5 10 7 0-10 29-39 
2 4-7 0 10 7 0-10 21-34 
3 4-7 0 10 7 10 31-34 
4 4-7 5 5-10 7 10 31-39 
5 7 5 10 7 10 39 
6 4-7 5 5-10 7 0-10 21-39 
7 7 7 5 7 10 36 
 
Where a range of score is shown for a criterion, this reflects data not provided in the 
case report or case series. The total MWF EAA Score provided in the final column, 
ranges from the lowest possible value (presuming that the missing data elements 
would all have been negative), to the highest possible value (presuming the missing 
data would all have been positive). For the fifty cases, there were only three cases 
where a definite MWF EAA Score could be calculated from the data provided and all 
of these would have been rated as definite cases (MWF EAA Score > 26.) A further 
eighteen cases would also have been rated as definite EAA cases using the MWF 
EAA Score, as the minimum of the range of possible scores were all greater than 26. 
In all of the remaining twenty-nine cases, the range of possible MWF EAA scores 
includes a score of 27, i.e. they may have been definite cases if more data were 
available. If the mid-range of these scores is taken as an approximate value, twenty 
of the twenty-nine would also have had MWF EAA Scores of at least 27.
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Discussion 
Study Findings 
By calculating the relative positive predictive value of the diagnostic elements for a 
diagnosis of EAA, combined with knowledge of previous EAA diagnostic criteria 1, it 
was possible to develop a new evidence-based EAA diagnostic score (the MWF EAA 
Score). This scoring system was designed to be a simple and reproducible tool, 
which would show high levels of agreement with the Expert Panel opinion and 
provide an evidence-based case definition suitable for use in future UK outbreaks.  
By applying the MWF EAA Score to the Powertrain data it was possible to 
demonstrate agreement with the Expert Panel Opinion in over 80% of the cases, with 
a greater number of workers correctly classified than with other published diagnostic 
criteria 1 260 293. In order to attempt to externally validate the new EAA rating system, 
the score was also applied to fifty previously published case series of workers 
diagnosed with MWF EAA from a number of different US outbreaks. The MWF EAA 
Score appeared to perform well, and there was sufficient data provided in twenty-one 
of these published cases, to establish that the MWF EAA Score would have shown 
agreement (i.e. MWF score greater than 26 equating to a definite case). In the 
remaining cases, there was not sufficient data provided in the publications to 
ascertain this for certain, although all cases had a range of MWF EAA Scores that 
included the score needed to be a definite case.  
 
Study limitations 
As the study was developed based on the Expert Panel review of Powertrain cases, 
the MWF EAA Score fits the Powertrain data very well, agreeing with expert clinical 
opinion in over 80% of cases. The MWF EAA Score did however identify two workers 
as having definite EAA (scores of 30/41 and 28/41) who were not identified by the 
Expert Panel as definite clinical EAA cases (both with Expert Panel Scores of 20%). 
Both of these workers had been identified as cases of EAA by the modified Fox case 
definitions used in the Powertrain investigation (one possible and one probable). 
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Although it is not possible to ascertain why the Expert Panel did not rate these as 
definite EAA cases, it is possible that these were false negatives i.e. cases missed by 
Expert Panel, reflecting the difficulty of diagnosis from a retrospective notes review. 
Alternatively they may have been truly negative cases i.e. other similar lung diseases 
that could only be separated from EAA with more detailed clinical input and follow-up.  
In order to attempt to externally validate the MWF EAA Score case definition it was 
applied to all previously published case series and case reports of definite EAA from 
other MWF outbreaks. Although this process was limited by the lack of detail 
provided in some of the case reports (particularly exact symptoms, examination 
findings, and results of blood tests), the scoring system seemed to perform well. In 
42% of these definite clinical cases, the MWF EAA Score would also have rated 
them as definite EAA. In the remaining cases it is not possible to tell this, although 
the mid-point of the range of possible MWF EAA Scores was at least 27 in a further 
40% of cases.  
 
Comparison to other studies 
Dangman et al. used the differences they had found between cases of EAA and 
controls to derive a hypersensitivity pneumonitis diagnostic index (HPDI) based on 
scoring points for, symptoms (one work-related systemic and two work-related 
respiratory), crackles on auscultation, abnormal pulmonary physiology (restrictive 
spirometry, reduced gas transfer, or increased A-a gradient), raised inflammatory 
markers (ESR), and abnormal radiology (on CXR, CT and gallium scan) 293. This 
formed the basis of an HPDI score out of 9, with 6 being a definite case, probable 4-
5, and possible 3. Unlike the Fox criteria, Dangman et al. applied some weighting to 
gas transfer and ESR, so that more abnormal results scored double points. For 
example, an ESR greater than 60 mm/hour scored double the points (2 points) of a 
CT consistent with EAA (1 point). The HPDI was then validated in a separate 
subgroup from the same outbreak, comparing the findings from 20 patients who were 
EAA cases on HPDI (at least possible cases) with 11 who were not.  
Dangman et al. went on to compare the HPDI case identification with the original Fox 
criteria 1 260 which agreed in 55 of 61 cases 293. Our study was broadly similar, but 
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each diagnostic criterion was weighted based on its positive predictive value giving 
each a possible score of 3-10. The diagnostic elements selected were chosen to be 
as inclusive of cases as possible, and to allow for the variability of EAA presentation 
and diagnosis. An example of this is that the respiratory symptoms included workers 
with progressive shortness of breath on exertion, in the absence of work-related 
symptoms, in an attempt to include chronic progressive EAA. Workers requiring time 
off work with recurrent acute EAA episodes, even if unrecognized as such, would 
also be included in the criteria. In addition, our criteria were developed from the 
Expert Panel review of suspected EAA and humidifier fever cases, an inclusion 
based on the similar constitutional symptoms that occur in these conditions. We 
therefore modified the recurrent flu-like symptom category to be more specific for 
EAA, being worse at the end of the working week (typical of EAA), rather than better 
(typical of humidifier fever). The remainder of the diagnostic elements in the MWF 
EAA Score are common to EAA investigation in general and other previously 
published case definitions 1 215 260 293 366.  
The main difference between our criteria and those previously published was that our 
criteria were relatively weighted in importance based on how predictive the positive 
symptom or test was in a real UK outbreak. An example is that in the MWF EAA 
Score, a positive lung biopsy consistent with EAA (score=10) has twice the 
diagnostic value of a raised blood inflammatory marker (score=5). By including a 
range of possible scoring elements in each category, the scoring system should allow 
a wider range of workers, investigated in different ways, to still meet the EAA case 
definition. By setting the diagnostic score around that best fitted the Expert Panel 
opinion it was possible to correctly classify 80% of definite, possible and definitely not 
EAA cases. As the criteria were generated by the data, as expected, this result was 
better than when any other published criteria were applied to the data outbreaks 1. 
Our study is the first to our knowledge to have developed evidence-based diagnostic 
criteria from one outbreak and apply it to cases from other outbreaks. Although 
limited by the detail provided in published case series the MWF EAA Score 
performed well during this external validation process, as applied to 50 cases of 
MWF EAA from nine US outbreaks published between 1996-2006 outbreaks 1. 
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Study Implications 
Investigating any ill health outbreak in large workplaces is logistically challenging due 
to the unexpected nature of the outbreak and the need to screen and diagnose large 
number of workers in a short period. Accurate and early diagnosis of allergic 
occupational lung diseases is key to improve prognosis in affected workers and 
prevent inappropriately disadvantaging symptomatic workers without disease. No 
single diagnostic test exists for EAA, and the diagnosis may be complex due to this 
and a number of other associated factors. Firstly, EAA may present as three different 
forms, acute, sub-acute or chronic disease, and symptom complexes and diagnostic 
test findings may differ markedly 246. Secondly, the respiratory and constitutional 
symptoms of EAA are non-specific and may be ignored or misdiagnosed as recurrent 
chest infections 293. Thirdly, due to the variable nature of acute and sub-acute EAA, 
the diagnostic value of certain tests varies based on the timing of that test. Lastly, 
particular difficulties exist in diagnosing EAA in MWF exposed populations where 
workers may also develop other forms of occupational lung disease with similar 
symptoms, OA, and humidifier fever 260. It is this variability in EAA, linked with 
unpredictable nature of MWF occupational lung disease outbreaks in large 
workforces, which has made case recognition so difficult and led to a variety of 
American MWF EAA case definitions being developed, often with little or no 
validation outbreaks 1.  
The MWF EAA Score provides a tool that can be used in future outbreaks of MWF 
EAA. By using a cut off of 19, all possible cases of EAA should be identified and 
these workers could then be clinically assessed as to their need for further 
investigations. The MWF EAA Score was developed using a cohort of MWF exposed 
workers, however future development of the scoring system to demonstrate its use in 
other groups of patients with EAA, particularly those without a measurable precipitin, 
could potentially expand the benefit of this research. 
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Conclusion 
This work has developed and validated an evidence based diagnostic scoring system 
in order to investigate future outbreaks of MWF-EAA in a consistent and evidence 
based manner. 
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Conclusions 
 
Impact of occupational lung disease 
Occupation related illness was first documented in the 4th century BC. Despite a 
change in industries, scientific understanding and legislation, it remains an important 
and preventable cause of disease. In 2012 there were 1770 new cases of 
occupational respiratory disease recorded by consultant chest physicians within the 
SWORD reporting scheme (Surveillance of work-related and occupational respiratory 
disease) 367. The incidence of occupational disease identified by reporting schemes 
such as SWORD is thought to be significantly under estimated 35 39. This burden of ill 
health comes at a personal and socioeconomic price. In 2011/12, Work related 
respiratory disease was responsible for the loss of 667 000 working days and 
accounted for around 2% of the total number of days of sickness absence certified 
due to all occupational illnesses 367 368. It is estimated that the annual cost to the UK, 
of OA alone, maybe be as large as £95-135 million 369. 
MWF continues to be an important cause of occupational lung disease. In 2012, 
there were 56 reported cases of occupational EAA compared to an annual average 
over the past 10 years of 41. Of the total occupational EAA burden, 39% is 
associated with MWF exposure. Between 2010 and 2012, MWF were the 4th most 
common cause of OA 4. 
 
Causative agent 
Despite reviewing outbreaks and collecting international data this research found no 
clear causative agent for MWF-EAA. Cases of MWF-EAA were found in factories 
using all different categories of soluble MWFs and many different contaminants were 
detected. Mycobacteria have been highlighted by some research groups as a likely 
inciting agent, however despite Mycobacterium sp. being a known cause of EAA, for 
example in hot tub lung 344, we did not find enough evidence to establish this. 
Muilenberg et al. were the first researchers to identify mycobacteria in MWF, 
M.chelonae, during an investigation involving 10 machinists in 1993 370. Bacterial 
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analysis of MWF led to the identification of a new species, M. Immunogenum 371. 
Wallace et al. found that the majority of mycobacteria isolates from MWF grew M. 
Immunogenum 372. Other studies have found a more equal split between M. chelonae 
and M. immunogenum, suggesting that both species are similarly prevalent 373. 
Tille LeBlond et al. conducted a study at a car engine manufacturing plant implicated 
in MWF-EAA, in order to identify the responsible antigen (Ag). Almost half of used 
fluids were confirmed to be contaminated with M. immunogeum, and a similar 
percentage grew Bacillus spp., with an additional smaller percentage isolating Gram-
negative bacteria, fungi and Aspergillus spp. Measurements made using 
electrosyneresis were interpreted by Tille LeBlond et al. as being indicative that M. 
immunogenum is the inciting agent in MWF-EAA. They went further, to calculate a 
threshold for differentiating MWF-associated HP patients from asymptomatic 
exposed workers 345. 
The difficulties of interpreting immunological findings in EAA were demonstrated in a 
detailed immunological investigation performed on workers in a MWF-EAA outbreak 
in the USA, where Mycobacterial contamination was identified. Measurements of 
immunity to M. immunogenum, such as interleukin 8 and tumour necrosis factor, 
were able to distinguish between MWF exposed and unexposed workers, but not 
between workers with and without MWF-EAA 301.  
Our study found, despite a thorough review of outbreaks of ill health associated with 
MWFs, although mycobacteria were identified in over half of outbreaks, it only 
comprised a small percentage of identified microbiological isolates. In outbreaks prior 
to the initial identification of mycobacteria as a potential contaminant of MWF, it is 
possible that it went undetected due to the necessary prolonged incubation time 
compared to that of a routine bacterial culture. However, for example, in Powertrain, 
the largest UK outbreak of respiratory disease associated with MWF, Mycobacterium 
sp were not identified either from culture or DNA extraction, despite specific 
investigation. Analysis of MWF samples from two other workplaces associated with 
UK MWF-HP outbreaks also found no detectable mycobacterial DNA. In addition, 
extracts from cultures including M. immunogenum, M. chelonae and M. fortuitum 
were used to look for the presence of precipitating antibodies in Powertrain UK 
workers, including cases of MWF-HP, OA and asymptomatic exposed controls. Over 
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half of the EAA patients had positive results for at least one microbial species, 
compared to only 5 % of asymptomatic controls. Precipitating antibodies to 
Mycobacterium spp, however were not detected in any workers. Further evidence 
against a mycobacterial cause came from specific challenges performed in two 
workers, where positive responses were seen after controlled exposure to used 
MWFs that did not contain mycobacteria  260 281.  
It is undeniable that mycobacteria are prevalent in some MWF systems, however this 
research study suggests that its presence is not ubiquitous and that it has been 
absent at sites where there have been large outbreak of EAA. Therefore, naming 
mycobacteria as the causative agent in MWF-EAA is unfounded at present. 
Thorough investigation of any plant using MWF where workers are diagnosed with 
EAA is essential, in the continuing research necessary to validate any hypothesis on 
the potential inciting agent in this form of EAA. 
 
Increasing incidence of idiopathic fibrosis 
Based on data from the Office of National Statistics, mortality rates from EAA show 
little variation, from 0.04 per 100 000 person years in the 1968-1972 calendar period 
to 0.08 per 100 000 person years in the 2005-2008 period. Between the same dates, 
the mortality of EAA rose slightly from 0.12 per 100 000 person years to 0.22 per 100 
000 person years, an increase of approximately 9% a year 374. This contrasts with the 
rising mortality of IPF, with death certification suggesting a six fold increase in the 
past two decades. Current findings suggest that the number of new diagnoses of 
idiopathic pulmonary fibrosis clinical syndrome (IPF-CS) increased by over a third 
between 2000 to 2008, with more than 5000 new cases being diagnosed each year 
375. Hubbard et al. studied national secondary care data to determine trends in 
hospital admissions in England and found that the number of hospital admissions 
from IPF-CS increased at an annual rate of approximately 5% 376. The highest 
incidence was found to be in older men, with a mean age of 71 yrs, particularly in the 
northwest of England 375 376. IPF is therefore an important health problem in the UK in 
terms of morbidity and mortality. 
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The diagnosis of IPF depends on the exclusion of other known causes of interstitial 
lung disease including occupational and environmental exposures, causing diseases 
such as EAA. The radiological and histopathological findings of EAA frequently 
overlap those of usual interstitial pneumonitis, which in the absence of an identifiable 
cause would be diagnosed as IPF 221. Previous work by Hubbard et al. looked 
specifically at the occupational risk of IPF (then referred to as cyptogenic fibrosing 
alveolitis CFA), collecting occupational histories from hundreds of patients and 
matched controls. It was concluded that occupational exposures to metal or wood 
dust are independent risk factors for CFA and could account for 20% of cases. The 
American Thoracic Society note, in their guidelines on IPF diagnosis and 
management, that an increased risk for IPF has been found to be associated with a 
variety of environmental exposures (ATS) 377 378. A significantly increased risk has 
been observed after exposure to metal dusts and wood dusts 379-381. 
IPF has also been significantly associated with farming, raising birds, hair dressing, 
stone cutting/polishing, exposure to livestock and vegetable dust/animal dust 382 383. 
With many of these agents being known to cause EAA 203, it is possible that a 
significant number of patients diagnosed with IPF actually have chronic EAA. 
Increased numbers of inorganic particles have been detected at autopsy, in lymph 
nodes of patients with pulmonary fibrosis, further supporting an environmental 
aetiology 384. If this is the case, the improved detection of EAA is of paramount 
importance to enable the correct identification of these workers and where possible, 
the cessation of exposure to the causative agent. It is well established that the 
prognosis in EAA can be improved where this can be achieved 198 207.  
Morell et al. studied a group of patients previously diagnoses with IPF and by using a 
questionnaire and then further immunological testing as appropriate, found that 43% 
of the patients actually had chronic EAA 385. It is clear that more research is needed 
in this area to verify the hypothesis that EAA could be accountable for at least some 
of the increasing incidence of IPF. The potential misdiagnosis of these conditions, 
although understandable due to the clinical, radiological and pathological similarities, 
would have potentially significant repercussions on not only the individual patients, in 
terms of treatment options and antigen avoidance, but also on presently undiagnosed 
exposed workers. Increased awareness of an enlarging health risk would hopefully 
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lead to an increase in health surveillance and subsequent faster disease 
identification. As an emerging cause of EAA, the early detection of respiratory 
symptoms in the MWF exposed population is an area which needs highlighting. 
 
Health Surveillance 
Secondary health prevention includes health surveillance which aims to identify 
disease at a pre-symptomatic stage or early stage. In a multi-centre hospital study, 
Fishwick et al. found that in a group of patients with inadequate or no annual health 
surveillance there was a mean delay of 4 years between the onset of symptoms and 
a confirmed diagnosis 148. Mackie et al. found a mean delay of nine months in those 
whose symptoms were detected at health surveillance and who attended for 
subsequent investigations 149. Although it is difficult to dissociate the effects of health 
surveillance from the effects of other risk management procedures it is felt that 
outcome is improved in workers who are included in a health surveillance programme 
150. 
This research has focused on the investigation of an outbreak of MWF associated 
respiratory disease, specifically EAA, by identifying the symptoms with a high 
sensitivity and positive predictive value and thus formulating a new case definition. In 
doing so we have highlighted several key areas that are likely to be useful for 
developing health surveillance for workers exposed to MWFs. In addition to the 
existing HSE guidance requiring questions relating to work-related respiratory 
symptoms such as cough, wheeze and chest tightness, our research has identified 
other more specific questions that might improve the value of secondary prevention 
screening in this group of workers. Presently, any employer browsing the HSE 
website for guidance on health surveillance for workers using MWFs, is directed to 
Control of Substances Hazardous to Health (COSHH) information for prevention of 
OA but not other lung conditions 386.  
When analysing questionnaire data from an outbreak of MWF-EAA, certain questions 
were found to have a relatively high PPV for EAA. One in four workers at Powertrain 
who complained of unexplained weight loss were found to have definite EAA, 
suggesting that a simple question referring to weight loss might be a useful addition 
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to the standard respiratory questionnaire. As well as weight loss, extreme shortness 
of breath including nocturnal symptoms, breathlessness worse at the end of the 
working week and flu like symptoms associated with particular work tasks are all 
complaints that should be noted with a high level of suspicion. It would seem sensible 
that questions referring to these symptoms should be included in any health 
screening questionnaire designed to detect MWF-EAA in exposed workers. The 
importance of identifying workers having time off with chest problems, or treatment 
for chest conditions (often thought to be recurrent chest infections) was also noted, 
as this may actually represent recurrent bouts of undiagnsosed EAA. Recognising 
that chronic EAA may present with slowly progressive ILD, it is also important to 
identify patients with gradual onset exertional breathlessness, to ensure they are 
picked up even in the absence of work-related respiratory symptoms.  
The development of a bespoke screening questionnaire for use in MWF exposed 
workers would require further research. If the screening was to include questions 
aimed at identifying MWF-OA and other respiratory disease associated with MWF 
exposure, this research could include extended analysis of the database to identify 
those questions with a high sensitivity and perhaps PPV for these conditions. This of 
course would limit the screening questions to those initially asked by the Birmingham 
group at the time of the outbreak, as retrospective addition of questions is not 
possible. 
Although HSE guidelines 387 would advocate spirometry as part of health surveillance 
for a MWF exposed population due to the risk of OA, it is difficult to advocate regular 
spirometry simply for EAA surveillance, as the FVC measurements in those 
Powertrain workers with definite EAA were often within the normal range. Although 
measuring gas transfer appeared more useful, it is unlikely that this more costly 
hospital-based test would provide a suitable alternative form of objective health 
surveillance. Whether serial estimates of spirometry looking for excessive annual 
declines are more predictive of early disease requires further study. Again, if the 
surveillance was designed to incorporated early detection of other respiratory 
conditions associated with MWF exposure, regular spirometry maybe validated. 
Additional to health surveillance measures, a high index of suspicion among exposed 
workers and medical staff is required, with clear referral pathways for workers 
 168 
developing respiratory or constitutional symptoms at work. If future outbreaks are to 
be avoided, new cases must be detected early, allowing improved control measures 
to be put in place to protect the remaining workforce. 
 
Future Outbreak Planning 
One possible approach to MWF outbreak investigation is shown in Figure 16. A 
single sentinel case of EAA in a workforce would prompt the occupational health 
provider to screen the other MWF exposed workers. In addition to questionnaire 
screening of the entire at risk workforce, there would be a review of sickness 
absence records, and the existing exposure control measures for MWF mist. All 
symptomatic workers would then be referred to an NHS occupational lung disease 
centre for an initial simple assessment, followed by further more detailed diagnostic 
tests where indicated. All workers with a definite diagnosis of OA or EAA (after 
applying the MWF EAA Score) would ideally avoid further exposures by relocation 
wherever possible. Workers with possible occupational asthma or EAA would have a 
reduction in exposure and regular clinical follow-up. Workers without EAA or 
occupational asthma would be reassured, and return to work with reduced exposures 
where possible, and continued occupational health surveillance. Ideally, this 
suggested approach and the EAA MWF case definitions need testing prospectively in 
future outbreaks. 
We have produced evidence-based diagnostic criteria specifically for EAA in workers 
exposed to MWFs, suitable for assessing the respiratory ill health of symptomatic 
workers in future UK outbreaks. Unlike certain other criteria 288 303, this does not rely 
on obtaining invasive lung biopsies in all workers, or complex radiological tests which 
are not routinely available in the UK 293. With knowledge of the predictive value of 
different diagnostic tests, it should be possible to streamline future investigations, 
minimizing the impact of the outbreak in terms of health and therefore also 
socioeconomic disadvantage to the patient.  In addition to being applicable to future 
EAA outbreaks due to MWF, it may be possible to utilise the MWF EAA Score when 
investigating similar outbreaks due to other organic agents such as in lifeguard lung 
354 and EAA due to water-damaged buildings 388 or contaminated humidifiers 389. In 
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such circumstance, when EAA is secondary to a known antigen, serum 
immunological testing has traditionally played a key role, therefore the MWF EAA 
Score although useful, may need adaptation in other settings. Equally, if further 
research identifies the causative agent or agents in MWF-EAA, additional criterion 
may need to be added to the diagnostic tool.  
MWF related ill health is still a relatively new and emerging problem. As industry 
continues to strive to improve the function of MWFs and consequently the 
formulations evolve to containing different chemical compounds, new potential health 
risks are a constant threat. Continuing research in to the cause of MWF-EAA, early 
identification and the measures that can be taken to reduce its incidence are clearly 
essential to reduce the incidence of this potentially preventable yet life threatening 
condition. 
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Figure 16: Health investigations precipitated by a sentinel case of EAA in a MWF 
exposed worker 
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Appendices 
 
Appendix 1 
Outbreaks of respiratory ill health associated with MWF reported in USA  
 
The literature review identified twenty separate NIOSH studies that met the selection 
criteria for an outbreak making up 20 of the 25 reports of outbreaks of respiratory ill 
heath attributed to MWF in the USA. These reports are briefly summarised in date 
order 
 
Studies of respiratory disease:  
Fourteen of seventeen outbreaks that investigated respiratory disease alone were 
from the USA and nine of these were NIOSH investigations. The investigations of 
respiratory disease were typically large and involved the collection of clinical, 
environmental, and exposure data.  
 
Bernstein, D. I. et al. 1995 279 
Background 
Bernstein et al. were amongst the first investigators to identify MWF as a potential 
cause of EAA amongst machinists.  
 
Methods and results 
They reported a case series of six workers from an automobile-manufacturing site, 
exposed to a synthetic MWF (introduced in October of 1991) from machines with an 
open and shared sump. The six workers were evaluated and treated for respiratory 
disease between April and September of 1992, and all had symptoms that improved 
on removal from the workplace. Five of the six workers had pulmonary restriction (as 
measured by simple spirometry), and four of the six had interstitial shadowing on 
chest X-ray. One worker had a bronchoscopy to rule out infection. Mycobacterium 
chelonae was identified in a sputum culture from one of the group but all others 
showed normal bacterial flora. For the four workers with abnormal chest X-rays, 
removal from exposure was associated with marked improvement in lung function, 
with an average 55% increase in forced vital capacity from baseline.  
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Two samples of used MWF were analysed and these contained less than 10 colony 
forming units (CFU) of fungi and approximately 1.3 x106/mL of bacteria. When 
cultured these samples grew eight microbial isolates, including Pseudomonas spp, 
Aspergillus spp, Staphylococcus spp and Bacillus spp. No air monitoring was 
performed in this investigation. Serum precipitins to one or more of the microbial 
isolates were found in all six workers, most commonly to Pseudomonas fluorescens. 
Positive precipitins were only present in blood samples taken from one out of nine 
non-exposed control subjects 
 
Conclusions 
The authors concluded that in their opinion the presence of positive precipitin 
reactions in all the EAA cases indicated an immunologically mediated response to 
aerosolized microbial antigen. They recommended environmental monitoring and 
medical surveillance for MWF exposed workers, as well as advocating further 
research in this area. 
 
Rose, C. et al. 1996 287 
Background 
The occurrence of cases of EAA prompted physicians to request NIOSH investigate 
occupational exposures at three different automobile manufacturing plants.  
 
Methods and results 
During 1994 – 1995, six cases of EAA were confirmed on biopsy and after a review 
of medical records of plant employee's fourteen additional 'probable' cases (not 
biopsy proven) were also discovered. Of the six biopsy proven cases, all but one 
reported recurrent respiratory and systemic symptoms that they attributed to working 
with MWF. The symptoms of one worker permanently resolved after his exposure to 
MWF ceased. One worker died after a myocardial infarction, but had a background of 
eighteen months of interstitial lung disease with work-related cough and shortness of 
breath. Autopsy showed chronic granulomatous lung disease suggestive of a 
diagnosis of chronic EAA.  For two workers, serum precipitin tests to a standard 
antigen panel (including bacteria, fungi and avian proteins that had been associated 
with EAA in other settings) were all negative. Four workers had abnormal spirometry, 
two showing a restrictive pattern, and two a mixed pattern of restriction with 
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obstruction, all of which improved with removal from exposure. Three workers had a 
measurable reduction in the gas transfer capacity of their lungs. 
 
Conclusions 
This report summarised the six biopsy proven cases of EAA, but did not document 
any investigation of the workplaces (i.e., hygiene assessment, or diagnostic 
evaluation of other illness). The report concluded that ongoing medical surveillance 
and exposure assessment is required for workers potentially exposed to MWFs. 
 
Fox, J. et al. 1999 1 
Background 
The 'Kenosha' outbreak occurred in an engine manufacturing plant, which employed 
1592 workers. Between July 1995 and April 1997, eighty-one of these staffs 
complained of respiratory symptoms to the company medical staff. A synthetic MWF 
had been in use since 1989, but this was changed to a soluble MWF between May 
and August of 1996 in response to an earlier outbreak of respiratory ill health.  In 
August 1996, the company had also installed new ventilation, steam cleaned sumps, 
and improved local exhaust ventilation. 
 
Methods and results  
All workers who had complained of respiratory symptoms, and a group of case 
controls who were asymptomatic were offered medical review. Seventy-one of 
eighty-one staff with symptoms agreed to this review. The medical officer then 
assessed these workers carrying out tests for serology, spirometry, radiological and 
in some cases biopsy of the airways. Case definitions for EAA were developed as 
either 'definite', 'probable' and 'possible' based on seven diagnostic criteria. These 
criteria have subsequently been used for other investigations.  
 
Thirty one percent (twenty two cases) of the seventy-one symptomatic staff 
investigated were diagnosed by a physician as meeting their criteria for EAA (with 
symptoms starting after July 1995). Only twenty of the twenty-two cases met the 
criteria for EAA set by the investigators (ten definite cases, five probable cases and 
four possible cases). Of these twenty, sixteen had interstitial infiltrates on radiological 
imaging. All definite cases of EAA had a reduced diffusion capacity (TLCO) and 
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restrictive spirometry. Four workers underwent biopsy, all showing non-causeating 
granuloma and lymphocytic infiltrates. Interestingly, two of the four workers biopsied 
were initially diagnosed with sarcoidosis (an idiopathic granulomatous lung disease), 
and only after long-term follow up was their diagnosis changed to EAA. This 
illustrates the difficulty with EAA, where there is no single gold standard diagnostic 
test. Even when lung tissue was biopsied and examined histologically, the findings 
were interpreted in conjunction with symptoms, exposure history, and the results 
from other diagnostic tests.  
 
Eighteen of the twenty cases of EAA, and fifty-one controls subjects also provided 
blood samples to analyse precipitating IgG antibodies. With the exception of two 
weak reactions, no positive precipitin results were found to any of seven unused 
MWFs, seven detergents, three hydraulic oils, or two biocides in use in the factory. 
When serum precipitin reactions to used MWFs were compared however, EAA cases 
had elevated odds ratios for 3 of the fluids; two synthetic, and one oil-soluble. Thirty-
four demographic factors were also compared between cases and controls, but no 
statistically significant differences were found.  
 
In addition to the EAA cases, OA was diagnosed in three employees, and a further 
twelve were diagnosed with occupational bronchitis (or potentially EAA despite not 
meeting the minimum diagnostic criteria). Six workers were diagnosed with non-
occupational bronchitis, three with chronic obstructive pulmonary disease (COPD) 
and ten with other diagnoses. 
 
The company records were examined to assess previous environmental monitoring 
data, and where biocide use was recorded this was taken as surrogate evidence that 
bacterial contamination of the MWF had occurred. When compared to typical 
amounts of biocides used from January 1994 to March 1996, the use of biocides 
peaked (two standard deviations above the average use) during May and June of 
1995. This peak preceded the outbreak of respiratory symptoms, which occurred 
from October to December 1995. According to the plant records, oil mist 
concentrations measured between January 1994 and March 1996 had not exceeded 
the OSHA permissible exposure limits (PEL) of 5 mg/m3 and no total particulate 
measurements exceeded the OSHA total particulate PEL of 15 mg/m3. No statistical 
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difference was seen in oil mist levels when comparing the values at workstations of 
workers with and without EAA. 
 
Conclusions 
The relative risk of EAA was 3.2 times higher in the exposed workers compared to 
unexposed and the authors suggested that the cause of the EAA was not MWF itself 
(as demonstrated by the lack of serum precipitin reactions to unused MWF) but a 
response to increased bacterial contamination of the MWF. The addition of large 
amounts of biocide prior to the outbreak was taken as an indication that bacterial 
contamination had preceded the outbreak of illness although no specific 'lead' 
pathogen was identified 1. 
 
Zacharisen, M. C. et al. 1998 288 
Background 
A spectrum of respiratory diseases was recorded amongst workers at an automobile 
manufacturing plant commencing in 1995. A total of 1600 workers were employed, 
and 800 were exposed to MWF. Seven different MWFs were used, six were synthetic 
and one was a soluble oil water mix.  
 
Methods and results 
Thirty workers presented to an 'Asthma and Allergen' centre because of work-related 
respiratory problems, and seven were diagnosed with EAA. The investigators 
devised their own criteria for EAA, which included evidence of work-related 
symptoms, and supportive features for example positive precipitins, chest x ray 
findings, pulmonary function tests, and biopsy results. These workers had been 
employed at the site for between two and thirty eight years. All EAA patients had 
positive precipitins to used water soluble and synthetic MWF, none had positive 
precipitins to Mycobacterium chelonae. All had decreased lung function and 
borderline low gas transfer (TLCO). After seven months out of the work place, four 
workers were able to return to work using personal protective equipment, one failed 
to return, and a further two were unable to return due to persistent symptoms. 
 
Twelve workers were diagnosed with OA and their average length of employment 
was seventeen years. OA was diagnosed on the basis of work-related symptoms, 
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reversible obstruction, or a positive methacholine challenge, and the presence of 
hyperinflation or atelectasis on chest X ray. Eleven of these workers were tested for 
precipitins and ten showed positive precipitin reactions to used MWF or bacterial 
extracts. Spirometry in five of the workers showed a reduced FEV1 with reversibility. 
One in four of the workers who underwent skin prick testing for inhalant allergens had 
a positive result. All workers with OA had a chest X ray, of which eight were normal, 
three demonstrated hyper-inflated lung fields, and one showed atelectasis. 
 
Six workers were diagnosed with occupational bronchitis based on work-related 
symptoms (including sputum production), and a normal methacholine challenge. 
Their average length of employment was 18.1 years. Three of the six workers with 
occupational bronchitis were unable to go back to work because of their symptoms. 
Five workers were diagnosed with unclassified respiratory symptoms of short 
duration. 
 
Air monitoring was performed, and MWF samples were collected. Airborne bacterial 
counts (taken in December 1995) revealed high levels of Gram-negative bacteria in 
areas close to areas where MWF was used. Concentrations ranged from 525 to 4200 
CFU/m3. Bacteria cultured included; Bacillus sps, Xanthomonas sps, Pseudomonas 
sps, Citrobacter sps, Acinetobacter sps and Klebsiella sps. Acid-fast bacilli identified 
as M.Chelonae were found in seven samples, six from synthetic MWF and one from 
water based MWF. The authors of this study concluded that a 'lead' pathogen in the 
outbreak could not be identified. 
 
Conclusions 
This outbreak demonstrated the occurrence of multiple occupational respiratory 
conditions (EAA, OA and bronchitis) associated with exposure to MWFs. The 
outbreak seemed to end spontaneously in 1996 with no clear temporal relationship to 
improvements made to the factory environment. 
 
Trout, D. R. et al. 1996 289 
Background 
This NIOSH investigation (HETA 96-0156-2712) involved a large factory producing 
automobile parts. The factory had an area of 1.7 million square feet and used semi 
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synthetic and soluble mineral oil-based MWFs in the compressor plant where 265 
staff worked. Workers suffering from recurrent respiratory complaints requested that 
NIOSH carry out the investigation.   
 
Methods and results 
The medical records of all workers diagnosed with EAA, or EAA like conditions, and 
all the workers restricted from work in the compressor area were reviewed. 
Shortness of breath and cough were common symptoms and twelve out of fourteen 
patients had crepitations on auscultation. Spirometry was abnormal in all cases 
showing a restrictive or mixed picture, which is a combination of obstructive and 
restrictive abnormalities. Ten of the cases underwent HRCT scans, all of which were 
abnormal. Eleven had abnormal chest X rays, and only one had normal radiology. 
Eight workers had lung biopsies, six of which showed histological evidence of non-
causeating granuloma and two showed lymphocytic alveolitis. Both pathologies are 
consistent with the diagnosis of EAA. Thirteen of the fourteen workers diagnosed 
with EAA had worked full time in the compressor room and were exposed to MWF; 
one of the other cases had visited this area frequently. 
 
Questionnaires were completed by 165 MWF exposed, and 87 non-exposed 
workers. Six of the fourteen workers who had recently been diagnosed with EAA 
were also included. The mean length of employment of these workers was ten years. 
Respiratory symptoms were more common in those workers who had worked in the 
compressor room, and fatigue with recurrent flu like symptoms were commonly 
reported. 
 
Mycobacterium immunogenum was the major microbiological contaminant (between 
1.4 x 103 and 1.0 x 107 CFUs/ml) of all the bulk MWF samples taken from the site. 
Endotoxin levels ranged from non-detectable to 44,375 EU/ml. It should be noted 
here that endotoxin are derived from Gram negative bacteria, not mycobacteria, 
therefore this suggests that bacteria other than mycobacteria were also present.   
 
Serum from participating workers was analysed using an enzyme linked 
immunosorbent assay (ELISA) and a precipitin assay to detect specific IgG to five 
different bacteria.  Mycobacterium chelonae antigen was prepared from organisms 
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isolated from MWF used in the compressor area. Twenty four percent of the 
employees who reported exposure to MWF had a positive precipitin reaction to 
Mycobacterium spp, and when an enzyme linked immunoassay (ELISA) forty-two 
percent of the serum sample were found to contain specific mycobacterium IgG 
suggesting that ELISA was a more sensitive tool to detect sensitisation. 
 
An additional site visit was carried out in 1997 and those employees previously 
diagnosed with EAA were asked to participate. The aim of this second study was to 
carry out challenge tests using isolated mononuclear blood cells in an ex vivo 
challenge with M. chelonae antigen. Seven workers with EAA and six asymptomatic 
workers agreed to participate. The potential for M. chelonae antigen to provoke an 
immune reaction was assessed by measuring cytokine expression comparing the 
reaction in workers diagnosed with EAA to that observed in the asymptomatic 
workers. No statistically significant difference in cytokine expression was found 
between the EAA versus the asymptomatic patients for any of the antigens tested. 
 
Twenty-one personal breathing zone (PBZ) samples and five general air (GA) 
samples were collected to measure total particulates. In addition, twenty-four real 
time particulate measurements were made using a real time light scattering aerosol 
spectrometer. The average PBZ exposure was 0.40 mg/ m3, with only three samples 
above the total particulate NIOSH REL for MWF of 0.5 mg/m3. In 1997, ventilation 
changes were made in the factory and NIOSH returned to re sample the PBZ. In 
many cases the same individual workers were used to collect personal exposure 
data. Of the nine PBZ samples taken post ventilation, six had concentrations of 
particulate above the NIOSH REL. 
 
Conclusions 
NIOSH concluded that although M. immunogenun was the predominant 
microorganism in the MWF sumps supplying the compressor area; there was no 
proof that mycobacterium was the causative agent of EAA. It was recommended that 
ongoing evaluation of the MWF environment and the exposed workers be carried out 
and that exposures be reduced below the NIOSH REL. Workers exposed to levels 
greater than this were also advised to wear respiratory protection. 
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Kiefer, M. T. et al. 1998 290 
Background 
NIOSH commenced an investigation (HETA 98-0030-2697) at a large, 1,000,000ft2 
factory manufacturing aircraft parts following complaints of flu like symptoms, skin 
problems, and irritation of the eyes. Of the total 1600 workers, eighty were exposed 
to a water based oil emulsion MWF.  
 
Methods and results 
The company’s log of reported illnesses was reviewed for the years 1995-1997. 
During this period there had been 29 entries, one regarding skin disease, one 
regarding sinus complaints and one regarding gastrointestinal upset, the others had 
been due to minor injuries.  
 
Seventy-seven exposed and eighty-four control workers completed symptom 
questionnaires, with an average employment time in the factory of 22.4 years. The 
results of the survey suggested that there was a much higher illness burden than that 
reported in the log and reported symptoms were more frequent in the exposed 
workers compared to the controls. Sinus problems were reported by 57% of exposed 
workers compared with 43% of the controls; 29% of the exposed group complained 
of having a tight chest compared to 13% of the controls; 40% of exposed workers 
complained of generalised aches compared to 23% of the controls; 30% reported 
trouble breathing compared to 19% of the controls; and 39% reported having a cough 
compared to 26% of the controls.  
 
Skin rash was reported in similar frequencies in the exposed and control group, 36% 
of the exposed workers complained of a rash compared with 32% of the controls. No 
attempt was made to determine if the control group was exposed to any specific 
irritants that increased their rate of rash. NIOSH recommended that despite similar 
prevalence of reported skin symptoms in the exposed and control groups, that there 
were measures that should be taken to reduce skin exposure to MWFs, for example 
wearing protective gloves. 
 
Environmental measurements were taken, which included air sampling for MWF and 
endotoxin, and bulk sampling of MWF from various points in the central distribution 
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system. In the PBZ samples for MWF, all but one was well below the NIOSH REL of 
0.5 mg/m3. No viable bacteria were identified in any of the bulk samples, however 
endotoxin was identified at concentrations of up to 7.5 x 104 EU/ml. Endotoxin levels 
were much higher in air samples from the workplace of the exposed workers 
compared to the areas where the non-exposed control group worked. 
 
Conclusions 
NIOSH concluded that skin problems were high in both groups, but not significantly 
higher in the workers exposed to MWF. Respiratory symptoms did however show a 
consistent trend towards exposed workers, with a statistical significance for 
increased prevalence of chest tightness and sore throat. Recommendations were 
given to generally lower exposure to MWF, monitor exposure of MWF especially for 
the machinists, and to encourage employees to report all potential work-related ill 
health. 
 
Trout, D. et al. 1996 291 
Background 
A NIOSH investigation (HETA 97-0118-2664) at a large factory covering 1 million 
square feet that used semi synthetic MWF in the production of firearms, was started 
following complaints from workers of headaches, sore throats, bloody noses, 
respiratory symptoms, skin irritation and rashes. The factory employed 1100 
employees with 450 being exposed to MWF. 
 
Methods and results 
Symptom questionnaires were given to all employees that agreed to participate in the 
study, and 950 employees took part. The mean length of employment of those 
workers exposed to MWF was eighty-one months compared to the unexposed 
workers whose mean length of employment was one hundred months. The 
prevalence of self-reported symptoms was more common in the exposed compared 
with the unexposed workers. Eye nose and throat irritation was documented in 26% 
of the exposed compared to 10% in the unexposed; shortness of breath was reported 
in 11% compared to 5% of the controls; dry cough in 26% compared to 11% of the 
controls; chest tightness in 11% compared to 6% of the controls; fatigue in 19% 
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compared to 10% of the controls; and wheeze in 15% compared to 8% of the 
controls.  
 
Eighty-four of the nine hundred and fifty employees responding to the questionnaire 
had previously been assessed by a physician, and diagnosed with a respiratory, skin 
or infectious conditions. The 'physician diagnosed' conditions were not reported any 
more frequently in the MWF exposed workers compared to those not exposed to 
MWF. Nine employees were randomly chosen and interviewed; six of these denied 
any work-related health problems, and three complained of work-related upper 
respiratory symptoms. An additional five workers chosen by the union were 
interviewed and of this group four complained of upper respiratory symptoms, three 
of eye symptoms and one had previously suffered a rash.  
 
Bulk samples of MWF were collected and analysed. Four samples yielded fungal 
colonies (yeast, Fusarium sps, and Candida spp) and ten samples yielded bacterial 
growth. Eight different gram-negative bacteria were identified including 
Pseudomonas spp, Burholderia spp and Acinetobacter spp, and Mycobacteria 
chelonae was identified in three samples. The concentration of bacterial 
contamination varied from <101 to >3x107 CFU/ml. 
 
Air sampling was not carried out during the initial investigation, but at a follow up 
review the results of sampling carried out by the company were reviewed. This 
showed all results below NIOSH REL for mineral oil mist of 5 mg/m3.  
 
Conclusions 
The authors concluded that there was a small but consistent increase in symptoms in 
the MWF exposed population compared to those workers not exposed. The 
significance of any particular bacterial contamination was difficult to assess. They 
recommended an improved health and safety program, maintenance of sump 
cleanliness and minimising where possible, generation of aerosols.  
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Hodgson, M. J. et al. 2001 293 
Background 
Three papers were published which described different aspects of an outbreak of 
respiratory illness that started in 1997 in a relatively small factory fabricating 
precision titanium and stainless steel parts for the aerospace industry. The factory 
covered 67,000 square feet and employed 120 workers, 105 involved in component 
production. A combination of semi synthetic, synthetic water soluble and straight oil 
MWFs were in use. The investigation was initiated after the Division of Occupation 
and Environmental Medicine (DOEM) diagnosed an employee with EAA in the 
autumn of 1997. Unlike most of the outbreaks of ill health due to MWF in the USA, 
this investigation was not undertaken by NIOSH. It led to in-depth study of the 
aetiological factors rather than a report of workers symptoms and working conditions. 
 
Methods and results 
Symptom questionnaires were distributed to all the employees at the outbreak plant 
and to employees in two control areas; one where there was exposure to MWF and 
one where there was not.  There were one hundred responders from the outbreak 
site. The results indicated that 79.6% of workers had respiratory and systemic 
complaints. Overwhelming fatigue was the predominant feature. The investigators 
ignored temporal relationships of symptoms due to the chronic nature of EAA and the 
fact that most workers worked a six or seven day week, which meant there was not a 
sufficient recovery period away from work to note a change in symptoms. This is 
contrary to many investigations for which evidence of work-related provocation of 
symptoms plays a critical role in recognising occupational risk factors as well as 
recognising the symptoms of work-related EAA. 
 
All symptomatic workers were offered further clinical assessment. Three workers had 
already been assessed elsewhere, and diagnosed on biopsy as having EAA. One 
had initially been diagnosed with usual interstitial pneumonitis (UIP), which is an 
idiopathic form of interstitial lung disease. The diagnosis of UIP was changed to EAA 
in view of the clinical setting. Another had been diagnosed twice with pneumonia 
before the final diagnosis of EAA was made. This illustrates how easily, and 
potentially frequently the diagnosis may be missed or at least delayed. The four 
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cases of 'biopsy confirmed' EAA were recognised even before the remaining 
symptomatic workers (identified from the questionnaire) had been investigated. 
 
In the first six months of the investigation, a physician reviewed sixty-one workers 
and forty-nine described systemic and respiratory symptoms consistent with EAA. 
There was no significant difference in the age or duration of work at the plant in those 
reporting symptoms compared to those workers who did not. The clinical evaluation 
included a combination of history taking, physical examination, pulmonary function 
testing, laboratory tests and radiology. On the bases of these results diagnoses of 
EAA, asthma, bronchitis, sinusitis, rhinitis or ‘other condition’ were made. If the 
results were inconclusive a biopsy was considered. Biopsies were carried out on 
twenty patients, including the four previously mentioned who had a biopsy prior to the 
outbreak investigation. The histological appearance of the biopsies from sixteen 
workers was consistent with a diagnosis of EAA.  
 
Some workers refused biopsy, and because of private health care costs some 
workers were unable afford to have a biopsy. The report authors suggested that the 
sixteen cases of EAA were likely to have been an underestimate of the true number 
of cases at this stage of the investigation. Ultimately thirty-eight out of forty-nine 
workers with symptoms consistent with EAA had the diagnosis confirmed and 
reported to the department of public health. Of the sixty-one workers reviewed, 
twenty-three did not receive a diagnosis of EAA. Ten out of the twenty three were lost 
to follow up before EAA was completely ruled out, seven were found to have work-
related asthma or asthma exacerbation; another four were found to have upper 
respiratory tract problems. Demographic data showed that the workers with a 
diagnosis of EAA were more likely to be older and 'non smokers'  compared to the 
general population at the plant. 
 
Exposure assessment included bulk MWF samples and air samples. Moraxella spp, 
Bacillus spp and Pseudomonas spp were isolated from the bulk samples. 
Mycobaterium spp was also identified in MWF from one sump. In some sumps there 
was a low concentration of fungal species including Acremonium spp, Cladosporium 
sps, Penicillium sps and Fusarium. Serum samples from 10 of the workers being 
investigated for respiratory symptoms and twelve asymptomatic controls were tested 
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for antibodies against isolates of bacteria and fungi found in the MWF samples, 
including Pseudomonas spp and Moraxella spp. The serological testing did not 
implicate any specific agent in the disease process. Bulk samples were also tested 
for endotoxin, and this correlated with sump bacterial concentrations. Air samples 
were tested for microbial growth, endotoxin content and levels of oil mist and at the 
time of sampling all measures were below recommended standards 293 294. 
 
Conclusions 
The authors concluded after the initial six months of investigation that there were no 
clear relationships between contamination and airborne exposure, and no single 
organism (and in particular M. Chelonae) could be attributed as the causative agent 
for development of EAA. The author's key conclusions from this study were three 
fold. In order to ensure cases of respiratory disease secondary to exposure to EAA 
are detected, physicians must have a high index of suspicion. The long-term 
consequence of EAA is not clear; although the progression of clinically identifiable 
disease often resolves as exposure is controlled but low-grade disease may remain 
unidentified. Apparent compliance with current health and safety standards does 
always prevent the development of disease, perhaps suggesting the present 
standards may need revising 294. 
 
On completion of the first stage of this investigation (and when the size of the 
outbreak was apparent) it was agreed that future diagnosis of EAA would be on the 
based on symptoms and 'non invasive' tests avoiding expense and potential 
complications of biopsy investigations. For the next stage of the study a diagnostic 
index for EAA was developed to reduce uncertainties in case definition. Clinical 
findings from workers likely to have EAA (i.e., the sixteen 16 biopsy confirmed cases) 
were compared to the clinical findings of cases categorised as not having EAA 
(based upon response to the symptom questionnaire) to develop Hypersensitvity 
Pneumonitis (HP) Diagnostic Criteria. The final version of this diagnostic index was 
validated by applying the criteria to thirty workers, some of whom had been 
diagnosed as cases of EAA and others who had not been diagnosed with EAA. The 
same sample of workers was also assessed using the Kenosha epidemiological case 
criteria 1. All four workers who were suspected clinically to have EAA, but whose 
biopsies were negative were diagnosed with EAA using both criteria 293. 
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After workers were diagnosed with EAA, the decision for them to return to work was 
a multidisciplinary team decision. After the initial environmental sampling had 
occurred, the investigators continued to collect longitudinal data to assess symptom 
changes following the implementation of the recommended interventions. In January 
1998, four months after the beginning of the outbreak, several workers attempted to 
return to work but experienced a prompt recurrence of their symptoms and a decline 
in their lung function. Further interventions were implemented, including a 
comprehensive MWF management program, machine enclosure with improved local 
exhaust ventilation, worker training and a reduction in overtime hours. After these 
interventions a statistically significant reduction in MWF sump bacteria and fungi was 
observed compared to levels at the start of the outbreak (October 1997). Whilst 
samples did not show any significant reduction in bacterial or fungi concentrations oil 
mist levels were consistently lower than previously measured 292.  
 
A cross sectional survey in November 1998 identified two further possible cases of 
EAA, but the onset of their symptoms was prior to the implementation of the major 
interventions.  In November 1999, over two years into the outbreak, 51% of the 
workers who had been clinically diagnosed with EAA successfully returned to work 
292. 
 
Trout, D. et al. 1998 295 
Background 
Trout led an investigation (HET ALA-98-0050-2733) at a 17.5-acre site where 
workers were drilling boring and milling truck axles. In total there were 1000 
employees, of which 338 were machinists. Semi synthetic, soluble and straight oil 
MWF were used at this site. After a case of EAA was documented in 1997, NIOSH 
was invited to carry out an investigation. 
 
Methods and results 
A symptom and exposure questionnaire was distributed to all employees and 111 of 
the 131 respondents (81%) reported systemic symptoms. Thirty-nine of the 131 
(30%) complained of work-related respiratory symptoms and of these thirty-five had 
been exposed to MWF.  Eleven of the 131 (28%) had changed job due to their 
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symptoms. Those workers identified by questionnaire as being exposed to MWF, 
having work-related respiratory symptoms and more than one systemic symptom, 
were offered a physician review. Of ten workers offered this review, all declined the 
invitation. Despite the evidence that staff had relevant symptoms for EAA no further 
clinical investigation took place. 
 
Nine PBZ air samples for MWF were collected and total particulate mass 
concentrations ranged from 0.33 to 1.29 mg/m3; five samples had levels over the 0.5 
mg/m3 NIOSH REL. Seventeen bulk samples of MWF were collected for analysis of 
bacteria, fungi and mycobacteria and several isolates were identified including 
Mycobacterium.chelonae. Some samples of MWF had bacterial concentrations 
ranging from 105 to 107 CFU/ml. 
 
Conclusions 
The clinical conclusions from this study were limited by the poor compliance with the 
clinical evaluations, however the respiratory symptoms reported were comparable to 
those observed during other investigations. The airborne exposure to MWF mist was 
above NIOSH REL and it was recommended that the company reduced exposure to 
MWFs and institute a health surveillance program. 
 
Shelton, B. G. et al. 1999 296 
Shelton et al. published a paper containing three case reports describing outbreaks 
of EAA amongst MWF exposed workers at three different sites. Case report one 
describes a single case of EAA, case report two describes two cases of EAA in a 
population of 700 machine workers, and case report three describes five cases of 
EAA in a site under investigation at the time of publication. Two of the three 
outbreaks were in engine manufacturing sites.  Detailed clinical data was only 
available for case one. In all factories, including the one under investigation, 
Mycobacterium.chelonae was identified in samples of the used MWF, at 
concentrations up to >107 CFU/ml. The authors hypothesised that Mycobacterium 
spp in MWF was the cause of EAA in these cases..  
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Trout, D. H. et al. 2000 297 
Background 
This involved an investigation of an automobile manufacturing plant where 250 
workers were exposed to semi synthetic water soluble MWF containing a Triazine 
biocide (HETA 99-0311-2790). NIOSH were asked to review the establishment due 
to concerns about respiratory health reported by ninety-three workers. The initial 
reports were made in June of 1999, with intermittent ‘outbreaks’ of symptoms from 
this date to the subsequent NIOSH investigation. The reports of ill health came from 
one of three manufacturing departments, although all three sites used the same type 
of MWF.  
 
Methods and results 
Symptom questionnaires were completed by 229 of the 462 workers, spread over the 
three sites and sixty-six of the 229 worked at the site under investigation. The 
questionnaire data was used to compare reported symptoms of workers at the site 
under investigation, with those from the other sites included in the study. Sixty two 
per cent of the workers at the site under question had cough compared to 28% at the 
other sites and there were complaints of increased shortness of breath in 52% of the 
workers at the site of investigation compared to 24% at the other sites.  
 
The medical records of seventy-one workers who had consulted the occupational 
physician were reviewed. Seventy two per cent of these workers complained of a 
cough, 45% of shortness of breath, 39% of chest tightness, 13% of wheeze, 17% of 
general fatigue, 6% of dermatitis, 39% of headache and 23% suffered dizziness. How 
the occupational physician then investigated these cases was not documented in the 
report but two workers were diagnosed as cases of 'new onset' asthma with work-
related symptoms, two as having exacerbations of previously asymptomatic asthma, 
and six as having "asthma like conditions". 
 
Area air sampling revealed trace amounts of volatile organic contaminants, none of 
which were thought to be significant. Seventy PBZ samples were collected to assess 
the level of MWF mist but only four of these showed levels either equal to or 
exceeding the NIOSH REL. Of note, three of these samples were from the other 
company sites, and only one from the department where the ill health had been 
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reported. Samples of bulk MWF contained gram-negative bacteria up to 108 CFU/mL 
and endotoxin levels were on average 105 EU/mL. 
 
Conclusions 
NIOSH concluded that the MWF did not appear to be solely responsible for the 
respiratory symptoms but noted that bacterial contamination was a continuing 
problem. It was recommended that the company continue to systematically monitor 
the health of its employees and to ensure good maintenance and cleaning of 
machinery and MWF. 
 
Trout, D. et al. 2002 298-300 
Background 
This study was of an outbreak of respiratory ill health in a factory manufacturing 
automobile brake calipers and drums (HET ALA 2001-0303-2893). An additional 
report on aerosol sampling at the same site followed [32], adding to the depth of 
information available about this outbreak. The factory site covered an area of 
200,000 ft2 and the company used a semi synthetic MWF containing a Triazine based 
biocide. The assembly and machining departments were separated by a wall and 
had separate ventilation systems; therefore the assembly workers should not have 
been exposed to high level of MWF mist. Approximately 150 workers were based in 
the machining area with a further 250 workers based elsewhere on site.  
 
Methods and results 
Initial respiratory symptoms and illness were reported in October 2000 and five 
patients were diagnosed with EAA between December 2000 and April 2001. In 
response to the reported ill health, the company cleaned the sumps, replaced the 
used MWF, installed new biocide, improved the ventilation, and provided medical 
screening for the workers. NIOSH were requested to investigate the workplace to 
further assess the cause of the ill health.  
 
NIOSH circulated a symptom questionnaire to all the employees, which was 
completed by 305 of the 335 workers. The results of the questionnaire were then 
compared for workers in high exposure jobs to those workers in low exposure jobs. 
This showed that all the reported symptoms were higher in prevalence amongst the 
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high exposure category workers, with prevalence ratios for symptoms ranging from 
1.2 to 2.2. 
 
Medical records of thirty-two of the workers who had complained of respiratory ill 
health were examined; for these workers, the mean length of employment in the 
factory was eighteen years. In the year preceding the NIOSH investigation, 107 
workers had had their work restricted due to respiratory problems and at the time of 
the investigation, thirty-seven workers remained on sick leave.  
 
Industrial hygiene evaluations were undertaken. These included bulk sampling of 
MWF, a review of hygiene records, and personal breathing zone (PBZ) and area air 
sampling during typical operations. Initially the central MWF system was found to 
contain up to 107 CFU/ml of total bacteria and 105 CFU/ml of Mycobacterium sps. 
Three months later, after the introduction of a biocide, no bacterial or fungal growth 
was identified in the used MWF. Personal breathing zone air sampling showed a 
range of total particulate between 0.14 to 0.68 mg/m3 (NIOSH REL for thoracic 
particulate mass= 0.5 mg/m3). 
 
As part of the clinical investigation, workers had a combination of tests including 
blood tests, lung function tests, and radiological tests. It was not documented 
whether any patient underwent lung biopsy. In total, thirty workers were diagnosed 
with EAA, fourteen with OA and six with work-related chronic bronchitis. Those 
patients with OA met the investigators defined criterion of one or more work-related 
symptom (cough, wheeze or chest tightness); an absence of systemic 
symptoms/signs; no infiltrates on the chest radiology; and spirometry pattern 
consistent with reversible airways obstruction (i.e., an obstructive pattern with > 12% 
improvement in forced expiratory volume in one second after administration of 
inhaled bronchodilators).  
 
The physician diagnosed eighteen of the total number of cases of EAA without using 
the chosen criteria. The remaining twelve were diagnosed using the following 
criterion: one or more work-related symptom (cough, wheeze or chest tightness); one 
or more systemic signs/symptoms (fever, chills, fatigue, myalgia, night sweats); 
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infiltrate on radiology and abnormal spirometry (either an obstructive or restrictive 
pattern). 
 
As well as the questionnaire data that categorised workers into 'high' or 'low' mist 
levels, the mist concentrations were measured objectively using mist collectors. Out 
of the thirty cases of EAA, six cases occurred amongst the low exposure category 
jobs (4% of the exposed), fourteen cases amongst the medium exposure jobs (19% 
of the exposed), and ten cases amongst high exposure jobs (34% of the exposed). 
 
Conclusions 
The conclusion was that higher MWF mist levels were associated with a higher 
reported prevalence of symptoms and a higher incidence of respiratory disease. 
 
Trout, D. et al. 2002 301 302 
Background 
This study involved a NIOSH investigation (HETA 2002-0155-2886) of another large 
automobile manufacturing site (with an area of 1.5 million square feet), employing 
2000 production workers using a semi synthetic water mix MWF containing a 
Triazine biocide with. This investigation addressed the use of serological tests to aid 
diagnosis of EAA and to aid identification of these pathogens causing respiratory 
allergy. 
 
Methods and results 
NIOSH were asked to investigate respiratory complaints in sixteen workers and in 
response one hundred and fifty questionnaires were sent out, of which one hundred 
and forty were completed, and one hundred and four of the workers agreed to further 
assessment. The aim of the questionnaire was to identify symptomatic and 
asymptomatic groups of employees who would take part in immunological testing to 
Mycobacterium immunogenum. The respondents were divided into four groups; 
workers exposed to MWF who had previously been assessed for respiratory 
problems (group 1); fifteen who were exposed and symptomatic but had not 
previously been assessed (group 2); thirteen exposed and asymptomatic (group 3) 
workers; and fourteen unexposed and asymptomatic (group 4). In those groups 
containing more than fifteen potential workers, fifteen were randomly selected so all 
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four groups contained the same number of workers. The fifty-six workers within these 
groups consented to donate blood to assess cytokine expression involved in 
regulating cell mediated and humoral immunity.  
 
Nineteen workers previously assessed for respiratory disease had medical records 
that were reviewed as part of the health hazard evaluation (HHE). Using the 
diagnostic criteria previously used by Fox et al. in the Kenosha outbreak 1, seven 
workers were diagnosed with either definite (3), probable (2) or possible (2) EAA. 
Some of the medical records were incomplete and more cases may have been 
recognised had the required information been documented. A further eight workers 
had work-related respiratory symptoms. Six out of seven possible cases of EAA and 
five out of eight with respiratory symptoms were found in group 1. The symptom 
questionnaire identified a further twenty out of one hundred and four exposed 
workers who complained of respiratory symptoms. 
 
The one significant difference in cytokine expression was an increased IL-8 secretion 
(expressed as a percent of LPS induced cytokine secretion) in MWF exposed 
workers. No other significant relationships between secretion of the cytokines tested 
and either the presence of EAA or exposure to MWF was found. Antibody levels 
against both M. immunogenum and M. fusarium antigens were greater in those with 
EAA compared to those without a diagnosis, however based on this test alone it was 
not possible to determine the causative agent. 
 
Conclusions 
A number of interventions were made by the company in response to the outbreak of 
EAA, after which some workers previously diagnosed with EAA were able to 
successfully return to their place of work suggesting that improved control of 
exposure to the causative agent(s) had been achieved. NIOSH recommended that 
the firm continue health surveillance and that workers should wear appropriate 
respiratory protection. 
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Gupta, A. et al. 2006 303 
Background 
Using data gathered by the state Occupational Disease Surveillance system and the 
Division of Occupational and Environmental Medicine (DOEM) seven cases of EAA 
were identified and assessed by a physician. These came from three different 
automobile manufacturing sites and the initial index case was diagnosed in 2003. 
The workers had been exposed to MWF for a mean of 6.2 years before their 
diagnosis and at the time of the investigation were using mainly semi synthetic MWF.  
 
Methods and results 
The Michigan Occupational Safety and Health Administration (MIOSHA) conducted 
an industrial hygiene investigation at the workplaces, with financial assistance from 
NIOSH. There were 2825 employees over the three sites. There was no health 
survey of the workers, the only clinical investigation was a review of those workers 
already diagnosed with EAA, and no additional symptomatic workers were identified. 
All seven workers demonstrated an improvement in lung function (FEV1) and 
radiology (HRCT) when their exposure to MWF ceased.   
 
EAA was identified using diagnostic criteria as defined by Schuyler and Cormier 246, 
which specified that the worker should meet four major and two minor criteria. In the 
seven cases assessed in this investigation, although all of them met four of the major 
criterion, only two cases met at least two of the minor criterion. 
 
Microbial analysis of MWF samples taken from the MWF system, demonstrated the 
presence of M. immunogenum at one site, an unclassifiable Mycobacterium at 
another site and no bacterial or fungal growth at the third site. Personal air monitoring 
data conducted by management at two of the three sites was reviewed. This 
revealed that the level of MWF in the air was well below the MIOSHA permissible 
exposure limits for mineral oil mist and total particulates. 
 
Conclusions 
At the end of the investigation, the management were recommended to continue 
monitoring levels of MWF in the air, and to regularly assess contamination with 
Mycobacterium spp. 
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Studies in the USA that investigated outbreaks of respiratory and skin disease  
 
Eight of the twenty-nine outbreaks identified by the literature review involved cases of 
workers with skin disease and workers with respiratory disease. Seven of these 
investigations were based in the USA, and one in Croatia (see section 3.4). In these 
investigations the respiratory disease was mostly documented alongside skin 
disease (as an obstructive disease process) but without a detailed investigation.  
 
Daniels, W. D. et al. 1988 305 
Background 
This investigation by NIOSH was of an outbreak of skin disease (HETA 88-268-
L1980) in a factory producing aluminium alloy pistons for automobiles for which water 
based soluble MWF was used. Part of the industrial process involved tin plating. Out 
of the one hundred and fifty two exposed workers, thirteen were chosen for interview, 
but the report did not specify whether these were chosen randomly or because they 
had complained of skin symptoms. Their mean length of employment was 9.5 years.  
 
Methods and results 
No microbiological or immunological investigations were reported. Airborne 
concentrations of MWF were measured and were well below the recommended 
NIOSH levels for oil mist (5mg/m3). Of the thirteen workers that were interviewed, ten 
complained of recurrent rash and on examination two had an eczematous like 
eruption with lichenification, suggesting chronic dermatitis. The general opinion of the 
workers was that the skin rashes were work-related.  
 
The workers also reported suffering from work-related cough and shortness of 
breath, specifically related to the MWF fumes. This was not investigated further.  
 
Conclusions 
Recommendations were made to the company to continue to maintain the local 
exhaust ventilation systems to keep exposure as low as possible to encourage good 
hygiene practice, to maintain employee education, and implement a medical 
surveillance program for early detection of MWF related skin disease.  
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Filios, M. B. et al. 1994 306. 
Background 
In 1990 NIOSH received a request to investigate a plant processing aluminium 
ingots, where staff had expressed concern about skin, eye and throat irritation as well 
as respiratory problems (HETA 90-0286-2428). One hundred and fifty employees 
were exposed to MWF, although the exact type was not documented.  
 
Methods and results 
Seventy-eight staff agreed to take part in a survey and these had an average 
duration of employment of fourteen years. The health survey consisted of a symptom 
questionnaire, cross shift spirometry, and serial peak flow monitoring. Eleven 
participants with work-related respiratory problems were identified. Six of these 
reported at least one work-related respiratory symptom, and one participant had a 
cross shift decrease in FEV1 of more than 10%. Four participants had a greater than 
20% work-related change in peak flow detected using serial peak flow analysis, but 
this was not associated with a particular work area. Seventy percent of the 
participants reported experiencing eye irritation on more than two occasions over the 
preceding year, and 44% complained of skin irritation.  
 
The industrial hygiene portion of the survey consisted of collecting PBZ and 'area' air 
samples, as well as microbiological examination of bulk liquid samples. The bacterial 
counts were very low in both the bulk and air samples. 
 
Piacitelli, C. W. et al. 1999 307 
Background 
This involved a health and hygiene investigation (HETA 96-0232-2776) of a factory 
involved in the manufacturer of steel roof bolts. The factory employed sixty-six 
workers and approximately fifty were reported as exposed to an oil water mix MWF 
used in the manufacturing process. The range of symptoms reported in the study 
were similar to that described in an earlier report (HETA 90-0286-2428). The main 
symptom described was a burning sensation in the eyes, and secondary to this 
heartburn, coughing, upper respiratory tract problems, headaches and shortness of 
breath. 
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Methods and results 
Thirty-seven of the fifty exposed workers completed a symptom questionnaire and 
spirometry tests. These employees had an average duration of employment of 7.5 
years.  Fourteen of those completing the survey reported having a rash on exposed 
body areas, and eight of these attributed the rash to exposure to MWF. Only one 
worker had sought medical attention and they were diagnosed with a skin infection. 
Sixty-five percent (24/37) complained of irritation of the eyes and seventeen of these 
attributed this irritation to their work. 
 
Of the thirty-seven workers who participated in the survey, twenty-seven reported 
moving to other workstations since their initial assignment, mainly because of 
respiratory complaints. Three of the thirty-seven surveyed complained of a dry 
cough, four of a cough productive of sputum, eight had wheeze and shortness of 
breath, and thirteen of symptoms of chronic bronchitis. Physician diagnosed 
bronchitis was documented for eight of the participating workers, and abnormal 
spirometry was noted for four of the participants, with an obstructive pattern in three 
and restricted pattern in one. Thirty-six of the participants performed cross shift 
spirometry measurements but this was negative in all cases.  
 
Twenty of the fifty current workers were interviewed and most of these complained of 
rashes and irritation of skin and mucous membranes, heartburn, as well as 
respiratory symptoms. None had constitutional symptoms or had sought medical 
attention for their complaints. 
 
Sampling to determine 8-hour time weighted average (TWA) concentrations of 
airborne MWFs found none to be in excess of the Occupational Safety and Health 
Administration (OSHA) Permissible Exposure Limits (PEL) and American Conference 
of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value (TLV) of 5 
mg/m3. However all the personal sample measurements taken at two of the three 
presses were above the NIOSH REL of 0.4 mg/m3 for thoracic aerosol. This finding of 
increase thoracic aerosol corresponds to the workers statements that they suffered 
symptoms when working at the presses.  
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Area sampling for endotoxin generally found levels below two endotoxin units per 
cubic meter of air (EU/m3) and none exceeded 11.5 EU/m3. Pseudomonas sps were 
predominant in the MWF supply system at concentrations of 2.5 x106 to 2.5x108 
colony forming units. Endotoxin contamination of the same fluids ranged from about 
68 to 537 thousand endotoxin units per milliliter (EU/ml).  
 
Conclusions 
The report noted that there appeared to be a high prevalence of chronic respiratory 
symptoms, and work-related skin and eye irritation within the workforce. Slightly more 
than a third of the participants met the definition of chronic bronchitis, although no 
specific investigations of EAA was instigated. It was recommended that methods to 
reduce the exposure of workers to MWF should be adopted. 
 
Kiefer, M. G. et al. 1999 308 
Background 
This involved an investigation of a large (500 000 square feet) factory manufacturing 
automobile parts using semi synthetic or straight oil based MWFs. The plant 
employed 850 workers (HETA 98-0246-2747). The investigation followed complaints 
of allergy, and irritation of the respiratory tract, skin and eyes. The investigation 
focused on one area of the factory (area 109) where thirteen employees (twelve 
machine operators and one inspector) worked. The mean length of employment of 
staff working in area 109 was 7.4 years compared to an average of 11 years for staff 
in the factory as a whole. Twelve of the thirteen workers in area 109 completed a self 
administered symptom questionnaire, of whom five complained of shortness of 
breath, four of wheeze and five of a rash. There were no controls subjects 
questioned for comparison. 
 
Methods and results 
Full shift PBZ air samples were collected with a size selective device to collect the 
thoracic particulate fraction of MWF. Two of the seven PBZ samples for MWF were 
higher than the NIOSH REL (0.4 mg/m3). Both these results were from machine 
operators using semi synthetic MWFs. Other chemicals such as petroleum naphtha 
were also monitored and these were all found to be below the NIOSH REL of 350 
mg/m3. A microbiological assessment was not made.  
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Conclusions 
Recommendations were made to reduce the workforce's exposure to MWF 
particularly by improving ventilation controls. A comprehensive health and safety 
program was also recommended, specifically addressing the needs of workers 
exposed to MWF. 
 
Roegner, K. T. 2001 310 
Background 
This involved an investigation at a factory manufacturing airplane parts, which 
employed nine hundred and twenty workers of whom two hundred and four 
machinists were exposed to MWFs. The initial request NIOSH received was for a 
Health Hazard Evaluation based on three employees who reported several health 
effects including respiratory and skin disease, which they considered due to synthetic 
MWF used in the machine shops. Four machinists had been diagnosed with new 
onset asthma in the year prior to the investigation, so the medical evaluation focused 
on respiratory effects rather than skin disease.  
 
Methods and results 
Prior to the NIOSH investigation, twelve machinists had complained of respiratory 
symptoms and were reviewed by the company’s occupational physician. Four of the 
twenty were referred for pulmonary function testing, and one was diagnosed with 
occupational asthma based on bronchial hyper responsiveness (BHR), two had work-
related respiratory symptoms, and the other saw a private physician who diagnosed 
OA on the basis of a positive BHR test.  
 
Symptom questionnaires were given to all employees in the machining area, and two 
hundred and eighty four questionnaires were completed and returned. Of the two 
hundred and eighty four, one hundred and eighty eight were considered as exposed 
to MWFs. Ninety-five percent complained of shortness of breath and twenty-three 
percent of asthma like symptoms. Of the sixteen workers referred to the occupational 
physician, fifteen had been exposed to MWFs, fourteen had work-related respiratory 
symptoms and ten had a rash. Workers were investigated depending on their 
symptoms; with sixty-six having spirometry tests and a smaller number undergoing 
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BHR tests. For a diagnosis of OA, the workers needed appropriate symptoms, a 
positive BHR test and peak flow variability showing work-related effects. Using this 
criteria only one case of OA was found, but there were eight workers who had 
recently diagnosed asthma with work-related symptoms.  
 
Environmental investigations were carried out which included collecting bulk samples 
of MWF. Microbiology tests demonstrated the presence of Bacillus spp and 
Pseudomonas spp but no fungi. MWF aerosol samples were also taken and the 
particulate mass for each sample was measured. With one exception all but one of 
the fifty-five PBZ samples measured below the NIOSH recommended limits of 0.4 
mg/m3.  
 
Conclusions 
The conclusion of the report was that despite the levels of MWF mist, there was a 
high incidence of respiratory symptoms and skin complaints in those workers 
exposed to MWF, and it was therefore recommended that efforts should be made to 
further lower exposure where possible. 
 
Achutan, C. N. 2003 311 
Background 
This involved an investigation (HETA 2003-0175-3033) of a workplace manufacturing 
steel bars and coils, which employed 50 staff in the production area. The NIOSH 
investigation was in response to concerns expressed by Union representatives about 
poor ventilation in the factory. Two different MWFs were used at this plant; a straight 
oil, and an oil water mix, which also contained 3% triethanolamine.  
 
Methods and results 
Fifty workers were identified as exposed to MWFs with some additional workers (for 
example forklift truck drivers) also considered as having limited exposure to MWFs. 
Thirty five of the exposed workers participated in a medical review and their median 
length of employment was 18 years. Respiratory symptoms were present in 66% of 
the interviewed workers (23/35) of which fourteen complained of upper airways 
problems, six suffered from bronchitis, three had been diagnosed with pneumonia, 
and two workers reported that their asthma symptoms had deteriorated since working 
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for the company. Thirty one percent of those interviewed (11 of the 35) complained of 
skin rashes. 
 
Environmental monitoring included area and personal breathing zone samples for 
detection of respirable particulates from soap powder, crystalline silica, MWF, and 
acid mists. Four bulk samples were taken for microbiological examination and 
Burkholderia spp, Enterobacter spp and Pseudomonas spp were identified but no 
Mycobacteria sps. Endotoxin levels of 4.2 x 105 EU/ml were measured in these 
MWFs.  
 
Conclusions 
The report concluded that the employees were exposed to excessive levels of MWF 
mist, and recommended reductions in mist levels, linked with medical surveillance.  
 
Tapp, L. et al. 2005 312 
Background 
This investigation (HETA 2005-0227-3049) was of a large factory producing bicycle 
chains. The factory site covered 600,000 ft2 and employed five hundred and twenty 
staff, with approximately 40 exposed to MWF. NIOSH started the investigation after 
receiving a request from union representatives to investigate complaints of skin rash 
among the staff. Medical records of two employees were reviewed and documented 
a previous diagnosis of allergic dermatitis, and irritant dermatitis, which had patch 
tested positive to colophony resin, abeitic acid and bioban.  
 
Methods and results 
Thirty-four workers were identified for interview, and twelve reported that their rash 
had appeared when the MWF was changed three years previously. All twelve had a 
diagnosis of dermatitis but only six had an active rash on examination. Two of the 
twelve also reported respiratory problems but these were not investigated further. 
 
Industrial hygiene investigations included bulk samples of used and unused MWF 
and of the biocides in use. Several of the MWFs were found to contain formaldehyde 
and formaldehyde producing chemicals (e.g. triazines), which are known to cause 
skin irritation and for some workers, allergic reactions. Improper work practices 
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leading to dermal exposure were observed and these were thought to have 
contributed to the high numbers with skin disease.  
 
Conclusions 
NIOSH recommended that poor maintenance and training were leading to excessive 
dermal exposure and therefore skin complaints. 
 
Outbreaks of skin disease associated with MWF reported in the USA 
 
Four outbreaks of skin disease with no documented respiratory disease were 
identified in this review of the literature. Three of these investigations were 
undertaken by NIOSH. The estimated number of exposed workers in each factory 
was documented in only one of these reports where there was an exposed 
population of one hundred and forty workers. Two of the four factories manufactured 
car parts, one made hydraulic pumps, and the fourth produced air compressors. The 
NIOSH medical investigations were based on interviewing a selection of the workers. 
In the one independent investigation a larger proportion of the work force was asked 
to report symptoms using a questionnaire.  Across these four plants different MWFs 
were used, straight oils, soluble oil, semi synthetic and synthetic MWFs, although 
one report did not identify the type of MWF used. 
 
Gupta, S. L. et al. 1989 313 
Background 
In December 1986 NIOSH were asked to evaluate a factory manufacturing hydraulic 
pumps (HETA 87-092-1967). The request was prompted by cases of dermatitis 
thought to be due to MWFs, although the type of MWF used was not specified in the 
report.  
 
Methods and results 
There were one hundred and forty workers who were exposed to MWFs and of these 
fifty-five were interviewed and examined. Thirty-four of the fifty-five reported having 
dermatitis and of these thirty had reported their skin complaint during the preceding 
four months. Most of the dermatitis was located on the workers’ hands, neck and 
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face. Examination identified chronic changes of lichenification and acute 
inflammatory eczema.  
 
Patch tests were carried out on twenty-six symptomatic workers. One worker tested 
positive to one of the MWFs used in the factory, another tested positive to one of the 
biocides used in the MWF, and two subjects reacted weakly to a different type of 
MWF. It is not clear whether new or used MWF samples were used in the patch 
testing. At the time of the outbreak of skin disease, the MWF was noted to be 
green/brown and foul smelling, but there were no environmental or microbiological 
investigations.  
 
Conclusions 
The authors concluded that most of the workers were suffering irritant dermatitis 
rather than allergic dermatitis. It was felt that this was most likely due to exposure to 
bacterial contamination and decomposition of various coolants. NIOSH advised 
improved fluid maintenance, employee education, hazard communication, personal 
protection and a medical program designed to decrease the incidence of dermatitis. 
 
Donavan Reh, B. et al. 1995 314 
Background 
This was an investigation of a plant that manufactured automotive aluminum 
castings. The number of workers employed was not documented.  The investigation 
was initiated by skin complaints of irritation and infection, along with upper and lower 
respiratory tract symptoms. These were attributed to the use of water mix MWF 
(HETA 95-0153-2549).   
 
Methods and results 
After reviewing work practices, air samples were taken to monitor levels of oil mist 
and formaldehyde. Formaldehyde samples were all less than 0.06 ppm. The oil mist 
samples had a total particulate weight of 0.27 mg/m3 and 0.47 mg/m3 (below the 
NIOSH REL of 0.5 mg/m3). Microbiological tests for the MWF samples identified 
gram-negative bacteria, specifically Pseudomonas spp and related species. Bacteria 
counts in bulk samples ranged from 9.8 x 105 to 9.8 x 107 cfu/ml.  
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Eight workers were randomly selected for interview but the method of randomisation 
was not detailed in the report. All of the interviewed workers complained of rashes on 
exposed areas such as hands, arms and face, but none of them complained of 
respiratory symptoms. Injury and illness records for the previous year collected by 
OSHA identified only sprain injuries and one reported case of rash. Of the eight 
workers that reported rash, five presented with visible evidence of a rash on the day 
of the survey. No further medical assessment of the rashes was documented.  
 
Conclusions 
Recommendations from the investigation were to reduce dermal contact with the 
MWF and to use protective clothing.  
 
Donovan Reh, B. P et al. 2000 390 
Background  
This investigation (HETA 2000-0356-2851) involved a large company with three 
hundred and fifty employees who produced air compressors and who were using a 
combination of straight, synthetic, semi synthetic and water soluble MWFs. The 
investigation was instigated when several employees reported skin problems to the 
management. The company then consulted an occupational dermatologist who 
recommended that exposure to potential skin irritants be reduced. Despite these 
recommendations workers continued to report problems with their skin and so 
NIOSH were contacted and began their investigation in August 2000.  
 
Methods and results 
The investigating team selected twelve workers for interview, and this group had a 
mean duration of employment at the plant of thirteen years. Five of this group were 
selected because they had reported dermatitis and a further seven participants were 
identified by the Union. At the time of interview five of the twelve participants had a 
skin rash and two of these were diagnosed with eczema and one with folliculitis. Two 
of the five workers, both of who were assemblers, had dermatitis on their forearms. 
Based on rashes observed on the day of the site visit, it was thought that the type 
and aetiology of the eruption might vary. It was concluded that a single cause of the 
rashes was unlikely but that limiting contact of skin with MWFs would minimize work-
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related exacerbations of dermatitis. The report did not mention whether the staff had 
reported respiratory symptoms. 
 
Environmental sampling was undertaken which included air and personal breathing 
zone (PBZ) sampling. The total particulate count, thoracic particulate and extractable 
MWF content were analysed and real time particulate concentration was also 
determined, along with PBZ to determine content of volatile organic compounds 
(VOC). Over half of the MWF particulate samples concentrations were over the 
recommended NIOSH limit (REL) of 0.5mg/m3 and the real time data suggested that 
a large percentage of the particulate mass concentration was in the respirable range. 
Bulk fluid samples also were collected for microbiological analysis and Pseudomonas 
spp and Citrobacter spp were identified, without any evidence of fungi or 
mycobacteria. 
 
Conclusions 
The NIOSH report concluded that a single cause for the different skin diseases was 
unlikely but they advised staff to minimise their dermal exposure to MWFs, washer 
detergents and rust inhibitors. They also recommended workers with skin problems 
to consult a dermatologist  
 
Awosika-Olumo, A. L. 2003 316 
Background 
This investigation was of a car component factory in Ohio that used water mix 
synthetic, and semi synthetic MWFs.  The size of the workforce was not documented.  
This investigation was precipitated by two cases of dermatitis and was a cross 
sectional study. The date of the sentinel case was not reported, but the publication 
was in 2003.  
 
Methods and results 
A self-administered questionnaire was given to forty-five workers considered as 
exposed to MWFs and to a group of thirty-six non-exposed controls. A trained field 
investigator examined all of the workers involved in the production operations. 
Seventy-one staff adequately completed the questionnaire, and twenty-one (26%) of 
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these complained of skin symptoms. Twenty of the twenty-one complaining of skin 
disease were exposed to MWFs. 
 
Workers exposed to MWFs were more likely to suffer from allergies than the non-
exposed workers (p<0.001). Twenty-two percent of the exposed workers had a past 
medical history of allergy, compared to 3% of the unexposed. Five workers with 
dermatitis underwent patch testing against a panel of chemicals including alcohols, 
isocyanates and a number of substances from the workplace. All five had negative 
results, suggesting that the dermatitis was not allergic. Exposure to MWF was a 
significant predictive factor for dermatitis, with 60% of the exposed manifesting 
symptoms but only 6% of the unexposed. The odds ratio for exposure to MWF was 
11.9 (df=1; p<0.001).  
 
Bacteria and yeasts were isolated from environmental samples but the same species 
were not isolated from the skin of affected workers. It was noted that nine of the 
twenty one workers used a plastic abrasive cleaning pad to wash their hands, and 
that workers with higher exposures to MWF had a higher incidence of skin disease 
with the hands being the most commonly affect dermal site.  
 
Conclusions 
Recommendations were made to limit dermal exposure using good hygiene practice. 
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Outbreaks of ill health associated with MWF reported in the UK  
 
Three UK outbreaks of respiratory disease were identified in the literature review, but 
these three incidents were very different. The initial report involved several cases of 
occupational asthma associated with exposure to MWF. This report preceded the 
reported outbreaks of EAA associated with MWFs but did involve the use soluble 
water mix MWF and not straight oil 261 278. The second report was of a large outbreak 
of 'mixed' respiratory disease that involved a thorough investigation 260. The later 
report was a minimal investigation of a site using MWFs where the prevalence of 
respiratory symptoms was high 304.  
 
Robertson, A. S. et al. 1988 261 
Background  
Hendy, M. S. et al. described one of the first reported cases in the UK of OA 
secondary to MWF in 1983 278. Subsequently in 1998, Robertson et al. included this 
case report in a collection of twenty five patients occupationally exposed to MWFs 
and who had been referred to an occupational respiratory clinic with work-related 
asthmatic symptoms 261. The report did not clarify whether these papers referred to 
an outbreak from one particular site, or whether they have been included as a 
collection of separate cases of MWF exposed workers with respiratory disease. 
 
Methods and results 
The twenty-five patients included in the case series had been identified following 
clinic referral. They were assessed using history taking, clinical examination, 
spirometry, skin prick testing, and serial two hourly peak flow analysis. All but one 
worker was exposed to water-soluble MWF rather than straight mineral oil. Six of the 
patients undertook bronchial provocation tests to used and unused MWFs. The 
bronchial provocation testing with clean MWF showed a progressive deterioration in 
peak flow in three of the six subjects. Deterioration after only one day of bronchial 
provocation was seen in only one subject and only to used MWF. One subject one 
reacted to a pine reoderant used in the MWF. 
 
Of the twenty-five patients assessed, thirteen had definite work-related asthma and 
equivocal evidence for work-related asthma was found in another seven staff. A 
 222 
further three staff had asthma unrelated to work and the remaining two staff were 
normal. 
 
Conclusions 
This study concluded that OA due to oil mist was common, and that the agent 
responsible was variable. 
 
Roberston A. S et al. 2005 391 260 
Background 
This paper summarised the largest reported outbreak of respiratory disease in the 
UK due to MWF at a car manufacturing plant in Birmingham. This part of the plant 
investigated (120,000 m2) was involved in the production of aluminium alloy or cast 
iron car engine parts as well as the assembly of engines. The machining process 
used MWF (oil water emulsions with chemical additives including biocides) but during 
use the MWF had became contaminated by lubricating and hydraulic oil (tramp oil). 
Transfer machines performing a number of sequential machining operations 
dominated the northern half of this building. Metal working fluids from large sumps of 
210,000, 55,000 and 19,000 litres capacity lubricated these machines. Individual 
metalworking and transfer machines with their own sumps predominated the 
southern half of the factory.  After machining the components were washed in twenty 
dedicated machines spread around the factory. The company employed 832 workers 
(33 subcontractors, 799 direct employees) and there were an additional four workers 
who were on sick leave because of EAA, making a total of 836. Employees were 
assigned to one of fifty-seven operational codes, which in most cases were closely 
linked to a specific workplace.  
 
Methods and results 
Hygiene data from previous HSE investigations at the plant included air samples for 
mist generation as well as bulk samples of used metal working fluids, sumps, tramp 
oil and machine wash solutions which were subjected to microbiological tests. 
Results of air monitoring between May 2002 and October 2003 showed that 
concentrations of metalworking fluid concentrate in air were generally below the then 
HSE guidance value of 1mg/m3. In October 2003, levels were between 1 and 4 
mg/m3 with an average concentration of just above 1 mg/m3.  Personal samples 
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taken at the same time indicated exposures of between 1 – 1.7 mg/m3, with an 
average exposure of 1.3 mg/m3.  Samples of MWF from the largest common sump 
showed no viable bacterial, mycobacterial or fungal growth, and no increase in 
endotoxin levels. Acinetobacter spp and Ochrobactrum anthropi were identified in the 
main common sump on the basis of DNA evidence and they were isolated as 
cultures from wash machine samples.  
 
In addition, information collected by the stewardship company that managed the 
MWF sump supplies included data on changes to pH, MWF concentration, tramp oil 
contamination and microbial growth (monitored using dip slide tests). Factory records 
showed a steep rise in tramp oil contamination of MWF in the large communal sump 
around April 2003, just after the hydraulic oil used in machines was changed. The 
rise in tramp oil bore a temporal relationship with the onset of workers reporting 
breathlessness. The factory records also indicated that there was an oil leak in March 
2003, which may have contributed to the outbreak of disease.  
 
Twelve employees from the plant were clinically diagnosed as having EAA from 2003 
to May 2004 and this led to the UK Health & Safety Executive starting an incident 
investigation in May 2004. Most of the twelve reported that their symptoms had 
started during the previous springtime. Staff from Birmingham Heartlands Trust 
hospital carried out the clinical investigation.  
 
This investigation involved four phases:  
 In the first phase 808 of the 836 (i.e., 96.7%) of the workers completed 
a 'self reporting' symptom questionnaire. The results of this phase 
demonstrated a prevalence of 9.3% for occupational bronchitis, 18.6% for 
work-related asthma and 2.1% for humidifier fever. 
 In the second phase, 481 (60%) workers who had complained of at 
least one respiratory symptom and forty-eight out of fifty (i.e., 96%) 
asymptomatic employees agreed to participate in further investigations. 
 In phase three, based on the results of the initial clinical assessment, 
one hundred and sixty one workers were seen for more detailed investigation 
at the Birmingham Chest Clinic. This included pulmonary lung functions, chest 
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x-rays, methacholine challenge tests (for bronchial hyperreactivity), skin prick 
tests for common environmental allergens, and high-resolution computer 
tomography (HRCT). Out of all the symptomatic workers one hundred and 
ninety eight returned peak flow records. 
 In phase four, case definitions for extrinsic allergic alveolitis (EAA) and 
occupational asthma (OA) were applied to define cases that met predefined 
objective criteria with onset of disease after January 2003.  
 
Based on clinical opinion, one hundred and two workers were diagnosed with 
probable or definite occupational lung disease including twenty-four with EAA, eighty-
eight with OA and seven with humidifier fever (some with more than one diagnosis). 
Fifteen workers were diagnosed with occupational chronic bronchitis and three 
workers were diagnosed with other respiratory conditions.  
 
Applying diagnostic criteria (based on that used by Fox et al. 1), nineteen workers 
were finally diagnosed with EAA. Using criteria for the diagnosis of OA based on a 
peak flow records in 2003-05 (i.e., an OASYS score of at least 2.67 and/or a mean 
day interpreted difference between work and rest days of at least 16 l/min) seventy-
four workers had serial peak flow recordings consistent with OA. Half of these 
experienced an onset of asthma like symptoms since January 2003. Eight of the 
seventy-four OA cases with a positive peak flow diary also met the diagnostic criteria 
for EAA. Considering the overlap of symptoms, 10.4% of the workforce met case 
definitions for at least one occupational respiratory disease.  
 
Comparing the control group to the workers with EAA, or with OA, no difference in 
smoking history, demographic characteristics, or the length of employment was 
observed. When the cases of illness were mapped to the area of the factory (using 
operational codes) it was found that 97% of the workers with OA and 100% of the 
workers with EAA had worked in the manufacturing area compared to 61% of the 
control group. 
 
Specific bronchial challenge tests were carried out on two individuals, with a positive 
challenge being defined as a fall in forced expiratory volume in 1 sec (FEV1) of 
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>15%.  One of the workers with EAA was challenged with 'used' and 'unused' MWF 
and demonstrated a positive response only to the used MWF.  
 
A total of one hundred and ninety three staff consented to give a peripheral blood 
sample including those who were symptomatic, non-symptomatic but exposed; and a 
group of non-exposed staff. In addition another sixty-five blood samples from healthy 
non-exposed staff working at another organisation were included for comparison. 
Immunological tests were then carried out to provide evidence of sensitisation status 
as well as evidence of inflammatory reactions in those exposed to metal working 
fluids.  Ouchterlony double diffusion gel precipitation tests were used to detect 
precipitating immunoglobulin G (IgG) antibodies to the prepared extracts of oils, 
washes and bacteria. The precipitin tests were carried out against Ochrobactrum spp 
and Acinetobacter spp derived from MWF, and which had been identified in the 
original sump oil sample from the Powertrain plant. In addition, species of 
mycobacteria (Mycobacterium immunogenum, Mycobacterium chelonae and 
Mycobacterium fortuitum) were included in the test panel to compare with the results 
of studies from the USA even though there was no evidence of their presence in 
MWF samples from Powertrain. Of the EAA cases, 59% had precipitating antibodies 
to at least one of the microbial species compared to only 10% of the workers with OA 
and 5% of the controls. No workers tested positive to mycobacteria.  
 
Specific IgE levels to common environmental allergens (Phadiatop – atopy) and to 
'mixed' fungi (Penicillium notatum, Cladosporium herbarum, Aspergillus fumigatus 
and Alternaria alternata) were determined for individuals participating in the study 
using the automated UniCAP system.  It was concluded that the balance of evidence 
suggested that contaminated MWF, and the bacterial contaminants Acinetobacter 
spp and Ochrobactrum spp had a contributory role in the development of 
occupational EAA at the Powertrain factory. The presence of precipitating antibodies 
in most of the symptomatic workers was not taken as proof that bacterial agents 
caused the development of this condition. Since the tests were only carried out 
against two specific organisms it remained a possibility that untested organisms were 
also involved in the development of EAA. The role of other chemical constituents 
(including biocides) of the used MWF and wash solutions in the development of 
these cases of EAA and OA remained unresolved. 
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Conclusions 
On completion of this investigation no further work was carried out because the plant 
subsequently ceased production in 2005 
 
Fishwick, D. et al. 2005 304 
Background 
This investigation involved a small engineering plant where less than 50 workers 
were employed in machining small components. Twenty-one of the workers were 
exposed to water soluble MWFs. The investigation started after one worker was 
diagnosed with EAA.  
 
Methods and results 
All of the workers gave written consent to participate and eleven of the exposed 
workers were assessed. Six of the exposed workers completed a demographic and 
respiratory symptom questionnaire, as well as spirometry and three of them provided 
peripheral blood samples. Two of the group underwent more detailed clinical 
investigation. The mean age of the workers undergoing evaluation was 46 years.  
 
Seventy-five percent of the workers completing the questionnaire complained of 
work-related respiratory symptoms, and fifty percent complained of ocular and nasal 
irritation as well as work-related cough, shortness of breath or chest tightness. Two 
individuals reported respiratory and flu like symptoms and six workers underwent 
spirometry but no abnormal patterns were recorded. Precipitating IgG antibodies to 
used MWF were detected in serum samples from three workers with work-related 
respiratory symptoms. Precipitating IgG to extracts of Pseudomonas spp were 
detected in four workers, two of who had work-related symptoms. No precipitating 
antibodies to used MWF or extracts of Pseudomonas spp were detected in the 
unexposed control subjects. 
 
Samples of MWF were taken from the sump of each machine. On the initial visit to 
the site, biofilm was present on the MWF in the sump; this was sampled and grew 
Fusarium spp. On future visits, this biofilm had reduced. A total of fifteen samples of 
MWF were collected and whilst half yielded less than 100 CFU/ml bacteria, others 
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yielded as high as 8.2 x 106 CFU/ml. The samples contained up to 2200 CFU/ml of 
fungi and endotoxin levels ranged from 56 to 680 EU/ml. Air sampling identified 
Pseudomonas fluorescens but endotoxin levels were below the limit of detection. 
 
This investigation was limited in its scope due to a clean-up operation that began 
before the workplace could be fully evaluated. Three of the eight staff interviewed 
spontaneously reported improvements in their symptoms following the changes in the 
working environment.  
 
Conclusions 
The authors recommend that physicians and public health professionals remain 
vigilant to the possible respiratory illness caused by the bio aerosol of contaminated 
MWF. 
 
 
Outbreaks of ill health associated with MWF reported in mainland Europe 
 
Despite cases of ill health being reported to surveillance schemes in Europe, few 
publications related to outbreak investigations were identified during the search of the 
literature.  
 
Outbreaks in Croatia 
Jaksic, S. 1998 309 
Background 
A paper was published referring to an automobile production plant in Croatia, where 
an increase in staff exposed to MWF who complained of ill health was reported. The 
first cases were observed in the spring and summer of 1992.  
 
Methods and results 
Eighteen workers were diagnosed with bronchitis and thirty-eight with skin infections 
of the hands and face. In total thirty-eight workers required medical care. The MWF 
was described as an emulsion. One hundred and fifty samples of the MWF were 
taken and examined for microbial growth. Several bacteria were isolated, most 
frequently Pseudomonas spp, Escherichia Coli and Proteus spp. The total bacterial 
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colony count in the tested samples was relatively high, and in most samples 
amounted to 3 x 105 CFU/ml. Moulds and yeasts were also isolated from all of these 
samples.  
 
Conclusions 
The conclusion of the paper was that the cause for the ill health associated with 
MWF was microbial infection. 
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Appendix 2 
Powertrain questionnaire phase 2 
 
Respiratory Survey June 2004 
 
Thank you for taking part in this survey of [Company Name]. Please complete all 
of the questions. If you are not sure what a question means then please ask one 
of the survey team. If you are not sure whether you have had a symptom or not, 
please answer “no” 
Thank you for your help. 
 
First Names……………………….……Last Name…………………………………………………………… 
Date of Birth…………………………   Payroll Number………………………………… 
Address………………………………………………………………………………………………..…………………………………
……………………………………………………………………………………………………………………... 
………………………………………………………………………………………… 
Cost Centre……………………..  Area of Work……………………………. 
General Practitioner……………………………………………………………………………………………….. 
Address……………………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………………………………………
…………………………… 
Sex( Please circle)   Male  /  Female   
 
Date……/…../……. 
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Job History 
1) Current employer 
[Company Name 1]   [Company Name 4]  
[Company Name 2]   [Company Name 5]  
[Company Name 3]   [Company Name 6]  
Other      …..(specify)………………………………….. 
2) When did you first start working in [Problem Area] 
 Month  Year   
3) On average, how many hours do you work in a week?   Hrs 
4) Where were you working in [Problem Area] 
 in January 2003?................................................................................................. 
5) Do you mostly work in the manufacturing areas?     Yes   No  
6) Have you ever worked on a machine that uses coolant oils?  
Yes   No  
        If “No” Go To Question 11      
7) When did you start working on a machine that uses coolant oils? 
         Month  Year  
8) Do you currently work on a machine(s) that uses coolant oils?  
Yes   No  
10) If NO when did you last work on a machine that uses coolant oils 
         Month  Year  
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Cigarette Smoking  
11) Do you smoke?                 Yes   No  
If YES go to Ques 14 
12) Have you ever smoked as much as one cigarette a day, or one cigar a week, 
or one ounce of tobacco a month for as long as a year?  
Yes  No   
If NO go to Question 19 
 
13) How long ago did you give up smoking all together? YearsMonths 
14) How old were you when you started smoking?  YearsMonths 
15) Do (did) you smoke manufactured cigarettes?  Yes   No  
If NO go to Ques 17 
If YES  16) How many per day?             How many years?... ...... 
17) Did you smoke something else?      Yes   No  
If YES  18) How much per week?             How many years?... ...... 
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Symptom – Shortness of Breath. 
19) Are you are disabled from walking by a disease other than heart or lung 
disease     Yes   No  
       If “YES” Go To Question 35 
If “No” -  On your worst day in the last 12 months;- 
20) Were you troubled by shortness of breath when hurrying on level ground or 
walking up a slight hill ?    Yes   No  
        If “No” Go To Question 35 
If Yes  21) Did you get short of breath walking with other people of your own 
age and sex on level ground?     Yes   No  
        If “No” Go To Question 24  
If “Yes”  22) Did you have to stop for breath when walking at your own pace on 
level ground?       Yes   No  
        If “No” Go To Question 24  
If “Yes” 23) Were you short of breath when washing or 
 dressing?          Yes  No  
          
24) On how many days do you have breathlessness?   (Tick one only) 
Never     
Less than monthly    
At Least monthly     
  At least once a week     
At  least once a day   
More frequently     
 
25) Are you breathless on waking?    Yes   No  
26) Are you breathless during the day?   Yes   No  
27) Are you woken from sleep by your breathlessness?  Yes   No  
 
Is your breathlessness worse ; 
 28) At the beginning of the working week?  Yes   No  
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 29) At the end of the working week?    Yes   No  
 30) No difference?     Yes   No  
 
31) On days away from work is your breathlessness   (Tick one only) 
Better      
 The same      than days at work  
Worse    
 
32) On holidays is your breathlessness ( Tick one only) 
Better      
 The same      than days at work  
Worse    
33) When did you first develop breathlessness?    Month   Year  
34) Do you suffer from breathlessness at present? Yes   No  
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Symptom – Cough. 
 
35) Do you cough?  Yes  No  
If “No” Go To Question 46 
36) When did you first develop a cough?     Month  Year  
37) On how many days do you cough      (Tick one only) 
Never     
Less than monthly     
At Least monthly      
At least once a week    
At  least once a day     
More frequently      
 
38) Do you cough on waking?    Yes   No  
39) Do you cough during the day?   Yes   No  
40) Are you woken from sleep by your cough?  Yes   No  
 
Is your cough worse ; 
 41) At the beginning of the working week?  Yes   No  
 42) At the end of the working week?    Yes   No  
 43) No difference?      Yes   No  
 
44) On days away from work is your cough   (Tick one only) 
Better      
 The same      than days at work  
Worse    
 
45) On holidays is your cough    ( Tick one only) 
Better      
 The same      than days at work  
Worse    
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Symptom – Phlegm (Sputum) 
 
46) Do you cough up phlegm (sputum) from your chest? Yes  No  
        If “No” Go To Question 58 
47) Do you do this for at least 3 months each year?  Yes  No  
48) Have you been doing this for the last 2 years 
 or more?         Yes  No  
 
49) On how many days do you cough up phlegm from your chest 
     (Tick one only) 
Never     
Less than monthly     
At Least monthly      
At least once a week    
At  least once a day      
More frequently      
 
50) Do you cough up phlegm on waking ?   Yes   No  
51) Do you cough up phlegm during the day?   Yes   No  
 
Is your phlegm production worse ; 
 52) At the beginning of the working week?  Yes   No  
 53) At the end of the working week?    Yes   No  
 54) No difference?     Yes   No  
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55) On days away from work is your phlegm   (Tick one only) 
Better      
 The same      than days at work  
Worse    
 
56) On holidays is your phlegm ( Tick one only) 
Better      
 The same      than days at work  
Worse    
 
57) When did you first develop phlegm?      Month   Year  
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Symptom – Eyes 
58) In the past twelve months have you had more than two episodes of irritation 
or watering of the eyes?   Yes  No  
        If “No” Go To Question 62 
59) On how many days do you have this? 
     (Tick one only) 
Never     
Less than monthly     
At Least monthly      
At least once a week   
At  least once a day      
More frequently      
 
60) On days away from work is this   (Tick one only) 
Better      
 The same      than days at work  
Worse    
 
61) On holidays is this      ( Tick one only) 
Better      
 The same      than days at work  
Worse    
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Symptom – Nasal 
62) In the past twelve months have you had more than two episodes of blocked 
or stuffy nose?    Yes  No  
        If “No” Go To Question 66 
63) On how many days have you had this? 
     (Tick one only) 
Never              
Less than monthly     
At Least monthly     
At least once a week    
At least once a day      
More frequently      
 
 64) On days away from work is this   (Tick one only) 
Better      
 The same      than days at work  
Worse    
 
65) On holidays is this ( Tick one only) 
Better      
 The same      than days at work  
Worse    
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Symptom –Throat 
66)  In the past twelve months have you had more than two episodes of a dry or 
sore throat?       Yes  No  
        If “No” Go To Question 70 
67) On how many days do you have this? 
     (Tick one only) 
Never     
Less than monthly     
At Least monthly     
At least once a week    
At  least once a day      
More frequently      
 
68) On days away from work is this   (Tick one only) 
Better      
 The same      than days at work  
Worse    
 
69) On holidays is this ( Tick one only) 
Better      
 The same      than days at work  
Worse    
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70) How many days off work have you had in the last 12 months  
due to chest illness?     Days   
 
Past Illnessess 
 
71) Have you ever had any  chest illnesses?    Yes   No  
Specify…………………………………………………………………………. 
 
72) Are you taking any treatment for your chest? Yes   No  
Specify............................ 
 
73) Have you ever had a lymphoma? Yes   No  
 
74) Have you lost weight since [Likely Start of Outbreak]        Yes   No  
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 Symptom – Asthma 
75) Has any doctor told you that you have asthma? Yes   No  
 
76) In the last 12 months has your chest ever felt tight or your breathing 
become difficult?    Yes  No  
        If “No” Go To Question 87 
77) When did you first develop this?     Year   Month    
78) On how many days do you had this       (Tick one only) 
Never     
Less than monthly     
At Least monthly      
At least once a week    
At  least once a day      
More frequently      
 
79) Do you have this on waking?    Yes   No  
80) Do you have this during the day?   Yes   No  
81) Are you woken from sleep by this?   Yes   No  
 
Is this worse ; 
 82) At the beginning of the working week?  Yes   No  
 83) At the end of the working week?    Yes   No  
 84) No difference?     Yes   No  
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85) On days away from work is this (Tick one only) 
Better      
  The same      than days at 
work  
Worse    
 
86) On holidays is your this    ( Tick one only) 
Better      
 The same      than days at work  
Worse    
 
 
87) In the past 12 months have you had wheezing or whistling in your chest? 
        Yes  No  
        If “No” Go To Question 98 
 
88) When did you first develop this?     Year ..Month    
89) On how many days do you have this?      (Tick one only) 
Never     
Less than monthly     
At Least monthly      
At least once a week    
At  least once a day      
More frequently     
 
90) Do you have this on waking?    Yes   No  
91) Do you have this during the day?   Yes   No  
92) Are you woken from sleep by this?   Yes   No  
 
Is this worse ; 
 93)At the beginning of the working week?  Yes   No  
 94) At the end of the working week?    Yes   No  
 95) No difference?     Yes   No  
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96) On days away from work is this   (Tick one only) 
Better      
 The same      than days at work  
Worse    
 
97) On holidays is this    ( Tick one only) 
Better      
 The same      than days at work  
Worse    
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Symptom –‘Flu 
98) In the past twelve months have you suffered recurrent flu like symptoms? 
        Yes  No  
    If “No” you have now completed the questionnaire.      
 
If yes please specify the symptoms below; 
 
99) Fever     Yes  No  
100) Shivering    Yes  No  
101) Tiredness    Yes  No  
102) Weakness    Yes  No  
103) Joint/ muscle pains   Yes  No  
 
104) How many episodes have you 
 experienced in the last year?  Number 
 
105) How long did these symptoms last  
   Less than 72 hours Yes  No  
   More than 72 hours Yes  No  
 
106) Do these symptoms occur more frequently after doing a particular job?  
      Yes  No  
If Yes specify……………………………………………………………………………………. 
 
107) Do these symptoms occur; 
 At the beginning of the working week? Yes   No  
 At the end of the working week?   Yes   No  
 No difference?     Yes   No  
 
108) Do these symptoms occur more frequently or are more severe on returning 
to work after a; 
   Weekend break from work  Yes   No  
   Holiday break from work   Yes   No  
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Doctor Diagnosis 
200) Exposure category 
High (Working with suds oil)   Low ( Visits area only)  
High (cleaning)     None ( Never in production area)  
Medium ( In suds area – not directly working)  
 
201) Asthma  No /Possible/ Probable/ Definite 
 
202) Occupational Asthma   No /Possible/ Probable/ Definite 
 
203) Rhinitis   No /Possible/ Probable/ Definite  
 
204) Alveolitis  No /Possible/ Probable/ Definite 
 
205) Humidifier Fever  No /Possible/ Probable/ Definite  
 
206) Chronic Bronchitis No /Possible/ Probable/ Definite  
 
Needs peak flows  Yes   No  
 
Would you like us to send your results to your General Practitioner   
         Yes   No  
Would you like us to send your results to the Occupational Health Dept? 
Yes   No  
 
Signed………………………………………………………… 
Advised needs appointment at Chest Clinic?   Yes   No  
Known case  Y?N 
 
Currently being seen Yes   No  
where?.........................................................................................................................................
............................................................................................................................ 
Permission to write? Yes   No Signed…………………………………………………… 
Physician …………………………………………………………………………………………………………………… 
 246 
Spirometry 
 
First Names…………………………Last Name…………………………………….. 
Date of Birth………………………   Payroll Number……………………………… 
 
Height………………cms  Sex( Please circle)   Male  /  Female   
 
Spiro Completed   Yes   No  
Quality check…….. Yes   No  
 
Ethnic Race ( Please tick box) 
White   Afro-caribbean    Oriental.    Asian   
Other ……………………….  
 
Blood taken………… Yes   declined  too difficult  
 
Already done adequate peak flows   Yes   No  
Given peak flow cards     Yes   No  
 
Given peak flow meter    Yes   No  
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Information Sheet 
 
As you may know there have been several workers at [Company Name] who have 
a chest problem that may be caused by their work. We are trying to find out 
how common this is and what the cause is. We would like your help. 
Many workers are exposed to coolant oils without problems. There have, 
however, been outbreaks of lung inflammation (alveolitis) in factories similar to 
[Company Name] in the USA, which have been caused by impurities in the used 
cooling oil. We are trying to find out if this is the cause at [Company Name]. The 
best method is to see if you are allergic to the oil from blood tests. Please 
would you complete the questionnaire and then have breathing and blood tests. 
Then you will be seen by a specialist who will tell you what we have found.  
This is a confidential study, your personal results will not be shown to anybody 
without your permission. We will send the results to you personally. If you want 
your results sent to your GP and/ or Occupational Health we will do so. This is 
often the best way forward if you are ill. 
 
Many thanks. 
 
Prof Sherwood Burge 
Dr Alastair Robertson 
Birmingham Chest Clinic, Solihull and Birmingham Heartlands NHS Trust 
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Appendix 3 
Phase 1 questionnaire calculations 
 
Qu 1: In the past 18 months, have 
you had any episodes of wheeze 
or chest tightness? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 13 323 336 
No 1 466 467 
Total 14 789 803 
 
Sensitivity = 13/14 x 100  
Sensitivity = 93% 
 
Specificity = 466/789 x 100 
Specificity = 59% 
 
Positive predictive value = 13/336 x100 
Positive predictive value = 4% 
 
Negative predictive value = 466/467 x 100 
Negative predictive value = 100% 
 
 
Qu 2: In the past 18 months, have 
you taken any treatment for your 
chest? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 14 151 165 
No 0 639 639 
Total 14 790 804 
 
Sensitivity = 14/14 x 100  
Sensitivity = 100% 
 
Specificity = 639/790 x 100 
Specificity = 81% 
 
Positive predictive value = 14/165 x100 
Positive predictive value = 8% 
 
Negative predictive value = 639/639 x 100 
Negative predictive value = 100% 
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Qu 3: In the past 18 months, have 
you woken at night with a cough or 
chest tightness? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 14 251 265 
No 0 538 538 
Total 14 789 803 
 
Sensitivity = 14/14 x 100  
Sensitivity = 100% 
 
Specificity = 538/789 x 100 
Specificity = 68% 
 
Positive predictive value = 14/265 x 100 
Positive predictive value = 5% 
 
Negative predictive value = 538/538 x 100 
Negative predictive value = 100% 
 
 
Qu 4: In the past 18 months, have 
you had any episodes of 
breathlessness? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 13 235 248 
No 1 552 553 
Total 14 787 801 
 
Sensitivity = 13/14 x 100  
Sensitivity = 93% 
 
Specificity = 235/787 x 100 
Specificity = 30% 
 
Positive predictive value = 13/248 x100 
Positive predictive value = 5% 
 
Negative predictive value = 552/553 x 100 
Negative predictive value = 100% 
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Qu 5: In the past 18 months, have 
you had any time off with a chest 
illness? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 14 92 106 
No 0 698 698 
Total 14 790 804 
 
Sensitivity = 14/14 x 100  
Sensitivity = 100% 
 
Specificity = 698/790 x 100 
Specificity = 88% 
 
Positive predictive value = 14/106 x100 
Positive predictive value = 13% 
 
Negative predictive value = 698/698 x 100 
Negative predictive value = 100% 
 
 
Qu 6: In the past 18 months, have 
you developed chest tightness or 
breathlessness after exercise? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 13 293 306 
No 1 493 494 
Total 14 786 800 
 
Sensitivity = 13/14 x 100  
Sensitivity = 93% 
 
Specificity = 493/786 x 100 
Specificity = 63% 
 
Positive predictive value = 13/306 x100 
Positive predictive value = 4% 
 
Negative predictive value = 493/494 x 100 
Negative predictive value = 100% 
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Qu 7: In the past 18 months, have 
you developed difficulty with 
breathing? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 13 162 175 
No 1 620 621 
Total 14 782 796 
 
Sensitivity = 13/14 x 100  
Sensitivity = 93% 
 
Specificity = 620/782 x 100 
Specificity = 79% 
 
Positive predictive value = 13/175 x100 
Positive predictive value = 7% 
 
Negative predictive value = 620/621 x 100 
Negative predictive value = 100% 
 
 
Qu 8: In the past 18 months, have 
you had irritation or watering of the 
eyes? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 9 317 326 
No 5 469 474 
Total 14 786 800 
 
Sensitivity = 9/14 x 100  
Sensitivity = 64% 
 
Specificity = 469/786 x 100 
Specificity = 60% 
 
Positive predictive value = 9/326 x100 
Positive predictive value = 3% 
 
Negative predictive value = 469/474 x 100 
Negative predictive value = 99% 
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Qu 9: In the past 18 months, have 
you had a stuffy nose? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 9 480 489 
No 5 303 308 
Total 14 783 797 
 
 
Sensitivity = 9/14 x 100  
Sensitivity = 64% 
 
Specificity = 303/783 x 100 
Specificity = 39% 
 
Positive predictive value = 9/489 x100 
Positive predictive value = 2% 
 
Negative predictive value = 303/308 x 100 
Negative predictive value = 98% 
 
Qu 10: In the past 18 months, 
have you had any soreness of the 
nose lips or mouth? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 223 229 
No 8 561 569 
Total 14 784 798 
 
Sensitivity = 6/14 x 100  
Sensitivity = 43% 
 
Specificity = 561/784 x 100 
Specificity = 72% 
 
Positive predictive value = 6/229 x100 
Positive predictive value = 3% 
 
Negative predictive value = 561/569 x 100 
Negative predictive value = 99% 
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Qu 11: In the past 18 months, 
have you had any unexplained 
weight loss? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 11 33 44 
No 3 753 756 
Total 14 786 800 
 
Sensitivity = 11/14 x 100  
Sensitivity = 79% 
 
Specificity = 753/786 x 100 
Specificity = 96% 
 
Positive predictive value = 11/44 x100 
Positive predictive value = 25% 
 
Negative predictive value = 753/756 x 100 
Negative predictive value = 100% 
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Phase 2 questionnaire calculations 
 
 
Shortness of breath 
 
Questions 24 and 33 are not included as the responses are in the style of  
continuous data and therefore the sensitivity, specificity, positive predictive  
value and negative predictive value cannot be calculated. 
 
Qu 20: On your worst day in the 
last 12 months, were you troubled 
by shortness of breath when 
hurrying on level ground or walking 
up a slight hill? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 14 212 226 
No 0 275 275 
Total 14 487 501 
 
Sensitivity =14/14 x 100  
Sensitivity = 100% 
 
Specificity = 275/487 x 100 
Specificity = 56% 
 
Positive predictive value = 14/226 x100 
Positive predictive value = 6% 
 
Negative predictive value = 275/275 x 100 
Negative predictive value = 100% 
 
 
Qu 21: On your worst day in the 
last 12 months, did you get short 
of breath walking with other people 
of your own age and sex on level 
ground? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 14 117 131 
No 0 366 366 
Total 14 483 497 
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It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity =14/14 x 100  
Sensitivity = 100% 
 
Specificity = 366/483 x 100 
Specificity = 76% 
 
Positive predictive value = 14/131x100 
Positive predictive value = 11% 
 
Negative predictive value = 366/366 x 100 
Negative predictive value = 100% 
 
 
Qu 22: On your worst day in the 
last 12 months, did you have to 
stop for breath walking at your own 
pace on level ground? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 13 45 58 
No 1 440 441 
Total 14 485 499 
 
It is presumed that the 366 workers who answered no to either the previous question, 
‘On your worst day in the last 12 months, were you troubled by shortness of breath 
when hurrying on level ground or walking up a slight hill?’ or On your worst day in the 
last 12 months, did you get short of breath walking with other people of your own age 
and sex on level ground? would answer no to this question. In reality they did not 
answer this question as they were requested to bypass to a different question. 
 
Sensitivity =13/14 x 100  
Sensitivity = 93% 
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Specificity = 440/485 x 100 
Specificity = 91% 
 
Positive predictive value = 13/58 x100 
Positive predictive value = 22% 
 
Negative predictive value = 440/441 x 100 
Negative predictive value = 100% 
 
 
Qu 23: On your worst day in the 
last 12 months, were you short of 
breath washing or dressing? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 9 14 23 
No 5 474 478 
Total 14 488 501 
 
It is presumed that the 440 who had not been diagnosed with EAA the expert panel, 
and the 1 worker who had has been diagnosed with EAA, who answered no to either 
the previous question, ‘On your worst day in the last 12 months, were you troubled by 
shortness of breath when hurrying on level ground or walking up a slight hill?’ or On 
your worst day in the last 12 months, did you get short of breath walking with other 
people of your own age and sex on level ground?’ or On your worst day in the last 12 
months, did you have to stop for breath walking at your own pace on level ground? 
would answer no to this question. In reality they did not answer this question as they 
were requested to bypass to a different question. 
 
Sensitivity = 9/14 x 100  
Sensitivity = 64% 
 
Specificity = 474/488 x 100 
Specificity = 97% 
 
Positive predictive value = 9/23 x100 
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Positive predictive value = 39% 
 
Negative predictive value = 474/478 x 100 
Negative predictive value = 99% 
 
 
Qu 25: Are you breathless on 
waking? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 7 46 53 
No 7 433 440 
Total 14 479 493 
 
It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 7/14x 100  
Sensitivity = 50% 
 
Specificity = 433/479 x 100 
Specificity = 90% 
 
Positive predictive value = 7/53 x100 
Positive predictive value = 13% 
 
Negative predictive value = 433/440 x 100 
Negative predictive value = 98% 
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Qu 26: Are you breathless during 
the day? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 14 118 132 
No 0 364 364 
Total 14 482 496 
 
It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 14/14 x 100  
Sensitivity = 100% 
 
Specificity = 364/482 x 100 
Specificity = 76% 
 
Positive predictive value = 14/132 x100 
Positive predictive value = 11% 
 
Negative predictive value = 364/364 x 100 
Negative predictive value = 100% 
 
 
Qu 27: Are you woken from sleep 
by your breathlessness? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 10 45 55 
No 4 437 441 
Total 14 482 496 
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It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 10/14 x 100  
Sensitivity = 71% 
 
Specificity = 437/482 x 100 
Specificity = 91% 
 
Positive predictive value = 10/55 x100 
Positive predictive value = 18% 
 
Negative predictive value = 437/441 x 100 
Negative predictive value = 99% 
 
 
Qu 28: Is your breathlessness 
worse at the beginning of the 
week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 1 14 15 
No 12 452 464 
Total 13 466 479 
 
It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 1/13 x 100  
Sensitivity = 8% 
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Specificity = 452/466 x 100 
Specificity = 97% 
 
Positive predictive value = 1/15 x100 
Positive predictive value = 7% 
 
Negative predictive value = 452/464 x 100 
Negative predictive value = 97% 
 
 
Qu 29: Is your breathlessness 
worse at the end of the working 
week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 11 56 67 
No 3 409 412 
Total 14 465 479 
 
It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 11/14 x 100  
Sensitivity = 79% 
 
Specificity = 409/465 x 100 
Specificity = 88% 
 
Positive predictive value = 11/67 x100 
Positive predictive value = 16% 
 
Negative predictive value = 409/412 x 100 
Negative predictive value = 99%
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Qu 30: Is your breathlessness no 
different at the beginning or end of 
the week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 125 128 
No 9 352 361 
Total 12 477 489 
 
It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 3/12 x 100  
Sensitivity = 25% 
 
Specificity = 352/477 x 100 
Specificity = 74% 
 
Positive predictive value = 3/128 x100 
Positive predictive value = 2% 
 
Negative predictive value = 352/361 x 100 
Negative predictive value = 98% 
 
 
Qu 31a: On days away from work 
is your breathlessness better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 11 108 119 
No 2 377 379 
Total 13 485 498 
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It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 11/13 x 100  
Sensitivity = 85% 
 
Specificity = 377/485 x 100 
Specificity = 78% 
 
Positive predictive value = 11/119 x100 
Positive predictive value = 9% 
 
Negative predictive value = 377/379 x 100 
Negative predictive value = 99% 
 
 
Qu 31b: On days away from work 
is your breathlessness the same 
than days at work? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 2 101 103 
No 11 384 395 
Total 13 485 498 
 
It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 2/13x 100  
Sensitivity = 15% 
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Specificity = 384/485 x 100 
Specificity = 79% 
 
Positive predictive value = 2/103 x100 
Positive predictive value = 2% 
 
Negative predictive value = 384/395 x 100 
Negative predictive value = 97% 
 
 
Qu 31c: On days away from work 
is your breathlessness worse than 
days at work? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 1 1 
No 13 484 497 
Total 13 485 498 
 
It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 0/13 x 100  
Sensitivity = 0% 
 
Specificity = 484/485 x 100 
Specificity = 100% 
 
Positive predictive value = 0/1 x100 
Positive predictive value = 0% 
 
Negative predictive value = 484/497 x 100 
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Negative predictive value = 97% 
 
 
Qu 32a: On holiday is your 
breathlessness better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 11 137 148 
No 2 348 350 
Total 13 485 498 
 
It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 11/13 x 100  
Sensitivity = 85% 
 
Specificity = 348/485 x 100 
Specificity = 72% 
 
Positive predictive value = 11/148 x100 
Positive predictive value = 7% 
 
Negative predictive value = 348/350 x 100 
Negative predictive value = 99% 
 
Qu 32b: On holiday is your 
breathlessness the same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 2 72 74 
No 11 413 424 
Total 13 485 498 
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It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 2/13 x 100  
Sensitivity = 15% 
 
Specificity = 413/485 x 100 
Specificity = 85% 
 
Positive predictive value = 2/74 x100 
Positive predictive value = 3% 
 
Negative predictive value = 413/424 x 100 
Negative predictive value = 97% 
 
 
Qu 32c: On holiday is your 
breathlessness worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 1 1 
No 13 484 497 
Total 13 485 498 
 
It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 0/13 x 100  
Sensitivity = 0% 
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Specificity = 484/485 x 100 
Specificity = 100% 
 
Positive predictive value =0/1 x100 
Positive predictive value = 0% 
 
Negative predictive value = 484/497 x 100 
Negative predictive value = 97% 
 
 
Qu 34: Do you suffer from 
breathlessness at present? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 12 132 144 
No 2 352 354 
Total 14 484 498 
 
It is presumed that the 275 workers who answered no to the previous question, ‘On 
your worst day in the last 12 months, were you troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill?’ would answer no to this question. 
In reality they did not answer this question as they were requested to miss this 
question. 
 
Sensitivity = 12/14 x 100  
Sensitivity = 86% 
 
Specificity = 352/484 x 100 
Specificity = 73% 
 
Positive predictive value = 12/144 x100 
Positive predictive value = 8% 
 
Negative predictive value = 352/354 x 100 
Negative predictive value = 99% 
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Cough 
 
Questions 36, 37 and 49 are not included as the responses as the answers 
are not in an appropriate style, for example continuous data, therefore the sensitivity 
and positive predictive value cannot be calculated. 
 
Qu 35: Do you cough? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 13 280 293 
No 1 216 217 
Total 14 496 510 
 
Sensitivity = 13/14 x 100  
Sensitivity = 93% 
 
Specificity = 216/496 x 100 
Specificity = 44% 
 
Positive predictive value = 13/293 x100 
Positive predictive value = 4% 
 
Negative predictive value = 216/217 x 100 
Negative predictive value = 100% 
 
 
Qu 38: Do you cough on waking? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 8 111 119 
No 5 367 372 
Total 13 478 491 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
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would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 8/13 x 100  
Sensitivity = 62% 
 
Specificity = 367/478 x 100 
Specificity = 77% 
 
Positive predictive value = 8/119 x100 
Positive predictive value = 7% 
 
Negative predictive value = 367/372 x 100 
Negative predictive value = 99% 
 
 
Qu 39: Do you cough during the 
day? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 12 250 262 
No 1 239 240 
Total 13 489 502 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 12/13 x 100  
Sensitivity = 92% 
 
Specificity = 239/489 x 100 
Specificity = 49% 
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Positive predictive value = 12/262 x100 
Positive predictive value = 5% 
 
Negative predictive value = 239/240 x 100 
Negative predictive value = 100% 
 
 
Qu 40: Are you woken from sleep 
by your cough? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 74 80 
No 8 412 420 
Total 14 486 500 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 6/14 x 100  
Sensitivity = 43% 
 
Specificity = 412/486 x 100 
Specificity = 85% 
 
Positive predictive value = 6/80 x100 
Positive predictive value = 8% 
 
Negative predictive value = 412/420 x 100 
Negative predictive value = 98% 
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Qu 41: Is your cough worse at the 
beginning of the working week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 1 15 16 
No 13 464 477 
Total 14 479 493 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 1/14 x 100  
Sensitivity = 7% 
 
Specificity = 464/479 x 100 
Specificity = 97% 
 
Positive predictive value = 1/16 x100 
Positive predictive value = 6% 
 
Negative predictive value = 464/477 x 100 
Negative predictive value = 97% 
 
 
Qu 42: Is your cough worse at the 
end of a working week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 7 71 78 
No 7 407 413 
Total 14 478 491 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
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would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 7/14 x 100  
Sensitivity = 50% 
 
Specificity = 407/478 x 100 
Specificity = 85% 
 
Positive predictive value = 7/78 x100 
Positive predictive value = 9% 
 
Negative predictive value = 407/413 x 100 
Negative predictive value = 99% 
 
 
Qu 43: Is your cough no different 
at the beginning and end of the 
week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 186 192 
No 8 304 312 
Total 14 490 504 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 6/14 x 100  
Sensitivity = 43% 
 
Specificity = 304/490 x 100 
Specificity = 62% 
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Positive predictive value = 6/192 x100 
Positive predictive value = 3% 
 
Negative predictive value = 304/312 x 100 
Negative predictive value = 97% 
 
Qu 44a: On days away from work, 
is your cough better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 9 127 136 
No 4 368 372 
Total 13 495 508 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity =  9/13 x 100  
Sensitivity = 69% 
 
Specificity = 368/495 x 100 
Specificity = 74% 
 
Positive predictive value = 9/136 x100 
Positive predictive value = 7% 
 
Negative predictive value = 368/372 x 100 
Negative predictive value = 99% 
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Qu 44b: On days away from work, 
is your cough the same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 152 155 
No 10 343 353 
Total 13 495 508 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 3/13 x 100  
Sensitivity = 23% 
 
Specificity = 343/495 x 100 
Specificity = 69% 
 
Positive predictive value = 3/155 x100 
Positive predictive value = 2% 
 
Negative predictive value = 342/353 x 100 
Negative predictive value = 97% 
 
 
Qu 45: On holiday is your cough 
better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 9 163 172 
No 4 332 336 
Total 13 495 508 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
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would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity =  9/13 x 100  
Sensitivity = 69% 
 
Specificity = 332/495 x 100 
Specificity = 67% 
 
Positive predictive value = 9/172 x100 
Positive predictive value = 5% 
 
Negative predictive value = 332/336 x 100 
Negative predictive value = 99% 
 
 
Qu 45b: On holidays is your cough 
the same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 115 118 
No 10 380 390 
Total 13 495 508 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 3/13 x 100  
Sensitivity = 23% 
 
Specificity = 380/495 x 100 
Specificity = 77% 
 
Positive predictive value = 3/118 x100 
 275 
Positive predictive value = 3% 
 
Negative predictive value = 380/390 x 100 
Negative predictive value = 97% 
 
 
Qu 45c: On holidays is your cough 
worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 1 1 
No 12 494 507 
Total 13 495 508 
 
It is presumed that the 1 expert panel definite EAA case and the 216 workers not 
diagnosed with definite EAA, who answered no to question 35, ‘Do you cough?’ 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity =  0/13 x 100  
Sensitivity = 0% 
 
Specificity = 494/495 x 100 
Specificity = 100% 
 
Positive predictive value = 0/1 x100 
Positive predictive value = 0% 
 
Negative predictive value = 494/508 x 100 
Negative predictive value = 97% 
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Qu 46: Do you cough up phlegm 
(sputum) from your chest? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 12 231 243 
No 2 265 267 
Total 14 496 510 
 
Sensitivity = 12/14 x 100 
Sensitivity = 86% 
 
Specificity = 265/496 x 100 
Specificity = 10% 
 
Positive predictive value = 12/243 x100 
Positive predictive value = 5% 
 
Negative predictive value = 265/267 x 100 
Negative predictive value = 99% 
 
 
Qu 47: On holidays is your cough 
worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 10 156 166 
No 3 340 343 
Total 13 496 509 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 10/13 x 100  
Sensitivity =77% 
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Specificity = 340/496 x 100 
Specificity = 69% 
 
Positive predictive value = 10/166 x100 
Positive predictive value = 6% 
 
Negative predictive value = 340/343 x 100 
Negative predictive value = 99% 
 
 
Qu 48: Have you been doing this 
for the last 2 years? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 5 167 172 
No 8 330 338 
Total 13 497 510 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 5/13 x 100  
Sensitivity = 34% 
 
Specificity = 330/497 x 100 
Specificity = 66% 
 
Positive predictive value = 5/172 x100 
Positive predictive value = 3% 
 
Negative predictive value = 330/338 x 100 
Negative predictive value = 98% 
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Qu 50: Do you cough up phlegm 
on waking? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 8 115 123 
No 5 375 380 
Total 13 490 503 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 8/13 x 100  
Sensitivity = 62% 
 
Specificity = 375/490 x 100 
Specificity = 77% 
 
Positive predictive value = 8/123 x100 
Positive predictive value = 7% 
 
Negative predictive value = 375/380 x 100 
Negative predictive value = 99% 
 
 
Qu 51: Do you cough up phlegm 
during the day? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 10 168 178 
No 4 322 326 
Total 14 490 504 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
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phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 10/14 x 100  
Sensitivity =71% 
 
Specificity = 322/490 x 100 
Specificity = 66% 
 
Positive predictive value = 10/178 x100 
Positive predictive value = 6% 
 
Negative predictive value = 322/326 x 100 
Negative predictive value = 99% 
 
 
Qu 52: Is your phlegm production 
worse at the beginning of the 
working week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 12 12 
No 14 469 483 
Total 14 481 495 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 0/14 x 100  
Sensitivity = 0% 
 
Specificity = 469/481 x 100 
Specificity = 98% 
 
Positive predictive value = 0/12 x100 
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Positive predictive value = 0% 
 
Negative predictive value = 469/483 x 100 
Negative predictive value = 97% 
 
 
Qu 53: Is your phlegm production 
worse at the end of the working 
week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 65 71 
No 8 416 424 
Total 14 481 495 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 6/14x 100  
Sensitivity =43% 
 
Specificity = 416/481 x 100 
Specificity = 86% 
 
Positive predictive value = 6/71 x100 
Positive predictive value = 8% 
 
Negative predictive value = 416/424 x 100 
Negative predictive value = 98% 
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Qu 54: Is your phlegm production 
the same at the beginning and end 
of the working week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 142 148 
No 8 352 360 
Total 14 494 508 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 6/14 x 100  
Sensitivity =43% 
 
Specificity = 352/494 x 100 
Specificity = 71% 
 
Positive predictive value = 6/148 x100 
Positive predictive value = 4% 
 
Negative predictive value = 352/360 x 100 
Negative predictive value = 98% 
 
 
Qu 55a: On days away from work 
is your phlegm better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 108 114 
No 7 388 395 
Total 13 496 509 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
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phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 6/13 x 100  
Sensitivity =46% 
 
Specificity = 388/496 x 100 
Specificity = 78% 
 
Positive predictive value = 6/114 x100 
Positive predictive value = 5% 
 
Negative predictive value = 388/395 x 100 
Negative predictive value = 98% 
 
 
Qu 55b: On days away from work 
is your phlegm the same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 5 123 128 
No 8 373 381 
Total 13 496 509 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 5/13 x 100  
Sensitivity = 38% 
 
Specificity = 373/496 x 100 
Specificity = 75% 
 
Positive predictive value = 5/128 x100 
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Positive predictive value = 4% 
 
Negative predictive value = 373/381 x 100 
Negative predictive value = 98% 
 
 
Qu 56: On holidays is your phlegm 
better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 8 131 139 
No 5 365 370 
Total 13 496 509 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 8/13 x 100  
Sensitivity = 62% 
 
Specificity = 365/370 x 100 
Specificity = 99% 
 
Positive predictive value = 8/139 x100 
Positive predictive value = 6% 
 
Negative predictive value = 365/370 x 100 
Negative predictive value = 99% 
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Qu 56: On holidays is your phlegm 
the same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 100 103 
No 10 396 406 
Total 13 496 509 
 
It is presumed that the 2 expert panel definite EAA case and the 265 workers not 
diagnosed with definite EAA, who answered no to question 46, Do you cough up 
phlegm (sputum) from your chest? would answer no to this question. In reality they 
did not answer this question as they were requested to miss this question. 
 
Sensitivity = 3/13 x 100  
Sensitivity = 23% 
 
Specificity = 396/496 x 100 
Specificity = 80% 
 
Positive predictive value = 3/103 x100 
Positive predictive value = 3% 
 
Negative predictive value = 396/406 x 100 
Negative predictive value = 98% 
 
 
Eyes 
 
Question 59 is not included as the answers are not in an appropriate style. 
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Qu 58: In the past twelve months 
have you had more than two 
episodes of irritation or watering of 
the eyes? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 9 247 256 
No 5 249 254 
Total 14 496 510 
 
Sensitivity = 9/14 x 100  
Sensitivity = 64% 
 
Specificity = 249/496 x 100 
Specificity = 50% 
 
Positive predictive value = 9/256 x100 
Positive predictive value = 4% 
 
Negative predictive value = 249/254 x 100 
Negative predictive value = 98% 
 
 
Qu 60a: On days away from work 
is this better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 5 142 147 
No 9 353 362 
Total 14 495 509 
 
It is presumed that the 5 expert panel definite EAA case and the 249 workers not 
diagnosed with definite EAA, who answered no to question 58, In the past twelve 
months have you had more than two episodes of irritation or watering of the eyes? 
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would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 5/14 x 100  
Sensitivity = 36% 
 
Specificity = 353/495 x 100 
Specificity = 71% 
 
Positive predictive value = 5/147 x100 
Positive predictive value = 3% 
 
Negative predictive value = 353/362 x 100 
Negative predictive value = 98% 
 
 
Qu 60b: On days away from work 
is this the same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 4 98 102 
No 10 397 407 
Total 14 495 509 
 
It is presumed that the 5 expert panel definite EAA case and the 249 workers not 
diagnosed with definite EAA, who answered no to question 58, In the past twelve 
months have you had more than two episodes of irritation or watering of the eyes? 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 4/14 x 100  
Sensitivity = 29% 
 
Specificity = 397/495 x 100 
Specificity = 80% 
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Positive predictive value = 4/102 x100 
Positive predictive value = 4% 
 
Negative predictive value = 397/407 x 100 
Negative predictive value = 98% 
 
 
Qu 60c: On days away from work 
is this worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 6 6 
No 14 489 503 
Total 14 495 509 
 
It is presumed that the 5 expert panel definite EAA case and the 249 workers not 
diagnosed with definite EAA, who answered no to question 58, In the past twelve 
months have you had more than two episodes of irritation or watering of the eyes? 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 0/14 x 100  
Sensitivity = 0% 
 
Specificity = 489/495 x 100 
Specificity = 99% 
 
Positive predictive value = 0/6 x100 
Positive predictive value = 0% 
 
Negative predictive value = 489/503 x 100 
Negative predictive value = 97% 
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Qu 61a: On holidays is this better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 157 163 
No 8 337 345 
Total 14 494 508 
 
It is presumed that the 5 expert panel definite EAA case and the 249 workers not 
diagnosed with definite EAA, who answered no to question 58, In the past twelve 
months have you had more than two episodes of irritation or watering of the eyes? 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 6/14 x 100  
Sensitivity = 43% 
 
Specificity = 337/494 x 100 
Specificity = 68% 
 
Positive predictive value = 6/163 x100 
Positive predictive value = 4% 
 
Negative predictive value = 337/345 x 100 
Negative predictive value = 98% 
 
 
Qu 61b: On holidays is this the 
same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 85 88 
No 11 409 420 
Total 14 494 508 
 
It is presumed that the 5 expert panel definite EAA case and the 249 workers not 
diagnosed with definite EAA, who answered no to question 58, In the past twelve 
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months have you had more than two episodes of irritation or watering of the eyes? 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 3/14 x 100  
Sensitivity = 21% 
 
Specificity = 409/494 x 100 
Specificity = 83% 
 
Positive predictive value = 3/88 x100 
Positive predictive value = 3% 
 
Negative predictive value = 409/508 x 100 
Negative predictive value = 81% 
 
 
Qu 61c: On holidays is this worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 3 3 
No 14 491 505 
Total 14 494 508 
 
It is presumed that the 5 expert panel definite EAA case and the 249 workers not 
diagnosed with definite EAA, who answered no to question 58, In the past twelve 
months have you had more than two episodes of irritation or watering of the eyes? 
would answer no to this question. In reality they did not answer this question as they 
were requested to miss this question. 
 
Sensitivity = 0/14 x 100  
Sensitivity = 0% 
 
Specificity = 491/494 x 100 
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Specificity = 99% 
 
Positive predictive value = 0/3 x100 
Positive predictive value = 0% 
 
Negative predictive value = 491/505 x 100 
Negative predictive value = 97% 
 
 
Nasal 
Question 63 is not included as the answers are not in an appropriate style. 
 
Qu 62: In the past twelve months 
have you had more than two 
episodes of blocked or stuffy 
nose? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 11 341 352 
No 3 154 157 
Total 14 495 509 
 
Sensitivity = 11/14 x 100  
Sensitivity = 79% 
 
Specificity = 154/495 x 100 
Specificity = 31% 
 
Positive predictive value = 11/352 x100 
Positive predictive value = 3% 
 
Negative predictive value = 154/157 x 100 
Negative predictive value = 98% 
 
 
 291 
Qu 64a: On days away from work 
is this better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 5 159 164 
No 9 335 344 
Total 14 494 508 
 
It is presumed that the 3 expert panel definite EAA cases and the 154 workers not 
diagnosed with definite EAA, who answered no to question 62, In the past twelve 
months have you had more than two episodes of blocked or stuffy nose? would 
answer no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 5/14 x 100  
Sensitivity = 36% 
 
Specificity = 335/494 x 100 
Specificity = 68% 
 
Positive predictive value = 5/164 x100 
Positive predictive value = 3% 
 
Negative predictive value = 335/344 x 100 
Negative predictive value = 97% 
 
 
Qu 64b: On days away from work 
is this the same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 180 186 
No 8 314 322 
Total 14 494 508 
 
It is presumed that the 3 expert panel definite EAA cases and the 154 workers not 
diagnosed with definite EAA, who answered no to question 62, In the past twelve 
 292 
months have you had more than two episodes of blocked or stuffy nose? would 
answer no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 6/14 x 100  
Sensitivity = 43% 
 
Specificity = 314/494 x 100 
Specificity = 64% 
 
Positive predictive value = 6/186 x100 
Positive predictive value = 3% 
 
Negative predictive value = 314/322 x 100 
Negative predictive value = 98% 
 
 
Qu 64c: On days away from work 
is this worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 1 1 
No 14 493 507 
Total 14 494 508 
 
It is presumed that the 3 expert panel definite EAA cases and the 154 workers not 
diagnosed with definite EAA, who answered no to question 62, In the past twelve 
months have you had more than two episodes of blocked or stuffy nose? would 
answer no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 0/14 x 100  
Sensitivity = 0% 
 
Specificity = 493/494 x 100 
Specificity = 100% 
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Positive predictive value = 0/1 x100 
Positive predictive value = 3% 
 
Negative predictive value = 493/507 x 100 
Negative predictive value = 97% 
 
 
Qu 65a: On holidays is this better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 9 192 201 
No 5 301 306 
Total 14 493 507 
 
It is presumed that the 3 expert panel definite EAA cases and the 154 workers not 
diagnosed with definite EAA, who answered no to question 62, In the past twelve 
months have you had more than two episodes of blocked or stuffy nose? would 
answer no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 9/14 x 100  
Sensitivity = 64% 
 
Specificity = 301/493 x 100 
Specificity = 61% 
 
Positive predictive value = 9/201 x100 
Positive predictive value = 5% 
 
Negative predictive value = 301/306 x 100 
Negative predictive value = 98% 
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Qu 65b: On holidays is this the 
same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 2 101 103 
No 12 392 404 
Total 14 493 507 
 
It is presumed that the 3 expert panel definite EAA cases and the 154 workers not 
diagnosed with definite EAA, who answered no to question 62, In the past twelve 
months have you had more than two episodes of blocked or stuffy nose? would 
answer no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 2/14 x 100  
Sensitivity = 14% 
 
Specificity = 392/493 x 100 
Specificity = 80% 
 
Positive predictive value = 2/103 x100 
Positive predictive value = 2% 
 
Negative predictive value = 392/404 x 100 
Negative predictive value = 97% 
 
 
Qu 65c: On holidays is this worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 1 1 
No 14 492 506 
Total 14 493 507 
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It is presumed that the 3 expert panel definite EAA cases and the 154 workers not 
diagnosed with definite EAA, who answered no to question 62, In the past twelve 
months have you had more than two episodes of blocked or stuffy nose? would 
answer no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 0/14 x 100  
Sensitivity = 0% 
 
Specificity = 492/493 x 100 
Specificity = 100% 
 
Positive predictive value = 0/1 x100 
Positive predictive value = 0% 
 
Negative predictive value = 492/506 x 100 
Negative predictive value = 97% 
 
 
Throat 
Question 67 is not included as the answers are not in an appropriate style 
 
Qu 66: In the past twelve months 
have you had more than two 
episodes of a dry or sore throat? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 10 305 315 
No 4 191 195 
Total 14 496 510 
 
Sensitivity = 10/14 x 100  
Sensitivity = 71% 
 
Specificity = 191/496 x 100 
Specificity = 39% 
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Positive predictive value = 10/315 x100 
Positive predictive value = 3% 
 
Negative predictive value = 191/195 x 100 
Negative predictive value = 98% 
 
 
Qu 68a: On days away from work 
is this better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 7 183 190 
No 7 313 320 
Total 14 496 510 
 
It is presumed that the 4 expert panel definite EAA cases and the 191 workers not 
diagnosed with definite EAA, who answered no to question 66, In the past twelve 
months have you had more than two episodes of a dry or sore throat? would answer 
no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 7/14 x 100  
Sensitivity = 50% 
 
Specificity = 313/496 x 100 
Specificity = 63% 
 
Positive predictive value = 7/190 x100 
Positive predictive value = 4% 
 
Negative predictive value = 313/320 x 100 
Negative predictive value = 98% 
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Qu 68b: On days away from work 
is this the same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 121 124 
No 11 375 386 
Total 14 496 510 
 
It is presumed that the 4 expert panel definite EAA cases and the 191 workers not 
diagnosed with definite EAA, who answered no to question 66, In the past twelve 
months have you had more than two episodes of a dry or sore throat? would answer 
no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 3/14 x 100  
Sensitivity = 21% 
 
Specificity = 375/496 x 100 
Specificity = 76% 
 
Positive predictive value = 3/124 x100 
Positive predictive value = 2% 
 
Negative predictive value = 375/386 x 100 
Negative predictive value = 97% 
 
 
Qu 68c: On days away from work 
is this worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 1 1 
No 14 495 509 
Total 14 496 510 
 
It is presumed that the 4 expert panel definite EAA cases and the 191 workers not 
diagnosed with definite EAA, who answered no to question 66, In the past twelve 
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months have you had more than two episodes of a dry or sore throat? would answer 
no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 0/14 x 100  
Sensitivity = 0% 
 
Specificity = 495/496 x 100 
Specificity = 100% 
 
Positive predictive value = 0/1 x100 
Positive predictive value = 0% 
 
Negative predictive value = 495/509 x 100 
Negative predictive value = 97% 
 
 
Qu 69a: On holidays is this better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 8 203 211 
No 6 293 299 
Total 14 496 510 
 
It is presumed that the 4 expert panel definite EAA cases and the 191 workers not 
diagnosed with definite EAA, who answered no to question 66, In the past twelve 
months have you had more than two episodes of a dry or sore throat? would answer 
no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 8/14 x 100  
Sensitivity = 57% 
 
Specificity = 293/496 x 100 
Specificity = 59% 
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Positive predictive value = 8/211 x100 
Positive predictive value = 4% 
 
Negative predictive value = 293/299 x 100 
Negative predictive value = 98% 
 
 
Qu 69b: On holidays is this the 
same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 2 101 103 
No 12 395 407 
Total 14 496 510 
 
It is presumed that the 4 expert panel definite EAA cases and the 191 workers not 
diagnosed with definite EAA, who answered no to question 66, In the past twelve 
months have you had more than two episodes of a dry or sore throat? would answer 
no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 2/14 x 100  
Sensitivity = 14% 
 
Specificity = 395/496 x 100 
Specificity = 80% 
 
Positive predictive value = 2/103 x100 
Positive predictive value = 2% 
 
Negative predictive value = 395/407 x 100 
Negative predictive value = 97% 
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Qu 69c: On holidays is this worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 1 1 
No 14 495 509 
Total 14 496 510 
 
It is presumed that the 4 expert panel definite EAA cases and the 191 workers not 
diagnosed with definite EAA, who answered no to question 66, In the past twelve 
months have you had more than two episodes of a dry or sore throat? would answer 
no to this question. In reality they did not answer this question as they were 
requested to miss this question. 
 
Sensitivity = 0/14 x 100  
Sensitivity = 0% 
 
Specificity = 495/496 x 100 
Specificity = 100% 
 
Positive predictive value = 0/1 x100 
Positive predictive value = 0% 
 
Negative predictive value = 495/509 x 100 
Negative predictive value = 97% 
 
 
Past illnesses 
Qu 71: Have you ever had any 
chest illnesses? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 7 179 186 
No 7 316 323 
Total 14 495 509 
 
Sensitivity = 7/14 x 100  
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Sensitivity = 50% 
 
Specificity = 316/495 x 100 
Specificity = 64% 
 
Positive predictive value = 7/186 x100 
Positive predictive value = 4% 
 
Negative predictive value = 316/323 x 100 
Negative predictive value = 98% 
 
 
Qu 72: Are you taking any 
treatment for your chest? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 11 62 73 
No 3 432 435 
Total 14 494 508 
 
Sensitivity = 11/14 x 100  
 
Sensitivity = 79% 
 
Specificity = 432/494 x 100 
Specificity = 87% 
 
Positive predictive value = 11/73 x100 
Positive predictive value = 15% 
 
Negative predictive value = 432/435 x 100 
Negative predictive value = 99% 
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Qu 73: Have you had a 
lymphoma? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 2 2 
No 14 485 499 
Total 14 487 501 
 
Sensitivity = 0/14 x 100  
Sensitivity = 0% 
 
Specificity = 485/487 x 100 
Specificity = 100% 
 
Positive predictive value = 0/2 x100 
Positive predictive value = 0% 
 
Negative predictive value = 485/499 x 100 
Negative predictive value = 97% 
 
 
Qu 74: Have you lost weight since 
January 2003? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 9 92 101 
No 5 401 406 
Total 14 493 507 
 
Sensitivity = 9/14 x 100  
Sensitivity = 64% 
 
Specificity = 401/493 x 100 
Specificity = 81% 
 
Positive predictive value = 9/101 x100 
Positive predictive value = 9% 
 303 
 
Negative predictive value = 401/406 x 100 
Negative predictive value = 99% 
 
 
Asthma 
Question 77, 78, 88, and 89 is not included as the answers are not in an 
appropriate style. 
Qu 75: Has a doctor told you that 
you have asthma? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 69 75 
No 8 426 434 
Total 14 495 509 
 
Sensitivity = 6/14 x 100  
Sensitivity = 43% 
 
Specificity = 426/495 x 100 
Specificity = 86% 
 
Positive predictive value = 6/75 x100 
Positive predictive value = 8% 
 
Negative predictive value = 426/434 x 100 
Negative predictive value = 98% 
 
 
Qu 76: In the last 12 months has 
your chest ever felt tight or your 
breathing become difficult? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 14 244 258 
No 0 251 251 
Total 14 495 509 
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Sensitivity = 14/14 x 100  
Sensitivity = 100% 
 
Specificity = 251/495 x 100 
Specificity = 51% 
 
Positive predictive value = 14/258 x100 
Positive predictive value = 5% 
 
Negative predictive value = 251/251 x 100 
Negative predictive value = 100% 
 
 
Qu 79: Do you have this on 
waking? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 67 73 
No 6 410 416 
Total 12 477 489 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 6/12 x 100  
Sensitivity = 50% 
 
Specificity = 410/477 x 100 
Specificity = 86% 
 
Positive predictive value = 6/73 x100 
Positive predictive value = 8% 
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Negative predictive value = 410/416 x 100 
Negative predictive value = 99% 
 
  
Qu 80: Do you have this during the 
day? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 13 196 209 
No 1 286 287 
Total 14 482 496 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 13/14 x 100  
Sensitivity = 93% 
 
Specificity = 286/482 x 100 
Specificity = 59% 
 
Positive predictive value = 13/209 x100 
Positive predictive value = 6% 
 
Negative predictive value = 286/287 x 100 
Negative predictive value = 100% 
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Qu 81: Are you woken from sleep 
by this? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 56 62 
No 6 420 426 
Total 12 476 488 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 6/12 x 100  
Sensitivity = 50% 
 
Specificity = 420/476 x 100 
Specificity = 88% 
 
Positive predictive value = 6/62 x100 
Positive predictive value = 10% 
 
Negative predictive value = 420/426 x 100 
Negative predictive value = 99% 
 
 
Qu 82: Is this worse at the 
beginning of the week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 11 11 
No 12 472 484 
Total 12 483 495 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
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breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 0/12 x 100  
Sensitivity = 0% 
 
Specificity = 472/483 x 100 
Specificity = 98% 
 
Positive predictive value = 0/11 x100 
Positive predictive value = 0% 
 
Negative predictive value = 472/484 x 100 
Negative predictive value = 98% 
 
 
Qu 83: Is this worse at the end of 
the working week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 9 57 66 
No 3 425 428 
Total 12 482 494 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 9/12 x 100  
Sensitivity = 75% 
 
Specificity = 425/482 x 100 
Specificity = 88% 
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Positive predictive value = 9/66 x100 
Positive predictive value = 14% 
 
Negative predictive value = 425/428 x 100 
Negative predictive value = 99% 
 
 
Qu 84: Is this no different at the 
beginning or end of the week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 162 165 
No 9 328 337 
Total 12 490 502 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 3/12 x 100  
Sensitivity = 25% 
 
Specificity = 328/490 x 100 
Specificity = 67% 
 
Positive predictive value = 3/162 x100 
Positive predictive value = 2% 
 
Negative predictive value = 328/337 x 100 
Negative predictive value = 97% 
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Qu 85a: On days away from work 
is this better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 10 116 126 
No 3 376 379 
Total 13 492 505 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 10/13 x 100  
Sensitivity = 77% 
 
Specificity = 376/492 x 100 
Specificity = 76% 
 
Positive predictive value = 10/126 x100 
Positive predictive value = 8% 
 
Negative predictive value = 376/379 x 100 
Negative predictive value = 99% 
 
 
Qu 85b: On days away from work 
is this the same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 121 124 
No 10 371 381 
Total 13 492 505 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
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breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 3/13 x 100  
Sensitivity = 23% 
 
Specificity = 371/492 x 100 
Specificity = 75% 
 
Positive predictive value = 3/124 x100 
Positive predictive value = 2% 
 
Negative predictive value = 371/381 x 100 
Negative predictive value = 97% 
 
 
Qu 85c: On days away from work 
is this worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 4 4 
No 10 488 501 
Total 13 492 505 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 0/13 x 100  
Sensitivity = 0% 
 
Specificity = 488/492 x 100 
Specificity = 99% 
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Positive predictive value = 0/4 x100 
Positive predictive value = 0% 
 
Negative predictive value = 488/501 x 100 
Negative predictive value = 97% 
 
 
Qu 86a: On holidays are you 
better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 12 142 154 
No 1 349 350 
Total 13 491 504 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 12/13 x 100  
Sensitivity = 92% 
 
Specificity = 349/491 x 100 
Specificity = 71% 
 
Positive predictive value = 12/154 x100 
Positive predictive value = 8% 
 
Negative predictive value = 349/350 x 100 
Negative predictive value = 100% 
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Qu 86b: On holidays are you the 
same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 1 96 97 
No 12 395 407 
Total 13 491 504 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 1/13 x 100  
Sensitivity = 8% 
 
Specificity = 395/491 x 100 
Specificity = 80% 
 
Positive predictive value = 1/97 x100 
Positive predictive value = 1% 
 
Negative predictive value = 395/407 x 100 
Negative predictive value = 97% 
 
 
Qu 86c: On holidays are you 
worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 2 2 
No 13 488 502 
Total 13 491 504 
 
It is presumed that the 251 workers not diagnosed with definite EAA, who answered 
no to question 76, In the last 12 months has your chest ever felt tight or your 
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breathing become difficult? would answer no to this question. In reality they did not 
answer this question as they were requested to miss this question. 
 
Sensitivity = 0/13 x 100  
Sensitivity = 0% 
 
Specificity = 488/491 x 100 
Specificity = 99% 
 
Positive predictive value = 0/2 x100 
Positive predictive value = 0% 
 
Negative predictive value = 488/502 x 100 
Negative predictive value = 97% 
 
 
Qu 87: In the past 12 months have 
you had wheezing or whistling in 
your chest? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 12 217 229 
No 2 279 281 
Total 14 496 510 
 
Sensitivity = 12/14 x 100  
Sensitivity = 86% 
 
Specificity = 279/496 x 100 
Specificity = 56% 
 
Positive predictive value = 12/229 x100 
Positive predictive value = 5% 
 
Negative predictive value = 279/281 x 100 
Negative predictive value = 99% 
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Qu 90: Do you have this on 
waking? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 7 76 83 
No 6 411 417 
Total 13 487 500 
 
It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity =  7/13 x 100  
Sensitivity = 54% 
 
Specificity = 411/487 x 100 
Specificity = 84% 
 
Positive predictive value = 7/83 x100 
Positive predictive value = 8% 
 
Negative predictive value = 411/417 x 100 
Negative predictive value = 99% 
 
 
Qu 91: Do you have this during the 
day? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 12 150 162 
No 2 338 340 
Total 14 488 502 
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It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 12/14 x 100  
Sensitivity = 86% 
 
Specificity = 338/488 x 100 
Specificity = 69% 
 
Positive predictive value = 12/162 x100 
Positive predictive value = 7% 
 
Negative predictive value = 338/340 x 100 
Negative predictive value = 99% 
 
 
Qu 92: Are you woken from sleep 
by this? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 7 49 56 
No 6 439 445 
Total 13 488 501 
 
It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 7/13 x 100  
Sensitivity = 54% 
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Specificity = 439/488 x 100 
Specificity = 90% 
 
Positive predictive value = 7/56 x100 
Positive predictive value = 13% 
 
Negative predictive value = 439/445 x 100 
Negative predictive value = 99% 
 
 
Qu 93a: Is this worse at the 
beginning of the week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 1 9 10 
No 13 470 483 
Total 14 479 493 
 
It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 1/14 x 100  
Sensitivity = 7% 
 
Specificity = 470/479 x 100 
Specificity = 98% 
 
Positive predictive value = 1/10 x100 
Positive predictive value = 10% 
 
Negative predictive value = 470/483 x 100 
Negative predictive value = 97% 
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Qu 94: Is this worse at the end of 
the working week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 8 56 64 
No 6 423 429 
Total 14 479 493 
 
It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 8/14 x 100  
Sensitivity = 57% 
 
Specificity = 423/479 x 100 
Specificity = 88% 
 
Positive predictive value = 8/64 x100 
Positive predictive value = 13% 
 
Negative predictive value = 423/429 x 100 
Negative predictive value = 99% 
 
 
Qu 95: Is there no difference at the 
beginning or end of the working 
week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 143 146 
No 10 350 360 
Total 13 493 506 
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It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 3/13 x 100  
Sensitivity = 23% 
 
Specificity = 350/493 x 100 
Specificity = 71% 
 
Positive predictive value = 3/146 x100 
Positive predictive value = 2% 
 
Negative predictive value = 350/360 x 100 
Negative predictive value = 97% 
 
 
Qu 96a: On days away from work 
is this better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 8 90 98 
No 5 404 409 
Total 13 494 507 
 
It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 8/13 x 100  
Sensitivity = 62% 
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Specificity = 404/494 x 100 
Specificity = 82% 
 
Positive predictive value = 8/98 x100 
Positive predictive value = 8% 
 
Negative predictive value = 404/409 x 100 
Negative predictive value = 99% 
 
 
Qu 96b: On days away from work 
is this the same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 123 126 
No 10 371 381 
Total 13 494 507 
 
It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 3/13 x 100  
Sensitivity = 23% 
 
Specificity = 371/494 x 100 
Specificity = 75% 
 
Positive predictive value = 3/126 x100 
Positive predictive value = 2% 
 
Negative predictive value = 371/381 x 100 
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Negative predictive value = 97% 
 
 
Qu 96c: On days away from work 
is this worse? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 0 2 2 
No 13 492 505 
Total 13 494 507 
 
It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 0/13 x 100  
Sensitivity = 0% 
 
Specificity = 492/494 x 100 
Specificity = 100% 
 
Positive predictive value = 0/2 x100 
Positive predictive value = 0% 
 
Negative predictive value = 402/505 x 100 
Negative predictive value = 99% 
 
 
Qu 97a: On holidays is this better? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 10 112 122 
No 3 381 384 
Total 13 493 506 
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It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 10/13 x 100  
Sensitivity = 77% 
 
Specificity = 381/493 x 100 
Specificity = 77% 
 
Positive predictive value = 10/122 x100 
Positive predictive value = 8% 
 
Negative predictive value = 381/384 x 100 
Negative predictive value = 99% 
 
 
Qu 97b: On holidays is this the 
same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 1 102 103 
No 12 391 403 
Total 13 493 506 
 
It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 1/13 x 100  
Sensitivity = 8% 
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Specificity = 391/493 x 100 
Specificity = 80% 
 
Positive predictive value = 1/103 x100 
Positive predictive value = 1% 
 
Negative predictive value = 391/403 x 100 
Negative predictive value = 97% 
 
 
Qu 97c: On holidays is this the 
same? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 1 102 103 
No 12 391 403 
Total 13 493 506 
 
It is presumed that the 2 expert panel definite EAA case and the 279 workers not 
diagnosed with definite EAA, who answered no to question 87, ‘In the past 12 
months have you had wheezing or whistling in your chest?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 1/13 x 100  
Sensitivity = 8% 
 
Specificity = 391/493 x 100 
Specificity = 80% 
 
Positive predictive value = 1/103 x100 
Positive predictive value = 1% 
 
Negative predictive value = 391/403 x 100 
Negative predictive value = 97% 
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Flu 
 
Questions 104 and 105 are not included due to the style of answer not been 
appropriate for these statistical analysis. 
 
Qu 98: In the past twelve months 
have you suffered recurrent flu like 
symptoms? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 8 202 210 
No 5 292 297 
Total 13 494 507 
 
Sensitivity = 8/13 x 100  
Sensitivity = 62% 
 
Specificity = 292/494 x 100 
Specificity = 59% 
 
Positive predictive value = 8/210 x100 
Positive predictive value = 4% 
 
Negative predictive value = 292/297 x 100 
Negative predictive value = 98% 
 
 
Qu 99: In the past twelve months 
have you suffered from fever? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 5 106 111 
No 8 345 353 
Total 13 451 464 
 
It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
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months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 5/13 x 100  
Sensitivity = 38% 
 
Specificity = 345/451 x 100 
Specificity = 76% 
 
Positive predictive value = 5/111 x100 
Positive predictive value = 5% 
 
Negative predictive value = 345/353 x 100 
Negative predictive value = 98% 
 
 
Qu 100: In the past twelve months 
have you suffered from shivering? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 5 94 99 
No 8 355 363 
Total 13 449 462 
 
It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 5/13 x 100  
Sensitivity = 38% 
 
Specificity = 355/449 x 100 
Specificity = 79% 
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Positive predictive value = 5/99 x100 
Positive predictive value = 5% 
 
Negative predictive value = 355/363 x 100 
Negative predictive value = 98% 
 
 
Qu 101: In the past twelve months 
have you suffered from tiredness? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 8 186 194 
No 5 299 304 
Total 13 485 498 
 
It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 8/13 x 100  
Sensitivity = 62% 
 
Specificity = 299/485 x 100 
Specificity = 62% 
 
Positive predictive value = 8/194 x100 
Positive predictive value = 4% 
 
Negative predictive value = 299/304 x 100 
Negative predictive value = 98% 
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Qu 102: In the past twelve months 
have you suffered from weakness? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 8 167 175 
No 5 307 312 
Total 13 474 487 
 
It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 8/13 x 100  
Sensitivity = 62% 
 
Specificity = 307/474 x 100 
Specificity = 65% 
 
Positive predictive value = 8/175 x100 
Positive predictive value = 5% 
 
Negative predictive value = 307/312 x 100 
Negative predictive value = 98% 
 
 
Qu 103: In the past twelve months 
have you suffered from joint or 
muscle pain? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 7 159 166 
No 6 317 323 
Total 13 476 488 
 
It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
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months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 7/13 x 100  
Sensitivity = 54% 
 
Specificity = 317/476 x 100 
Specificity = 67% 
 
Positive predictive value = 7/166 x100 
Positive predictive value = 4% 
 
Negative predictive value = 317/323 x 100 
Negative predictive value = 98% 
 
 
Qu 106: Do these symptoms occur 
more freq after doing a particular 
job? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 3 15 18 
No 9 476 485 
Total 12 491 503 
 
It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 3/12 x 100  
Sensitivity = 25% 
 
Specificity = 476/491 x 100 
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Specificity = 97% 
 
Positive predictive value = 3/18 x100 
Positive predictive value = 17% 
 
Negative predictive value = 476/485 x 100 
Negative predictive value = 98% 
 
 
Qu 107a: Do these symptoms 
occur at the beginning of the 
working week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 2 16 18 
No 11 455 466 
Total 13 471 484 
 
It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 2/13 x 100  
Sensitivity = 15% 
 
Specificity = 455/471 x 100 
Specificity = 97% 
 
Positive predictive value = 2/18 x100 
Positive predictive value = 11% 
 
Negative predictive value = 455/466 x 100 
Negative predictive value = 98% 
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Qu 107b: Do these symptoms 
occur at the end of the working 
week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 4 35 39 
No 9 437 446 
Total 13 472 485 
 
It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 4/13 x 100  
Sensitivity = 31% 
 
Specificity = 437/472 x 100 
Specificity = 93% 
 
Positive predictive value = 4/39 x100 
Positive predictive value = 11% 
 
Negative predictive value = 437/446 x 100 
Negative predictive value = 98% 
 
 
Qu 107c: Are these symptoms no 
different at the beginning or end of 
the working week? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 2 134 136 
No 10 352 362 
Total 12 486 498 
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It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 2/12 x 100  
Sensitivity = 17% 
 
Specificity = 352/486 x 100 
Specificity = 72% 
 
Positive predictive value = 2/136 x100 
Positive predictive value = 1% 
 
Negative predictive value = 352/362 x 100 
Negative predictive value = 97% 
 
 
Qu 108a: Do these symptoms 
occur more frequently or are more 
severe on returning to work after a 
weekend break from work? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 42 48 
No 7 429 436 
Total 13 471 484 
 
It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 6/13 x 100  
Sensitivity = 46% 
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Specificity = 429/471 x 100 
Specificity = 91% 
 
Positive predictive value = 6/48 x100 
Positive predictive value = 13% 
 
Negative predictive value = 429/436 x 100 
Negative predictive value = 98% 
 
 
Qu 108b: Do these symptoms 
occur more frequently or are more 
severe on returning to work after a 
holiday break from work? 
 Expert panel 
definite EAA 
cases 
Respondents 
not 
diagnosed 
with definite 
EAA 
Total 
Yes 6 50 56 
No 7 420 427 
Total 13 470 483 
 
It is presumed that the 5 expert panel definite EAA case and the 292 workers not 
diagnosed with definite EAA, who answered no to question 98, ‘In the past twelve 
months have you suffered recurrent flu like symptoms?’ would answer no to this 
question. In reality they did not answer this question as they were requested to miss 
this question. 
 
Sensitivity = 6/13 x 100  
Sensitivity = 46% 
 
Specificity = 420/470 x 100 
Specificity = 89% 
 
Positive predictive value = 6/56 x100 
Positive predictive value = 11% 
 
Negative predictive value = 420/427 x 100 
Negative predictive value = 98% 
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